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Abstract:
The aim of this PhD project is to analyse the RET-dependent signalling pathway and to block it 
with small molecule inhibitors, thus promoting innovative approaches to cure papillary thyroid 
carcinoma (PTC).
The first goal was to determine the three-dimensional structure of RET catalytic domain to obtain 
detailed knowledge of the target molecule. The Baculovirus expression system and purification 
procedure was optimised to produce high amount of recombinant protein (rRET) to perform 
biochemical characterization and crystallization attempts. rRET was active and properly folded, 
thus resulting a suitable reagent for inhibitors screening and crystallization experiments.
The crystallization screening was performed using rRET (complete kinase domain) and three other 
constructs, in which different deletions were introduced. No crystals were obtained after many 
attempts in two independent laboratories.
Concurrently, the members of 2-indolinone family, a promising class of compounds studied with 
molecular modelling, were screened in an ELISA-based assay to identify the best inhibitor of RET. 
SU5416 demonstrated an efficient inhibition of RET and was further analysed both in vitro and 
cellular systems, showing good specificity and selectivity. In animal model SU5416 blocked RET 
phosphorylation, indicating feasible pharmacological properties also in in vivo system.
Since B-RAF hyperactivation leads to transformation of thyroid cells, we also used siRNA 
technology to investigate whether B-RAF represented a target for selective treatment and tested a 
new inhibitor that showed activity in B-RAF positive melanoma cell lines, in B-RAF and RET/PTC 
thyroid models. The current study demonstrated that B-RAF inhibition by siRNA and small 
molecule inhibitor determined re-expression of thyroid specific proteins, thus indicating a restoring 
of the differentiation process, and block of the proliferation.
This work has proposed the rational identification of RET and B-RAF inhibitors by analysing their 
signalling pathway. These results raise the possibility that PTC could be treated effectively with 
small molecule inhibitors.
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1 INTRODUCTION
1.1 Overview about protein kinases and their role in cancer
1.1.1 The kinome
Ever since the discover nearly 50 years ago that reversible phosphorylation regulates the 
activity of glycogen phosphorylase, there has been intense interest in the role of protein 
phosphorylation in regulating protein function. The completion of the human genome 
sequence now allows the identification of almost all human protein kinases, 
representing 1.5- 2.5% of all eukaryotic genes. Most protein kinases belong to a single 
superfamily containing a eukaryotic protein kinase (ePK) catalytic domain.
In addition, forty atypical protein kinases have been identified. These proteins retain the 
catalytic activity even if they have lost the sequence similarity to the ePK domain and 
their close homologs.
All known 518 kinases have been classified into a hierarchy of groups, families and 
subfamilies primarily by sequence comparison of their catalytic domain, aided by the 
knowledge of sequence similarity and domain structure outside of the catalytic domain, 
known biological functions and similar classification of the yeast, worm and fly 
kinomes [1]. A scheme of this relationship is shown below.
Family comparison shows that the major kinase groups and most kinase families are 
shared among metazoans and many are also found in yeast, reflecting the breadth of 
conserved functions mediated by kinases.
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Figure 1.1.1 Kinome tree [1] RET and B-RAF belong to TK and TKL family, respectively.
Indeed, comparison of the yeast (Saccaromyces Cerevisiae) kinome with those of worm 
(Caernorhabditis Elegans), fruit fly (Drosophila Melanogaster) and human 
demonstrates the presence of at least 97 kinases shared with higher organisms. 
Conversely, only in the common ancestor of worm, fly and human there are additional 
94 subfamilies, including tyrosine kinase and tyrosine kinase-like groups, that are 
specific for metazoans and required for the signaling functions and the sophisticated 
control of the development, differentiation and intercellular communication [2]. 18 
families found only in fly and human and not in worm might encode more recent 
functions that developed after their divergence from nematode lineage. Within these 
coelomate- specific families there is a preponderance of kinases associated with 
immunity, cell cycle control, neurobiology and morphogenesis. The human genome has 
approximately twice as many kinases as those of fly or worm; accordingly, most kinase 
families have twice as many human members as they have in worm or fly, even if  this 
expansion is not uniform [1]. The human expansion of many of these families can be 
traced both to large duplications of multigene loci and to local tandem duplications of 
smaller loci often containing just one gene. For instance, each of the four human
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epidermal growth factor receptors (EGFR) maps close to one of HOX clusters in D. 
Melanogaster, implying that the proposed double duplication of that cluster early in 
vertebrate evolution created the EGFR family from a single ancestral EGFR gene [3]. 
Most protein kinases act in a network of kinases and other signaling effectors, and are 
modulated by autophosphorylation and phosphorylation by other kinases. Other 83 
domains, in addition to the catalytic domain, have been identified in 258 of the 518 
kinases. These domains regulate the biochemical activity, determine the subcellular 
localization of the corresponding kinase and link it to other signaling molecules. 
Comparison of members of the same family demonstrates that the general structure is 
conserved but some domain shuffling is seen to confer peculiar properties to each 
kinases. The most common domains mediate interactions with other signaling proteins, 
for instance 24 kinases contain the SH2 domain that binds to phosphotyrosine residues; 
other domains link to small guanosine trisphosphatase signaling, lipid signaling and 
calcium signaling, target the protein to the cytoskelethon or mediate interactions with 
other proteins or RNA [1]. The presence of these non catalytic domains is crucial in 
ePKs that have lost their biochemical activity: nearly 10% of all kinase domain appear 
to be enzimatically inactive. However, these domains are well conserved and likely to 
maintain the typical kinase domain fold. These have been postulated to act as kinase 
substrates and scaffolds for assembly of signaling complexes. The inactive kinase 
domains fall into three main categories: the first is represented by domains that may act 
as modulators of the other catalytic domains; the second group contains kinases with 
high similarity to the canonical ePK profile, for instance several receptor tyrosine kinase 
(RTK) where the inactive kinase may dimerize and act as substrate of another RTK. The 
third group consists of members exhibiting very weak similarities to the kinase domain 
profile and may have quite divergent function [1].
6
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1.1.2 Structure of a protein kinase and mechanisms of 
phosphorylation reaction control
The protein kinase fold is extremely well conserved among serine/threonine and 
tyrosine kinases and is composed by two lobes. The smaller N-terminal lobe is 
characterized by a five-stranded p sheet and one prominent a helix, called helix aC. The 
C-terminal lobe is larger and is predominantly constituted by helices. The two lobes are 
joined by a polypeptide chain that functions as a hinge. ATP is bound in a cleft between 
the two lobes and sits beneath a high conserved loop connecting strands pi and p2.
1.1.2.1 Regulation in serine/threonine kinase
The three-dimensional structure of cyclic-AMP dependent protein kinase (PKA, shown 
in Figure 2), the first serine/threonine kinase to be solved by X-ray diffraction [4], has 
enabled its mechanism of reaction to be clarified.
A
N-terminal
subdom ain
C*termmal
subdom ain Activationloop
Catalytic
loop
c
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Figure 1.1.2 A: Schematic representation of catalytic subunit of protein kinase A: the most 
important amino acid involved in its regulation are labelled in ball and sticks. (A) shows the 
complete structure of PKA, (B) and (C) represent N-terminal and C-terminal. B sheet are ribbon 
and helices are cylinder. B: Mechanism of phosphorylation reaction, as described in the text.
The adenine of ATP is located in a hydrophobic pocket and the sugar is stabilized by 
hydrogen bonding; the phosphates y are involved in the catalysis by interactions with 
the Lys-72, Mg2+ ions and the main chain nitrogen of a glycine-rich loop, a sequence
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(Gly-X-Gly-X- Tyr or Phe-Gly) very flexible in absence of ATP that can easily bind 
small molecule inhibitors. The catalytic Asp 166, invariant in all kinases, is located in 
the C-terminal lobe in the catalytic loop, and acts as a base to remove a proton from the 
protein substrate hydroxyl group. The resulting alcoholate (in the case of serine and 
threonine) or phenolate (in the case of tyrosine) ion is positioned to nucleophilic attack 
the y phosphate of ATP. The activation loop begins at the highly conserved DFG motif 
(Asp-Phe- Gly) with Asp 184. The segment continues with a region that adopts 
remarkably different conformations between the active and inactive kinase structures. In 
PKA there is a short p strand followed by a loop containing the autophosphorylation site 
Thr 197. The segment ends in the region that has a 3io helix structure and includes 
residues that are important for the peptide substrate recognition. The final residue 
glutamate 208 is a part of APE (Asp-Pro-Glu) which is conserved in most kinases and is 
hydrogen bonded to the conserved arginine 280 [5].
The autophosphorylation reaction involves the threonine 197, in the activation loop, that 
has an important role in the kinase activation. Indeed, the phosphate is placed inside a 
positive charge cluster, composed by His 87 of N-terminal lobe, Arg 165, Lys 189, 
stabilizing it. In particular the interaction with Arg 165 promotes the correct orientation 
and electrostatic environment for the catalytic Asp 166. The activation loop is located in 
the convenient conformation to allow the peptide substrate recognition, while the 
interaction of P-Thr 197 with Lys 189 promotes the contact between Asp 184 and
I
activatory Mg ion. Finally, the contact with His 87 allows the correct domain-domain 
interaction, which is also critical for ATP binding. The structural studies has clarified 
the mechanism of control of PKA, that is very similar to those of other serine/threonine 
kinase proteins.
9
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Another mechanism of control is the association of other regulatory proteins, e.g. the 
complex CDK2- cyclin A. CDK2 shows, in the helix corresponding to helix C of PKA, 
the sequence P ST AIRE, important for the recognition of cyclin A. When cyclin A binds 
CDK2, the activation loop changes its position and Thr 160 is exposed and available for 
the phosphorylation. P-Thr 160 stabilizes the positive cluster, disposed in the same line 
as that of PKA. The phosphorylated complex CDK2- cyclin A is totally active and can 
promote the activation of downstream substrates [6].
1.1.2.2 Regulation in protein tyrosine kinases
A different model has been proposed for the regulation of protein tyrosine kinases.
This family is composed by two groups of proteins: receptor tyrosine kinase (RTK) and 
non receptor tyrosine kinase (NRTK). The wide majority of RTKs is a single 
polypeptide chain, consisting of an extracellular portion, a transmembrane helix and a 
cytoplasmatic region that contains the catalytic domain. Otherwise, NRTKs are 
localized in the cytoplasm, after lacking the extracellular portion and the transmebrane- 
spanning region. In addition to a tyrosine kinase domain, NRTKs possess domains that 
mediate protein- protein, protein- lipid or protein- DNA interactions. Schematic 
examples are shown in Figure 1.1.3
A
SH2 SH3 TYROSINE 
KINASE DOMAIN
DNA F-actin 
binding binding
D H \—\ ABL
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RET FG FR KIT INSR
Figure 1.1.3 Examples of NRTKs (A) and RTKs: (B) the most significant domain in both 
intracellular and extracellular regions are represented.
The mechanism of control of NRTKs is dependent on the presence of tyrosine residues 
for phosphorylation. For instance, Src has two regulatory tyrosine phosphorylation sites: 
the first is Tyr 527 in the C-terminal lobe that repress the catalytic activity when 
phosphorylated by the NRTK Csk. In this case, the interactions between P-Tyr 527 and 
SH2 domain favors and stabilizes the contact of SH3 domain with a short polyproline 
type II helix, causing a misalignment of amino acids important for the kinase reaction 
and the consequent block of the enzymatic activity. Src is activated when the binding of 
high- affinity ligands disrupts these intramolecular restrains. The second tyrosine (Tyr 
416) is located in the activation loop and is autophosphorylated to reach the maximal 
activity of the kinase [7, 8].
Receptor tyrosine kinases contain between one and three tyrosines in the activation loop 
that regulate the catalytic activity and the biological function of the proteins. In general,
Protein kinases a n d  their role in c a n c e r
the autophosphorylation could occur either in cis, eg. when the ligand-induced 
dimerization causes conformational changes that favor intramolecular phosphorylation 
or in trans, when a simple proximity effect provides opportunity to phosphorylate 
another receptor molecule. Ligand-induced oligomerization triggers the activity of 
RTKs. Ligand non-covalently binds the extracellular region, favors the dimerization and 
induces structural rearrangements that activate the autophosphorylation process. Crystal 
structures of the un-phosphorylated form of insulin receptor kinase (IRK) provide the 
molecular basis to explain how the catalytic activity is repressed before receptor 
activation [9]. Crucially, Tyr 1162, in the activation loop, forms hydrogen bonds with 
conserved aspartic acid and arginine. In addition, the conserved aspartic acid of DFG 
motif in the beginning of the activation loop, involved in Mg-ATP binding, is not 
properly positioned for the catalysis. Autophosphorylation of IRK induces a 
repositioning of the activation loop. This new conformation is stabilized by hydrogen 
bonds between P-Tyr 1163 and the conserved arginine in the beginning of the activation 
loop and a backbone amide nitrogen in the latter half of the loop [10]. The analysis of 
mode of substrate binding to tyrosine kinases has been performed co-crystallizing three- 
phosphorylated IRK kinase domain with 18-residues peptide containing YMXM motif 
present also in IRK activation loop. The backbone- backbone interactions between the 
peptide and the activation loop ensure that only tyrosine residues can conveniently fit 
into the active site, while the methionine side chains sit into two shallow hydrophobic 
pockets on the surface of C-terminal lobe [10]. Another model of regulation of tyrosine 
kinase domain has been proposed by Kuriyan et al (2007). The kinase domain of EGFR 
is itself responsive to the dimerization of the receptors, converting from an inactive 
conformation to an active one in response to an increase in the local concentration of the 
receptor. The fundamental on/off switch utilized by EGFR is the same used by CDK/
12
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cyclin complexes, except that EGFR and its relatives serve as their own "cyclins". In 
this asymmetric dimer the C-lobe of one kinase domain is juxtaposed against the N-lobe 
of the other molecule with extensive interactions spanning helix C. The C-lobe takes the 
relative position in the dimer analogous to that of cyclin in the active CDK/Cyclin 
complex [11].
Additional mechanisms to control the biological activity of RTKs are the action of 
phosphatases that temporarily limits the activity of the receptors and the downregulation 
mediated by endocytosis or ubiquitin-directed proteolysis.
1.1.3 Role of protein kinases in cellular biochemistry and alteration 
in cancer
Protein kinases regulate several functions during cell life, e.g. cell cycle, apoptosis, 
migration, differentiation and in multicellular organism control embryonic development, 
metabolism and the function of the immune system. In particular, PKs are crucial actors 
in signaling pathways that enable cells to communicate with the environment. It is 
therefore clear that alterations in the activation of this class of proteins determine a 
drastic deregulation of cellular biochemistry; consequently, a wide variety of diseases 
are associated to misregulation of PKs.
In cancer, mutations in signaling pathway have frequently been observed: cancer cells 
divide inappropriately in respect to environmental context, develop robust anti-apoptotic 
stimuli and molecular mechanism to escape the immune response [12].
For these reasons, selectively targeting signaling elements altered only in tumour cells 
represents a promising alternative to cytotoxic agents normally used in therapeutic 
approaches. Moreover, the results of structural studies have identified the properties of
13
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the ATP binding site in several kinases, giving the basis for a rational design of new 
drugs that block the enzymatic activity of PKs [13].
1.1.4 Rational drug design on protein kinases as therapeutic 
intervention in cancer
One approach to inhibit kinases is to find small molecules that immobilize the kinase 
domain in its inactive state. An example of such an inhibitor of the inactive 
conformation is represented by Gleveec (STI571) that inserts its pyrimidine and 
pyridine rings in the ATP binding site of Abl with high specificity. The rest of the 
molecule is wedged between C helix and the activation loop, locking the kinase in an 
inactive conformation [14]. Another inhibitor of Abl is PD173955; in this case the 
compound blocks both active and inactive conformations of Abl, thus improving the 
potency in anti-kinase effects [15]. Targeting the active conformation could be 
advantageous because conservation of the correct 3D structure is required for the 
enzyme functionality and, therefore, this conformation is less tolerant of mutations, 
which makes it less likely to develop resistance to inhibition.
The alignment of 491 kinases demonstrated that the combination of the amino acids in
the ligand binding site was characteristic for each protein kinase or a limited number of
PKs. This observation suggested that the selectivity could be reached by interaction
between inhibitor and the set of amino acids constituting the ligand binding site.
The interaction between p38 and several chemical entities, such as pyrimidine
imidazoles, quinazolines and pyridol-pyrimidines, occurs in a small hydrophobic pocket
at the back of the ATP- binding site that ATP does exploit, giving high selectivity for
p38 [16]. This indicates that less conserved domains can also be successfully targeted.
Sometimes the presence of a single specific amino acid guarantees the formation of
hydrogen bonds that stabilize the interaction with small molecule inhibitors. For
14
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instance, the binding of aspargine 568 to the oxindole ring of SU5402 confers 
selectivity for fibroblast growth factor receptor 1 (FGFR 1) [17].
Furthermore, it is possible to target the extracellular domain as in the case of HER2 and 
the monoclonal antibody trastuzumab (Herceptin®, Genentech, San Francisco, CA). 
Herceptin binds close to the juxtamembrane region of the extracellular domain of the 
receptor. This may allow engagement with the endocytotic machinery while avoiding 
receptor dimerization and kinase activation, which would explain its inhibitory effects 
on receptor signaling [18].
1.1.5 The problem of resistance
The major problem related to targeted therapies is the resistance that cancer cells tend to 
acquire after prolonged treatment, thus rendering the therapy ineffective. For instance, 
in patients affected by chronic myeloid leukemia, STI571 produces hematological 
remission if administrated in appropriate doses in nearly all cases during the chronic 
phase of the disease and in >50% during blast crisis. However, patients in remission 
frequently relapse and become resistant to further Imatinib treatment. Two different 
mechanisms of resistance have been identified: the first is Bcr-Abl gene amplification, 
the second is the acquisition of mutations within the catalytic domain [19]. Indeed, 
STI571 treatment imposes a potent selection for drug- resistant alleles.
Agents active against these new mutated targets that arise during therapy with first- 
generation tyrosine kinase inhibitors, are being rapidly developed. For example 
BMS354825, a dual Src-Abl inhibitor, is active in patients resistant to Imatinib because 
it binds Abl with less stringent structural requirements [20].
The second generation of kinase inhibitors confirm the potential of mutation- specific
anti-cancer therapies, and it is yet to be verified if the combination of first and second
15
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generation inhibitors will delay or avoid resistance [21]. In solid tumors it’s important to 
consider the complexity of intercellular network and the possibility that other normal 
signaling pathways could compensate for the blocking of oncogenic pathways obtained 
by chemiotherapic approaches. Therefore, the combination of several inhibitors against 
different molecular targets could improve the outcome of therapies, compared to single 
agent treatments [21].
Future researches will focus on the identification of new small molecule inhibitors as 
well as on the application of known compounds to novel type of cancer.
1.1.6 Papillary thyroid carcinoma: a model for targeted therapies 
against protein kinases
In this scenario, a good model for specific therapy against protein kinases is represented 
by papillary thyroid carcinoma. Indeed, alterations in expression and activation of both 
tyrosine and serine/threonine protein kinases involved in mitogen-activated protein 
kinase (MAPK) signaling have been proposed as initiating events. These proteins could 
be considered as targets for small molecule inhibitors, offering a new strategy for the 
care of thyroid malignancies.
16
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1.2 Papillary, poorly differentiated and anaplastic thyroid 
carcinomas
1.2.1 Classification
Papillary thyroid carcinoma (PTC) is the most common malignancy of the endocrine 
system, with an incidence of half million new cases per year. It affects females more 
frequently than males and while it may occur at any age, the mean age at diagnosis is 40 
years. In general, PTCs have favourable prognosis: 80-90% of all patients survive at 
least 10 years after diagnosis.
World Health Organization classifies PTC into eleven categories, based on morphologic 
pattern and putative diagnostic implication (WHO: Classification of tumours. Pathology 
and genetics of tumours of endocrine organs 2004).
• Papillary microcarcinoma (PMC): the term microcarcinoma is usually applied to 
masses measuring 1 cm or less in diameter. Prognosis is excellent and distant 
metastases are extremely rare; indeed PMCs are considered to be clinically 
insignificant, when patients are >19 years old. After Chernobyl disaster an 
increased incidence of PMCs has been observed in young patients.
• Encapsulated variant: this lesion is totally surrounded by a capsule, 
characterized by the gross appearance of an adenoma and architectural and 
nuclear features similar to conventional papillary thyroid carcinoma. This 
variant represents 10% of cases of PTC and has never been associated to distant 
metastases, even if some nodal metastases have been observed.
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• Follicular variant: this PTC has predominantly follicular pattern of growth; the 
diagnosis is the same of typical PTC with nodal and not distant metastases. The 
lesion is frequently infiltrative.
• The macrofollicular variant: this tumour exhibits secretory activity, like 
hyperplastic nodules.
• The solid variant: occurring prevalently in children, especially after strong 
exposure to ionising radiation, these tumours are typified by sheets of cancer 
cells with evident features of PTC.
• Diffuse sclerosing variant: this type of PTC presents dense sclerosis, extensive 
solid foci, squamous metaplasia and massive lymphocytic infiltration. This 
tumour frequently metastasises in lung, and the survival rate is lower than those 
of conventional PTCs.
• Oncocytic variant: it is associated with autoimmune thyroiditis and usually 
affects women. It’s composed of oncocytic cells with classic nuclear features.
• The Warthin-like variant: this PTC resembles the salivary gland tumour and 
overexpresses the Retinoblastoma protein (Rb) and E2F-1 transcription factor.
• The tall cell variant: affecting older men, this tumour is associated to a poorer 
prognosis than other variants. Extrathyroid extension and vascular invasion are 
common; the papillae are well formed and covered by tall cells.
• Columnar cell variant: this variant shows the presence of nuclear stratification in 
association with clear cytoplasm
• Cribiform morular variant: Found in young women with sporadic or familial 
mutations of adenomatous poliposis coli (APC) gene, this PTC is encapsulated 
with a cribiform pattern. The follicles are without colloid and there are papillary
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formations of tall cells. Strong protein expression and genetic aberrations of (3- 
catenin have been observed.
Poorly differentiated thyroid carcinomas are another class of thyroid malignancies that 
have a survival rate intermediate between PTCs and anaplastic carcinoma. Cells have 
molecular features characteristic of PTC with a trabecular or solid growth pattern. E- 
cadherin expression is suppressed and mutations in P-catenin are reported in many 
studies.
Finally, undifferentiated thyroid tumours arise as anaplastic transformation of well 
differentiated papillary carcinoma. The mass grow quickly and bulky neck mass that 
invades adjacent structures, often causes hoarseness, dysphagia and dyspnoea. 
Microscopically, there are two main categories: squamoid pattern with occasional focal 
keratinisation and a mixed pattern composed by giant cells like osteoclasts and spindle 
cells resembling sarcoma. Fortunately, this tumour is rare; it occurs in patients older 
then 65 years and there is no effective treatment: death usually ensues within one year 
(reviewed in [22]).
1.2.2 Epidemiology
Thyroid carcinoma comprises approximately 1% of all malignancies. In Europe and 
United States of America about three out of 100,000 people develop a thyroid 
malignancy, but significant regional differences exist. Generally, thyroid cancer is more 
common in women that in men.
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Papillary thyroid carcinoma (PTC) is the most common malignant in countries with 
sufficient iodine diet and comprises up to 80% of all thyroid malignancies; it 
prevalently occurs in the third to fifth decade of life.
Other thyroid cancers are less frequent: for instance, follicular thyroid carcinoma (FTC) 
represents 10-20% of all thyroid malignancies and arises in regions with insufficient 
iodine diet during fifth and sixth decade, while undifferentiated thyroid carcinoma 
(UTC) accounts for up to 10% in patients beyond the sixth decade [23].
1.2.3 Aetiology
The aetiology of the more common sporadic forms of thyroid cancer that consist of 
papillary thyroid carcinoma, follicular thyroid carcinoma and poorly and 
undifferentiated thyroid carcinoma, is not, as yet, well clarified. External radiation is the 
only exogenous factor that has been clearly correlated with thyroid carcinomas. After 
Chernobyl disaster (1986) the impact of nuclear fallout on the incidence of thyroid 
cancer has been demonstrated with an increased number of cases in new people 
observed between 1986 and 1991 [24].
Other factors under consideration for the aetiology of thyroid carcinoma are iodine 
excess and deficiency, but further studies are necessary to better understand their role.
1.2.4 Diagnosis
Thyroid cancers are commonly diagnosed in presence of a thyroid nodule. At this stage 
most patients present lymph node metastases and often distant metastases in lung, bone 
and brain. The first examination is a fine-needle aspiration cytology to determine the
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histological type [25]. In follicular thyroid carcinoma it’s possible to measure calcitonin 
levels to verify whether the nodule is malignant [26]; otherwise, no other tumoral 
markers give consistent information in diagnosis.
1.2.5 Prognosis
The overall 5 year survival rate in patients with papillary thyroid carcinoma is about 90- 
95%, the 10 year survival rate is about 80-95%. In follicular thyroid carcinoma survival 
rate is slightly lower, around 70-95%, compared to PTCs. Finally, most of patients with 
undifferentiated thyroid carcinoma die within one year after diagnosis [23].
Several factors influence the prognosis of thyroid cancers, such as histological type and 
subtype, tumour stage, age, gender, differentiation, DNA euploidy, microvessel count, 
CD97, E-cadherin expression, telomerase activity, capsular and vascular invasion. 
However, the most important parameters to determine the outcome are primary tumour 
size, extra thyroidal extension and distant metastases.
A variety of prognostic scoring systems is available, but unfortunately none of them is 
widely used and is not possible to make a comparison of different studies.
1.2.6 Treatment
Generally, surgery is the treatment of choice. At the first intervention, ultrasound should 
be performed, to identify the extent and localization of the primary tumour and 
coexisting nodules, and also to diagnose enlarged cervical lymph nodes. Distant 
macrometastases should, however, be ruled out, prior to extensive operation.
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In papillary thyroid carcinoma, there is a controversy regarding the extent of thyroid 
gland resection. Total thyroidectomy is commonly recommended in Europe, while in 
United States partial ablation is preferred [23]. Totally thyroidectomy is advocated 
because PTCs are often multifocal and the rate of local recurrences is increased after 
less than total gland removal. During the follow up, measurement of thyroglobulin can 
be used as marker. By contrast, partial thyroidectomy is chosen because there is no 
difference in survival as compared to total gland removal, and, if necessary, ablation of 
thyroid remnant can be accomplished by radioiodine without morbidity.
In follicular thyroid carcinoma, total thyroidectomy is widely accepted as the treatment 
of choice, while in undifferentiated thyroid carcinomas this approach is desirable but 
often unfeasible. In this case the goal must be to prevent trachea and oesophagus 
obstruction by a multidisciplinary therapeutic strategy, consisting of surgery, external 
radiation and chemotherapy.
As a post-operative treatment in PTCs and FTCs, radioiodine is often used, mainly after 
total thyroidectomy. Radioiodine has effects in ablation of small thyroid remnants and 
pulmonal metastases, while bone metastases is less responsive. External radiation can 
be well indicated for the treatment of bone metastases. In undifferentiated carcinomas 
and in medullary thyroid carcinoma radioiodine is not useful because tumoral cells 
don’t internalise iodine, while the use of chemotherapy is limited to paclitaxel for UTCs 
and octreotide for MTCs [23].
1.2.7 Medullary thyroid carcinoma
Medullary thyroid carcinoma represents 5-10% of all thyroid malignancies. It derives 
from the parafollicular C-cells that produce calcitonin. High levels of calcinotin
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secretion serve as a reliable marker for neoplastic tissue diagnosis. Prognosis usually 
depends on the stage of tumour progression at the time of diagnosis, with a mean 10- 
year survival of approximately 75%. Familial MTC occurs as part of three different 
clinical phenotypes: multiple endocrine neoplasia (MEN) type 2A and type B and 
familial MTC-only syndrome. Activating RET mutations are the underlying cause of 
these diseases, these mutations mainly occur in the kinase domain, even if mutations in 
the cystein-rich region in the extracellular portion have been observed. Because of the 
tendency of MTC to progress and metastatize rapidly, prophylactic thyroidectomy is 
recommended. [27]
1.3 Molecular alterations of papillary thyroid carcinoma
Several oncogenes, all encoding for important effectors of the MAPK signaling 
pathway, have been involved in the pathogenesis of PTC. This pathway is normally 
involved in physiological response to growth factors, while the effects of thyroid- 
stimulating hormone (TSH, also known as thyrotropin) are mediated by cAMP [28].
The MAPK cascade is activated by the binding of a ligand to its receptor tyrosine 
kinase; autophosphorylation or trans-phosphorylation of specific residues in the 
intracellular portion of the receptor enables the recognition of downstream effectors, 
such as She protein that mediates the recruitment of Grb2-SOS complexes and Ras. Ras, 
in turn, activates components of the Raf family (A-RAF, B-RAF, C-RAF) and then, 
through MEK1/2 and ERK1/2, the signal reaches the nucleus and cellular response to 
the initial stimulus is achieved.
A scheme of the reaction is shown in figure 1.3.1
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Figure 1.3.1 Schematic representation of MAPK pathway, where RET, RAS and B-RAF are 
often altered in papillary thyroid carcinoma. Mutations in these genes are mutually exclusive.
In PTCs, genetic alterations occurring in the effectors of the MAPK signaling pathway 
are mutually exclusive, thus suggesting that the proteins work in tandem along one 
common signaling cascade and mutations at more than one site do not provide an 
advantage to cells. RET, NTRK1, RAS and BRAF gene mutations are the most common 
events in PTC. RET and NTRK1 genes encode for dysregulated RTKs that are 
constitutively activated in PTCs following chromosomal translocation resulting in the 
generation of fusion proteins. Ras protein is altered in numerous human cancers, 
including pancreatic, colorectal and lung cancer, and melanoma with point mutations 
prevalently occur at codons 12, 13 and 61. Finally, B-Raf is a serine/threonine protein
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kinase in which the substitution of valine 600 with glutamate, due a single nucleotide 
transversion, leads to hyperactivation.
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1.3.1 Aberrations in RET  gene
1.3.1.1 Translocation
Chromosomal translocation is the most important genetic alteration, involving RET  
gene.
Before translocation After translocation
Figure 1.3.2 Schematic representation o f  chromosomal translocation.
Translocation (Figure 1.3.1) is a chromosomal alteration in which chromosome 
fragments change their position and as a consequence, genetic sequences, normally 
distant, are juxtaposed. If the position change involves only one chromosome, 
intrachromosomal translocation is achieved. Conversely, when two chromosomes are 
involved, an interchromosomal translocation occurs. In this case, genetic material can 
move from one chromosome to the other or portions of both chromosomes can invert 
their position. During translocation, genetic information are never lost; by contrast, as a 
consequence of this juxtaposition, new genes are generated and new proteins are 
expressed, termed fusion proteins.
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In papillary thyroid carcinomas several fusion proteins encoded by RET gene fused with 
different partner genes are detected. RET (rearranged during transfection) gene encodes 
for a receptor tyrosine kinase. The extracellular portion contains four cadherin-like 
repeats, a calcium binding site, and a cysteine-rich domain important for the 
dimerization after ligand-induced stimulation, while the intracellular region contains 
typical tyrosine kinase domain. RET protein forms a cell-surface protein complex with 
glycosylphosphatidylinositol (GPI)- anchored co-receptors, designated GDNF family 
receptor alpha (GFRa), that recognize the glial cell-derived neurotrophic factor family 
members (GDNF, persephin, artemin, neurturin). When the ligand binds the complex 
RET- GFRa, dimerization and activation RET occurs. Some tyrosines (e.g. Y1015 or 
Y1062), crucial for signal transduction, are then phosphorylated with the activation of 
downstream signalling cascade. During embryogenesis the activation of RET by GDNF 
is essential for the development of the sympathetic, parasympathetic and enteric nervous 
system and the kidney, as well as for the differentiation of spermatogonia [29]. 
Expression of RET is also found in central motor, dopamine and noradrenaline neurons 
and its function is strictly regulated and limited in embryonic life.
In contrast, RET fusion partners are normally ubiquitously expressed. Thus, RET/PTC 
rearrangements result in the aberrant expression of RET fusion proteins in thyroid cells 
in childhood and adults, where deregulation of the tyrosine kinase domain can lead to 
the generation of tumours.
The most common rearrangements at locus lOql 1.2 generate RET/PTC 1 and RET/PTC3 
oncogenes, in which the sequence encoding the kinase domain of RET is fused with the 
sequence for the amino terminal region of H4/D10S170 and EleI/ARA70 (also 
designated as RET-fused gene, RFG), respectively. Recently, H4/D10S170 has been 
characterized as a pro-apoptotic protein that loses its regulative domains during the
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fusion [30, 31], whereas Elel is a transcriptional co-activator and appears to inhibit the 
peroxisome proliferator-activated receptor gamma (PPARy) steroid hormone receptor 
that also exerts pro-apoptotic function [32]. At present, it is unclear whether the loss of 
these pro-apoptotic functions executed by H4/D10S170 and Elel could contribute to 
tumorigenesis in thyroid cells.
Other genes have been identified as involved in the rearrangement at locus 10qll.2, 
such as GOLGA5 (also known as golgin84 or RFG5), generating the RET/PTC5 fusion; 
human transcriptional intermediary factor 1 (HTIF1) gene for RET/PTC6; RFG7 gene 
for RET/PTC7; RFG9 gene for RET/PTC9; the glutamic-leucine-lysine-serine-rich 
protein (ELKS) gene causes the ELKS/RET rearrangement; finally, the pericentriolar 
material 1 (PCM1) and the RET finger protein (RFP) genes give rise to the PCM/RET 
and RFP/RET fusions [33].
1.3.1.2 Mechanism of constitutive activation
The RET/PTC2 fusion contains a portion of the regulatory subunit of the PKA 
serine/threonine kinase (RIa). RIa exists in native form as a dimer of two subunits 
whose interaction could be stabilized by interchain disulfide bonds. The sequence 
involved in the rearrangement with RET gene retains the information to code for the 
cysteines, providing the redox environment necessary to form these disulfide bridges 
[34]. In accordance with the general model of the activation of tyrosine kinase 
membrane receptors, RET/PTC2 dimerization could explain the observed constitutive 
tyrosine phosphorylation of this protein. Indeed, all fusion proteins provide an interface 
of dimerization, essential to obtain the constitutive activation of the kinase domain of 
RET. For example, in RET/PTC8, the translocated amino termini of Kinectin fused to 
RET could be folded in coiled coils that facilitate the protein-protein interaction.
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Kinectin is a cytoplasmic-oriented vescicle membrane anchored protein that interacts 
with the molecular motor kinesin, promoting kinesin-dependent organelle movement 
along the microtubules. The two leucine zipper motifs present in the Kinectin sequence 
are juxtaposed to the TK domain of RET and are responsible for the ligand-independent 
activation of the RET TK domain and for its ectopic expression [35].
Furthermore, the subcellullar localisation of the partner proteins could result in the 
relocation of the RET fusion proteins to the cytoplasm (rather than the cell surface) thus 
while preventing the interaction of RET with its usual signal transducers, would allow 
the phosphorylation of other substrates.
1.3.1.3 Oncogenic pathways
The mechanisms by which RET/PTC fusion proteins trigger cellular transformation are 
only partly known. RET/PTC oncoproteins can activate diverse signalling pathways 
including the PI3-K/AKT [36, 37], RAS/ERK [38, 39] and PLC-y [40] pathways. The 
activation of these pathways has been shown to be important for RET/PTC induced cell 
transformation. For example, RET/PTC2 mutants unable to activate the PLC-y pathway 
or bind to the adaptor molecule SHC, important for the activation of the PI3-K/AKT 
and RAS/ERK pathways, displayed drastically reduced transforming ability in NIH3T3 
cells [40-42]. In the case of RET/PTC1 it has been recently demonstrated that PI-3K 
pathway is activated by the constitutive interaction between RET/PTC and RAI, a 
member of She family and GAB1, promoting the phosphorylation of the downstream 
effector Akt [37]. Finally, RET directly phosphorylates tyrosine residues of FAK, 
ERK1/2, DOK1, the p85 subunit of PI-3K, JNK 1 and 2, p38, and PLC-y. These data 
indicate a direct interaction between RET and a broad range of effector molecules that 
may contribute to tumor pathogenesis [43].
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The detection of RET/PTC expression by immunohistochemistry and RT-PCR in occult 
PTCs provides evidence that RET-PTC fusion proteins expression is an early event in 
papillary thyroid carcinoma genesis [44]. Two different animal models for PTC have 
been generated to confirm this role of RET in thyroid malignancies. In the first case, 
two lines of transgenic mice expressing RET/PTC 1 oncogene in the thyroid gland were 
produced. Thyroid disease with cellular features comparable to human papillary thyroid 
cancers arose after one month of age in all animals. This finding indicates that 
RET/PTC1 is not only a biomarker associated with PTC but also the only proven 
specific event leading to the development of papillary thyroid carcinoma [45]. The same 
results have been obtained from the animals transgenic for RET/PTC3. Again, transgene 
expression was controlled by thyroglobulin promoter, that guarantees an organ-specific 
expression in murine thyroid. These transgenic mice developed thyroid hyperplasia and 
solid tumour variants of papillary thyroid carcinoma with metastatic spread, similar to 
those as observed in human cases of thyroid carcinomas in children expressing 
RET/PTC3. The fact that these tumours are reportedly more invasive than other 
papillary thyroid carcinomas suggests that RET/PTC3 fusion protein confers this 
increased malignant phenotype in transformed thyroid cells: the transgenic mice provide 
an ideal model system to study the genes that distinguish the variants of papillary 
thyroid carcinoma as well as the pathways controlling follicular cell differentiation [46]. 
In conclusion, tumour development in RET/PTC transgenic mice provides support for 
the theory that thyroid specific fusion proteins can initiate malignant transformation of 
thyroid follicular epithelium.
Inhibition of the constitutive activity of RET could be a way to block the development 
of thyroid cancer: the demonstration that the expression of oncogenic variants alone is 
sufficient to transform NIH3T3 fibroblasts indicates how RET accounts for multiple
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mechanisms leading to the transformed phenotype, thus making it a potential 
therapeutic target [47, 48]. The presence of the same portion of RET in all fusion 
proteins implies that the same drug may be used against all RET/PTC oncoproteins.
1.3.1.4 Small molecule inhibitors of RET
In recent years, numerous small molecule compounds, developed as inhibitors of other 
kinase targets, have been identified as RET inhibitors. These compounds belong to 
different chemical classes: pyrazolo-pyrimidines (PP1, PP2), aniloquinazolines 
(ZD6474), indolocarbazoles (CEP-701, CEP-751), the 2-indolinones (RPI).
PP1 (4-amino-l-ter/-butyl-3-(p-methylphenyl) pyrazolo[3,4-d]pyrimidine) and PP2 (4- 
amino-5-(4-chlorophenyl)-7-(t-butyl) pyrazolo[3,4-d]pyrimidine) have been described 
as selective Src family kinase inhibitors [49].
n h 2n h.
HjC
PP2 PP1
However, these compounds are also active against other kinases including RET. In in 
vitro kinase assays, PP1 and PP2 have been shown to have IC50 values of approximately 
50 nM and 100 nM, respectively [50-52]. PP1 and PP2 inhibited cell growth of NIH3T3 
cells transformed with RET/PTC3 of RET/PTC1, as well as the human PTC cell lines, 
TPC-1 and FB2, expressing RET/PTC1 [50, 51]. Moreover, PP1 was effective in
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reducing tumour size in nude mice that had been injected with NIH3T3-RET/PTC3 
cells.
Crystallographic and mutational studies have allowed an insight into the structural basis 
for the specificity of pyrazolo-pyrimidines. The crystal structure of PP1 bound to Hck 
revealed that the methylphenyl group inserts into the selectivity pocket adjacent to the 
ATP binding site [49]. In addition, the gatekeeper residue has been identified by 
mutational analysis, as a critical structural determinant controlling the binding of PP1 to 
kinases. Src-family kinases contain a small threonine residue at the gatekeeper position, 
explaining their sensitivity to PP1 [53]. The presence of a large gatekeeper residue was 
associated with a decreased potency of PP1, while kinases with small residues were 
more sensitive to PP1 inhibition. RET possesses a valine residue at the gatekeeper 
position (aa 804 of full length RET), which is small enough to allow pyrazolo- 
pyrimidine compounds to bind. Indeed, when valine 804 is substituted with a 
methionine or leucine, RET becomes resistant to PP1 and PP2 [54]. These RET 
gatekeeper mutations (V804M or V804L) have been identified in some patients affected 
by sporadic and familial medullary thyroid carcinoma (MTC) [54] and will certainly be 
relevant in deciding treatment regimes in the future, given the correlation between large 
gatekeeper residues and inhibitor resistance [55]. As pyrazolo-pyrimidine compounds 
are not specific for RET it is possible that the clinical application of these compounds 
may generate unwanted side-effects. However, it is also possible that selectivity profile 
of these compounds could be advantageous in terms of hitting multiple signal 
transduction pathways involved in tumour formation. For example, the inhibition of 
PDGFR and c-Src could prevent vascular remodelling and restenosis controlled by these 
kinases, respectively [56].
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ZD6474 ([N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(l-methylpiperidin-4-
yl)methoxy]-quinazolin-4-amine) is a selective inhibitor of the VEGFR and EGFR 
tyrosine kinases [57].
In preclinical studies, ZD6474 has been shown to inhibit VEGF-dependent tumour 
angiogenesis and EGFR-dependent tumour cell growth and survival in numerous solid 
tumour model systems [58-60], The targeting of two key tumour-promoting pathways 
by a single agent has stimulated much interest in ZD6474. In phase I clinical trials, 
ZD6474 demonstrated low toxicity and good oral bioavailability [61]. Phase II clinical 
trials are ongoing to assess the efficacy of ZD6474 as a monotherapy or in combination 
with certain chemotherapies for the treatment of non small cell lung cancer and 
metastatic breast carcinoma [62, 63]. ZD6474 has also been demonstrated to inhibit 
RET, with an IC50 of 100 nM in an in vitro kinase assay [64], Five micromolar ZD6474 
completely arrested growth of RET/PTC transformed cells after 24h of treatment. Cell 
cycle analysis showed that ZD6474 caused an increase in the G0 G 1 and sub-Gj 
fractions, indicating an arrest in Gi and pro-apoptotic activity. In nude mice injected 
with NIH3T3-RET/PTC3 cells, the daily treatment with 1 mg of ZD6474 completely 
arrested tumour development [64]. In addition, ZD6474 has recently been shown to be 
effective at inhibiting oncogenic forms of RET in an in vivo Drosophila model system 
[65]. These data indicate that ZD6474 may be an effective treatment for RET-dependent 
carcinomas and clinical trials are merited. As with PP1 and PP2, mutation of the
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gatekeeper residue desensitizes RET to ZD6474, presenting a possible mechanism for 
the development of resistance [54]. However, the activity of ZD6474 on multiple 
tumour-promoting pathways, may reduce this risk.
CEP-701 and CEP-751 are synthetic derivatives of the indolocarbazole K252a.
These compounds showed inhibitory activity on RET in an autophosphorylation assay 
with an IC50 of 50 nM, and in a proliferation assay obtaining complete growth cessation 
and significant cell loss at 100 nM [66]. Cell cycle analysis indicated that CEP-701 and 
CEP-751 arrested cell growth without inducing apoptosis. In nude mice bearing 
subcutaneous MTC cell xenografts only CEP-751 and its pro-drug CEP-2563 
suppressed tumour growth, while CEP-701 was ineffective. CEP-2563 has undergone 
phase I clinical trials as monotherapy in patients with refractory solid tumours and 
showed an acceptable toxicity profile [67]. CEP-701 has also been used as a 
monotherapy to treat refractory AML expressing activating FLT3 mutations [68]. 
Recent evidence has pointed to the potential value of these compounds in combination 
therapy. CEP-751 augmented the anti-tumour activity of Irinotecan, a topoisomerase I 
poison, in a pre-clinical model of MTC [69]. It will be interesting to see if 
indolocarbazoles have clinical efficacy against PTC harbouring RET fusion tyrosine 
kinases.
The 2-indolinone derivatives were the first small molecules identified as selective RET 
inhibitors [70]. In particular, RPI-1 (l,3-dihydro-5,6-diemthoxy-3-[(4-
HN
'-OH
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hydroxyphenyl)methylene)-2H-indol-2-one) inhibited cell proliferation and reverted the 
transformed phenotype in cells expressing RET/PTCl [70, 71]. RPI-1 induced an 
accumulation of cells at the G2-phase of the cell cycle that was mediated by the cyclin- 
dependent kinase inhibitor, p21WAFl, and related to a decrease in activation of AKT 
and JNK2 [72]. This cellular response was controlled by the decrease in 
phosphorylation of the multifunctional docking site Tyrl062, and SHC binding [41, 73]. 
RPI-1 has been identified as a reversible, ATP competitive kinase inhibitor by 
biochemical studies, which is supported by the findings of structural studies of another
2-indolinone derivative complexed with FGFR-1 [17].
1.3.2 Aberrations in NTRK gene
The second gene involved in papillary thyroid carcinogenesis is TRK gene that encodes 
for nerve growth factor receptor. As occurs for RET gene, the main genetic aberration is 
translocation.
Indeed, the TRK family of oncogenes results from a genetic fusion of the 3’ end of 
NTRK1 to the 5’ end of different partner genes. A paracentric inversion of chromosome 
1 joins the 5’ end of the gene coding for tropomyosin to NTRK1 [74]. Similarly, TRK- 
T1 results from the paracentric inversion of chromosome 1 joining the 5’ end of TPR to 
the 3’ end of NTRK1. Different rearrangements involving these same two genes 
generate TRK-T2 and TRK-T4, while TRK-T3 results from the translocation of 
chromosomes 1 and 3 that fuses the genes TFG (TRK fused gene) and NTRK [75-77]. 
NTRK1- related translocations are found less frequently than the rearrangements that 
involve RET gene, with a reported incidence of 0-12% in patients with PTC [78]. 
Although the NTRK1 protein is known to function as a receptor for nerve growth factor, 
little is understood about its pathological role in the genesis of human papillary thyroid
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carcinoma. Some evidences suggest that it may be important for cancer development in 
a manner analogous to RET/PTC. In vitro, the TRK-T1 oncogene transforms NIH3T3 
cells, even if it’s unable to promote growth in soft agar or nude mice when it was 
transfected into rat epithelial thyroid cell line PC C l3 [79]. Transgenic mice encoding 
the human TRK-T1 have been generated: the oncogene was expressed under control of 
thyroglobulin promoter to obtain a tissue targeted expression. The development of 
differentiated carcinomas in these mice supports a direct role for TRK-T1 in the thyroid 
tumorigenesis [80].
1.3.3 Aberrations in R A S  gene
RAS genes code for the members of a super-family of ubiquitously expressed signal 
transduction intermediates that are crucial for cell growth and differentiation. Four 
mammalian RAS proteins (H-RAS, N-RAS, K-RASA/B) are guanine nucleotide 
binding proteins with intrinsic low level GTPase activity, which transduce signals 
generated by activation of growth factor plasma membrane receptors or G protein- 
coupled receptors to downstream effector pathways. Many cellular responses to RAS 
are transduced through ERK MAPKs pathway, resulting from sequential activation of 
RAF, MEK and p42-44 MAPK. Moreover, RAS can also activate the PI3K pathway, 
JUN N-terminal kinase (JUNK) and p38 kinase.
RAS is frequently mutated in tumours. Point mutations affecting the guanosine 
triphosphate GTP binding domain (codons 12/13) or GTPase domain (codon 61) 
determine the substitution of specific amino acid residues that lock p21RAS in the 
active GTP bound form by decreasing GTP hydrolysis rate or enhancing the GTP 
binding affinity [81]. Despite of the large number of studies on RAS oncogene, the 
mechanisms by which hyperactive RAS causes cell transformation are not well
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understood yet: mutated RAS is not sufficient alone to induce transformation and 
secondary events, such as gene amplification, are required.
A possible explanation of its role in the cancerogenesis could be that RAS mutations 
may predispose cells to accumulate other genetic abnormalities. Indeed, RAS over­
expression has been observed to generate genetic instability and chromosomal 
aberrations in several cell lines, for instance rat mammary carcinoma cells, rat prostatic 
tumour cells and in PCCL3 rat thyroid cells [82].
PCCL3 cells are derived from rat thyroid follicular cells and are dependent on TSH for 
growth; they also retain differentiated properties as they trap iodide, express 
thyroglobulin, thyroid peroxidase and the TSH receptor in TSH dependent manner. 
Saavedra et al. [82] set up a conditional system to express HRASV12 under control of 
tetracycline to analyse RAS contribution in genetic instability. To compare RAS activity 
with other effectors, also MEK1, RET/PTC1, RET/PTC3 and RAC1V12 were stably 
transfected in PCCL3 cells. Over-acute expression of RAS causes formation of 
micronuclei (small nuclear-like structures which contain chromosomes or chromosome 
fragments that arise during mitosis as result of chromosomal missegregation). This 
process was mediated by MAPK pathway activation because the induction of MEK1 
expression results in an increased number of micronuclei, while RAC 1V12 which signals 
through SEK-JNK or SEK-p38MAPk had no effects. Acute expression of RET fusion 
protein did not induce micronucleation, either. Micronuclei are generally believed to 
form either by disruption of the mitotic spindle, leading to the loss of a whole 
chromosome (aneugenic event) or by induction of double strand DNA breaks with loss 
of a portion of the chromosome (clastogenic event). RAS induces micronuleation with 
both mechanisms, suggesting that the development of chromosomal abnormalities 
occurs within the first few cell cycles after activation. In conclusion, this study
37
Molecular alterations in PTCs
demonstrated that RAS mutations predispose thyrocytes to large scale genomic 
abnormalities, promoting a transformed phenotype.
In thyroid, activating RAS mutations have been identified in benign neoplasms but are 
more prevalent in malignant follicular tumours and are often associated to poorly 
differentiated phenotype [28]. Although this point is still controversial, some 
experimental evidence demonstrate that RAS could play an important role in the 
dedifferentiation process in tumoral cells, for example, by suppressing thyroid-specific 
gene expression. Missero and co-workers [83] showed that the activation of RAF-MEK- 
ERK by RAS inhibits TTF-1 transcriptional activity, through direct TTF-1 
phosphorylation by ERK observed both in vitro and in vivo, while the other well 
characterized signal pathways, such as PI3K, RAL GDS, Rac, Rho pathways were not 
effective. TTF-1 is a transcription factor that belongs to the Nkx-2 class of 
homeodomain-containing proteins that function as regulator of regional specification, 
cell fate determination and organ morphogenesis during embryonic development. In 
adults, TTF-1 positively controls thyroglobulin (Tg), thyroperoxidase (TPO), thyroid- 
stimulating hormone receptor and sodium-iodide simporter (NIS). Rat thyroid cell line 
FTRL5 was transfected with thyroid-specific promoters driving the expression of CAT 
reporter gene and with a plasmid expressing oncogenic forms of RAS. The authors [83] 
used V12-RAS and other mutant forms to measure the TTF-1 transcriptional activity 
inhibition to identify which signalling pathway is mainly involved in TTF-1 inhibition. 
They observed that only V12S35 RAS mutant, that signals through RAF-MEK-ERK 
blocks significantly TTF-1 transcriptional activity. The confirmation of these results 
was achieved using RAF BxB, a constitutively activated form of RAF capable of strong 
activation of ERK, obtaining an arrest of TTF-1, and MEK inhibitors, such as PD98059 
and U0126, partially restoring TTF-1 activity. Furthermore, they identified a mutant
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unable to activate ERK but able to interfere with TTF-1 activity, suggesting that also a 
RAF-independent pathway participates in repression of thyroid specific gene 
transcription.
1.3.4 Aberrations in B-RAF  gene
RAF protein family is constituted by three proteins A-RAF, B-RAF and C-RAF that 
share a common architecture with three conserved regions: CR (Conserved Region) 1 
and 2 at the N-terminal and CR3 in the kinase domain. RAF proteins are serine 
threonine kinases important in MAPK signalling because they are directly activated by 
RAS and phosphorylate MEK. The main differences between these three proteins are 
related to distribution in human tissues and to the regulation mechanism. Therefore, A- 
RAF is expressed in urogenital organs, while B-RAF is produced in two forms with 
alternative splicing in neuronal tissue and C-RAF is ubiquitously expressed.
C-RAF has six important phosphorylation sites: Ser 259 and Ser 621 are involved in 14-
3-3 protein binding when RAF is phosphorylated in Ser 259 and avoids the interaction 
with RAS. When RAS-RAF-MAPK pathway must be activated, PP2A protein 
phosphatase A removes phosphate group from Ser 259, 14-3-3 protein leaves RAF that 
is recruited to the plasma membrane by RAS. In the N-terminal region, phosphorylation 
at the Ser 338 and Tyr 341 (essential for the catalytic activity, as well as 
phosphorylation in Ser 494 and Thr 491 in the activation segment) determines the 
activation of C-RAF, by disrupting the interaction between the activation segment and 
the glycine rich region. In B-RAF protein the most important phosphorylation site is 
represented by Ser 445, while the presence of aspartate 448, negatively charged, 
increases twelve fold the activity of B-RAF compared to that of C-RAF [84].
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Crystal structures of wild type B-RAF and V600E mutant in complex with BAY43- 
9006 have been analysed: both forms adopt similar conformation in the presence of the 
inhibitor that spans the length of interfacial cleft between N and C-lobes. Numerous 
interactions, described as follows, stabilize the binding of BAY43-9006 to B-RAF: the 
distal pyridyl ring occupies the ATP binding pocket, interacting with three aromatic 
amino acids in hinge region, P loop and DFG motif; the lipophilic trifluoromethyl 
phenyl ring inserts into a hydrophobic pocket constituted by aC and aE helices. The 
urea group forms two hydrogen bonds with the catalytic Glu 500 and Asp 593 in the 
DFG motif. A similar interaction was observed in Abl in complex with STI571 [15]. 
More generally, all structures of B-RAF resemble that of Abl in inactive conformation, 
because the position of N and C lobes, aC helix and DFG motif in the two proteins are 
super-imposable. BAY 43-9006 contributes to block B-RAF in the inactive 
conformation, in which inverted DFG motif orients the adjacent segment of activation 
loop towards the P-loop in N-lobe, while the amino acids between Gly 595 and Val 600 
constitute an array of hydrophobic interactions with the P-loop residues. While the 
activation segment and DFG motif remain in an unfavourable position to bind ATP, 
other amino acids crucial for the reaction in the catalytic sites are correctly positioned as 
in an active kinase. Therefore, only a change in DFG motif/ activation segment is 
required for the conversion to the active state [85].
B-RAF is frequently mutated in human cancers, including melanomas (30-60% of 
cases), colorectal cancer (5-20%) and papillary thyroid carcinoma (30-50% of cases). 
The most frequent alteration is a tranversion that substitutes thymidine nucleotide with 
adenine with the consequent change in amino acid sequence. Indeed, mutated B-RAF 
presents glutamate in 600 position instead of valine, causing constitutive activation.
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Structural studies have determined how different mutations deregulate the activity of B- 
RAF. In particular, three groups of mutants have been classified. The first comprises 
mutants with high activity in which V600E, K601E or G469A substitutions mimic the 
conformational changes induced by activation segment phosphorylation. The second 
group is represented by mutants with intermediate activity that have a sub optimal 
catalytic efficiency due to the interference of mutated amino acid during the interaction 
between P loop and phosphate group of ATP. Finally, in the third group of mutants, 
amino acids conserved in the catalytic site are lost and the activity is impaired [85].
The role of B-RAF in thyroid tumorigenesis has been studied in PCCL3 rat thyroid cell 
lines. Mitsutake et al [86] demonstrated that conditional BRAF V600E expression, 
under control of doxocyclin inducible system, decreases the dependence from 
thyrotropin for growth and impairs the synthesis of characteristic thyroid proteins such 
as sodium iodine simporter (NIS), thyroglobulin (Tg) and Pax8. As previously reported 
for RAS oncoprotein, BRAF also causes genetic instability, inducing micronuclei and 
mitotic bridge formation. This is in contrast to RET/PTC1 and RET/PTC 3 which do not 
generate such abnormalities. A possible explanation for this difference may be the 
different levels of MAPK activation induced by BRAF and RET/PTC. Activated ERK 
plays a direct role in chromosomal segregation and mitosis, and phosphorylation and 
de-phosphorylation steps are needed for orderly progression. The constitutive activation 
of MAPK by RAS or B-RAF mutants may disrupt one step and deregulates the entire 
process. RET/PTC evokes less intense ERK phosphorylation because it can signal 
through many other effectors, therefore genetic instability is less frequent in RET/PTC 
positive cells.
Two novel mutational events in B-RAF gene have recently been identified in papillary 
thyroid carcinoma cells: a chromosomal rearrangement encoding for 170KDa AKAP9-
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BRAF fusion protein and an insertion of three nucleotides named B-RAF599 ins. 
AKAP9-BRAF results from a paracentric inversion of chromosome 7 inv(7)(q21- 
22q34) since BRAF gene is located on chromosome 7q34 and AKAP9 (A-kinase anchor 
protein 9) on 7q21-q22. The wild-type AKAP9 is a protein capable of binding the type 
II regulatory subunit (RII) of protein kinase A as well as other signalling proteins, 
anchoring them to the centrosome and the Golgi apparatus; its localization is prevalently 
perinuclear. The AKAP9/BRAF fusion protein is, however, preferentially located in 
cytoplasm. As a result of the chromosomal inversion, B-RAF loses the regulatory 
conserved regions at the N-terminal and has 6-fold higher activity than wild type 
protein. Also its transforming ability, evaluated by NIH3T3 focus formation assay, is 
increased in comparison with wild type and V600E mutant. In vivo the tumorigenicity is 
confirmed by tumour growth in nude mice two weeks after the injection.
Similar to chromosomal alterations involving the RET gene, AKAP9-BRAF 
rearrangement is associated with a recent history of radiation exposure, confirming that 
paracentric inversion represents a common genetic mechanism of radiation- associated 
thyroid carcinogenesis [87]. In a 66 year old patient affected by PTC classical variant, a 
heterozigous in-frame insertion (GTT) has been identified at position 1795, predicting 
the insertion of a valine residue in position 599. B-RAF V599 ins has been 
biochemically characterized with kinase assay and focus assay in NIH3T3 cells to 
evaluate its transforming ability. B-RAF V599 ins showed similar catalytic activity on 
MEK phosphorylation to B-RAF V600E and higher than that of wild-type B-RAF. In 
focus formation assay, a significant number of transformation foci grew in plates of 
NIH3T3 cells transfected with B-RAF V599 ins and B-RAF V600E. These results 
confirmed that B-RAF V599 ins mutation confers to the protein a gain of function that 
determines deregulated activity. This alteration has been reported both in PTCs and in
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non thyroidal tumours. It is a rare event because it requires a nucleotide triplet insertion 
exactly between two codons, an event statistically far less probable than a simple base 
substitution [88].
1.3.5 Minor genetic alterations in PTCs
Other genetic alterations have been identified in papillary thyroid carcinoma.
MET protein is a transmembrane receptor with tyrosine kinase activity, its ligand 
HGF/SF is a powerful mitogen for epithelial cells. MET is frequently overexpressed in 
human cancers, including PTC. Increased transcription of the MET gene is modulated 
by RET and RAS in primary tumors and is frequently associated with tissue hypoxia, an 
event often more pronounced at the tumor periphery. The clinico-pathologic 
consequence of elevated MET expression is unclear at present [89, 90].
Phosphatase and tensin homolog (PTEN) is a tumor suppressor gene mapped at 
chromosome 10q22-23. PTEN is a protein phosphatase and exerts its tumor suppressor 
effect by antagonizing TK activity, through PI3K and the AKT/ PKB pathways. 
Hemizygous deletions have been found in 10-20% of adenomas and carcinomas, but 
rarely in PTCs [91].
1.4 Correlation between genetic alterations and clinical 
behaviour of the tumour
Several studies have been performed in order to relate genetic mutations in RET, RAS
and B-RAF genes to clinical behaviour of the tumour. Results were not exhaustive but
there was a general agreement of an association of the RAS and B-RAF mutations to a
less differentiated phenotype and poor prognosis.
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To this aim, Adeniran et al [92] analysed 97 samples of papillary thyroid carcinoma 
carrying RET/PTC, RAS and B-RAF mutations. They performed morphologic 
assessments scoring nine microscopic features, namely, nuclear enlargement, 
irregularity of nuclear contour, chromatin clearing, nuclear overlapping, nuclear 
grooves, nuclear pseudoinclusions, tumour fibrosis, psammona bodies and 
inflammatory response. The study confirmed the presence of mutations previously 
reported in the literature {B-RAF 42%, RET/PTC 18%, RAS 15%, no mutation 25%) and 
the absence of overlap between these mutations.
There were, however, correlations between specific mutations and clinicopathologic 
features. B-RAF mutations occurred in tumours of older patients who generally had 
stage III and IV of the disease, while RET/PTC was mainly present in younger people. 
RAS mutation was prevalent in females and generated tumour of larger size. Moreover, 
among all papillary carcinomas, the majority was represented by classic variant with 
RET/PTC and B-RAF mutations, while RAS-positive tumours were all follicular 
variant, 6% with only B-RAF alteration was tall variant, an aggressive form of PTC. The 
frequency of extra-thyroidal extensions was significantly higher in B-RAF positive 
tumours, RET/PTC showed lymph node metastasis. Significant differences in the 
occurrence of microscopic features were found between the groups of papillary thyroid 
carcinoma. RAS-positive tumours had low prevalence of all microscopic features, while 
in RET/PTC tumours they were more frequent. Tumours with B-RAF mutations showed 
a high level of chronic inflammation. Summarizing this work, B-RAF mutations, 
normally found at all levels of progression from microcarcinomas to poorly 
differentiated PTCs, could be associated with an aggressive phenotype and the advanced 
stage of disease. RET/PTC is more common in pediatric patients, often with external 
radiation history, and even if it is significantly associated with lymph node metastasis,
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most of these neoplasms are stage I or II, indicative of a good prognosis. Finally, RAS 
tumors are prevalently of the follicular variant and their genotype is closer to those of 
follicular thyroid carcinoma. Their stage at presentation is intermediate between the 
more advanced B-RAF positive tumors and mostly early stages of tumors harboring 
RET/PTC.
Another interesting group of studies published in 2004 tried to identify the major 
mutational events occurring in the Chernobyl area, following the nuclear accident, to 
clarify the role of external radiation in thyroid tumorigenesis in both children and adults. 
A lower frequency of B-RAF mutations (12%) has been observed in children than in 
adults, and 41% of these tumors carried RET/PTC rearrangements. This could reflect 
the nature of the aetiological agent since ionizing radiation is particularly effective in 
inducing DNA double-strand breaks rather than point mutations. The presence of B- 
RAF positive cases could, however, represent a normal background incidence since it is 
usually rare in sporadic childhood carcinoma, although the major event in adult. 
Therefore, it is possible that the route to thyroid carcinogenesis involving a B-RAF 
mutation may have a longer latency period than that involving chromosomal 
rearrangement. Additional long-term studies are necessary to obtain more information 
on this aspect [93]. Another subset of young patient samples has been detected with 
FISH procedure [94] to verify the distribution of RET/PTC positive cells in tumours. 
FISH (Fluorescence in situ hybridization) was performed using yeast artificial 
chromosome (YAC) DNA probes, specific for a sequence in RET gene and a distal 
sequence; both probes are labelled with digoxigenin-ll-dUTP and biotin-16-dUTP that 
gives red green signal at confocal laser scanning microscope. Cell nuclei exhibiting a 
rearranged RET gene showed a split FISH signal in red and green in addition to an
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overlapping signal, whereas normal cells showed two overlapping signals. Seventy two 
percent of 32 post-Chernobyl cases showed RET rearrangement in some of the tumour 
cells. Statistical analysis confirmed a non-homogeneous distribution with subclones of 
tumour cells with or without any RET rearrangement. This observed genetic 
heterogeneity in RET/PTC alteration can be explained in two different ways: either 
RET/PTC rearrangement was the first event and new clones emerged later, or RET/PTC 
rearrangement is a late event in radiation-induced thyroid carcinogenesis. The majority 
of PTCS harbour clones of cells with a RET rearrangement, indicating that RET is 
crucial for the generation and maintenance of the tumour, perhaps through paracrine 
interaction with negative cells.
To further validate that RET/PTC rearrangement is the major event in childhood thyroid 
carcinoma, [95] demonstrated that the percentage of B-RAF positive childhood thyroid 
carcinoma was low both in non-Chernobyl area (Japan 3.4%) and in Ukraine (0%). 
These percentages are lower than those of adulthood PTC where B-RAF mutations are 
detected in 30-50% of cases. By contrast, RET/PTC rearrangement occurred in 35% of 
cases in Ukrainian population and in 3.2% in Japanese children. One case with B-RAF 
transversion presented typical characteristics of poorly differentiated follicular 
carcinoma, that could be likely considered a progression of papillary carcinoma to a 
more dedifferentiated status. Consistent with this result, other data reported in literature 
confirmed that poorly differentiated and anaplastic carcinomas with B-RAF mutation 
can arise from well differentiated papillary carcinoma [96].
In conclusion, RET/PTC rearrangement is the most important mutational event in 
childhood carcinoma and is frequently associated to radiation exposure, while B-RAF 
transversion is prevalently present in adult patients and often causes dedifferentiated 
status.
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The investigation of B-Raf mutation in primary tumours and in matched lymph nodes 
metastases revealed that B-RAF mutation was present in all metastases but only in 62% 
of primary tumours. Possible explanations include PTC multicentricity or because the 
primary lesion that had B-RAF mutation was too small to be identified in SSCP (Single 
strand conformational polymorphism) at the RNA level. Interestingly, a new mutation 
was found in 3/8 metastases, originating from a deletion of three nucleotides with the 
consequent loss of Lysine (K) in position 601 while preserving the B-RAF V600E 
substitution and the translation frame. This new mutation may be seen as a cumulative 
additional secondary genetic event crucial for cells to acquire metastatic ability in some 
circumstances. Therefore, B-RAF mutation is frequently present in lymph nodes 
metastases, supporting the correlation between B-RAF 1799 T-A transversion and more 
advanced clinical stage and aggressive tumour behaviour [97].
As with the B-RAF transversion, RAS mutations are in general associated with 
histological features and clinicopathologic parameters indicative of aggressive 
behaviour, reflecting the strong link between RAS mutations and poorly or 
undifferentiated thyroid tumours, as demonstrated by Garcia-Rostan et al. [98]. In their 
study, RAS mutations were present in 8.2% of well differentiated carcinomas -both 
papillary and follicular variants- in 55.2% of poorly differentiated carcinomas and 
51.7% of undifferentiated carcinoma, thus supporting a significant prevalence in less 
differentiated phenotypes. By contrast, no association was observed between RAS 
mutation and morphological features or sex and age or presence of lymph modes 
metastases, as reported in other papers [99].
RAS mutational status was strongly correlated with tumour related death, indicating that 
RAS mutation analysis may provide a tool to identify those thyroid tumours which, 
apart from fatal but rare undifferentiated carcinoma, could be associated with patient
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death. Therefore, treatment of RAS-positive thyroid cancer with therapeutic agents that 
target RAS, such as famesyl transferase inhibitors, could be of benefit to patients with 
poorly differentiated and undifferentiated carcinoma.
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2 AIM OF THE THESIS
2.1 Analysis and inhibition of RET-dependent signalling
As previously described, a large part of mutations found in PTCs patients lead to 
hyperactivation of protein kinases, such as RET or B-RAF proteins. The aim of this 
PhD project is to analyse the RET-dependent signalling pathway and to block it with 
small molecule inhibitors, thus promoting innovative approaches to cure PTC. The 
success of STI571 (Imatinib) in chronic myeloid leukaemia and ZD 1839 (Gefltinib) in 
non- small cell lung cancer to block aberrant tyrosine kinases, provide a paradigm to 
study the application of targeted treatment to thyroid cancer, that is prevalently related 
to a single gene alteration.
The usual way to identify new lead compounds is to test a large number of chemical 
entities against the target in a simple and time-saving assay to select molecules active at 
submicromolar concentrations, that could be further modified to improve their 
biochemical characteristics, such as specificity, selectivity, solubility. This random 
approach can be rationalized when a computational model of the protein is available to 
enable the analysis of simulated binding between the target protein and potential 
inhibitors. In this model, libraries can be virtually screened and only the best fitting 
molecules will be tested in biological assays. If the in vitro assay confirms the results 
obtained by molecular modelling, modifications can be introduced, firstly at the virtual 
level and then chemically to improve the binding to the protein. Once a promising 
compound(s) has been identified that inhibits kinase activity at a submicromolar range 
and induces cell cycle arrest or apoptosis in appropriate cellular systems, further 
validation can then be performed in animal models to evaluate its activity in vivo in 
more complex system.
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To successfully identify an active and selective inhibitor, a good structural model and a 
reproducible assay is essential.
2.2 Outline of proposed project
In the absence of a three-dimensional structure of RET, other kinase domains were used 
as templates for a RET model calculation. RET model was produced in the laboratory 
led by Prof. Leonardo Scapozza at the University of Geneve and was based on the 
structural characteristics of Abl kinase domain in the inactive conformation and IRK 
kinase domain in active conformation.
The first goal of this project was to determine the three-dimensional structure of RET 
catalytic domain and obtain detailed knowledge of the target molecule. The expression 
system and purification procedure was then optimised to produce high amount of 
recombinant protein to perform biochemical characterization and crystallization 
attempts.
At the same time, using virtual modelling, members of the 2-indolinone derivatives 
family were screened. Results were confirmed using in vitro assays and the biological 
and pharmacological properties of submicromolar amounts of inhibitor were 
investigated. Although several small molecule inhibitors have been reported in literature 
as active on RET, the advantage of studying 2-indolinone derivatives is related to wide 
knowledge of this chemical class and to clinical trials in fieri in numerous solid 
tumours. Since the pharmacological parameters have already been set, once it has been 
demonstrated that an indolinone compound represents an effective blocker of RET, then 
they could be rapidly administrated to RET-positive PTC patients. Since B-RAF 
hyperactivation leads to transformation of thyroid cells, we also used siRNA technology 
to investigate whether B-RAF represented a target for selective treatment and, if so, test
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a new inhibitor that showed activity in B-RAF positive melanoma cell lines, in B-RAF 
and RET/PTC thyroid models. Blocking RAF activity may be a logical site to interfere 
with the effects also of RET/PTC and RAS oncoproteins in thyroid cells.
Characterization of RET catalytic  dom ain
3 RESULT
3.1 Expression, purification and characterization of RET 
catalytic domain
3.1.1 Introduction
In the first part of my PhD project, I expressed the catalytic domain of RET in 
Baculovirus, then purified and characterized it using conventional biochemical 
techniques. The goal was the production of a suitable reagent with which to start 
crystallization analyses and use in inhibitor screening. The biochemical characterization 
of rRET is essential to verify its enzymatic properties and physical state.
3.1.1.1 Baculovirus expression system
The Baculovims expression system provides a versatile and reliable system for the 
production of recombinant proteins in insect cells. Although many different viruses 
belong to the Baculovirus family, the most widely used is Autographa Califomica 
multiple capsid nucleopolyhedrovirus (AcMNPV) which can be propagated in 
Spodoptera Frugiperda (Sf), Trichoplusia Ni (Tn) insect cell lines.
Virus genes are expressed in early, late and very late phases of infection: the early and 
late genes are largely related to the production of viral particles which then bud from the 
infected cell thus spreading infection to other cells. The very late genes that encode for 
polyhedrin and plO are required for the production of the occlusion bodies containing 
the virus particle in the nucleus of the host cell. Both of these genes are under the
52
Characterization of RET catalytic  dom ain
control of strong promoter, but can be deleted from the virus genome without 
interfering with the production of infectious virus particles. As consequence, foreign 
genes can substitute the polyhedrin and plO  sequences to derive expression vector 
[100].
Several strategies have been followed to make recombinant Baculovirus. The first one 
used linearized viral DNA and removed the LacZ gene reporter and part of viral genome 
using restriction enzymes and the resulting recombinant viral particles were non 
infectious and could be recognized by plaque assay. The major difficulty, however, was 
to distinguish recombinant plaques from wild type [101]. The second attempt involved 
the direct ligation of foreign genes in a multiple cloning site ad hoc inserted in viral 
genome. In this case, high insertion efficiency was observed although specific 
infectivity of the virus was low [102]. Finally, an in vivo transposition method was 
developed in which a foreign gene was moved from a donor plasmid to a cloned 
Baculovirus DNA, such that the foreign gene was controlled by the polyhedrin 
promoter. Since E. Coli clones containing the recombinant Bacmid DNA acquired 
antibiotic resistance and lost a LacZ marker, they could be quickly selected and 
distinguished. Viral DNA was isolated from positive bacterial clones and used to 
transfect insect cells and produce recombinant virus. This method did not require any 
plaque assay for the selection of recombinant virus; however, the virus stock may be, 
nevertheless, polyclonal [103, 104].
The Bac’ N Blue system was used in the current study. In this system the transposition 
of the gene of interest from a donor plasmid to viral DNA occurs in vitro, and a plaque 
assay is necessary after the transfection in order to recognize recombinant viruses.
The advances in Baculovirus studies have permitted the development of this system to 
produce virion displays, (similar to bacterial phage displays), which can be screened
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against a complex library of molecules. Foreign proteins were inserted into the 
Baculovirus envelope fusion protein (GP67) at a site between the signal peptide and the 
mature protein and displayed on the virus particle surface [105].
An important limitation of Baculovirus-Sf9 expression system using insect cells is, 
however, their inability to produce the complex biantennary N-linked oligosaccaride 
sidechain(s) containing penultimate galactose and terminal sialic acid residues 
frequently present in cell surface proteins, and more, generally in mammalian proteins. 
A transgenic lepidopteran insect cell line was, therefore, set up to overcome the 
glycosylation problem: these cell lines were stably transfected with foreign gene 
encoding N-glycan processing activity. Baculovirus infection led to the production of 
protein of interest with terminally [3-galactosylated n-glycans [106]. The Baculovirus 
genome could also be modified to express protein in mammalian cells. The addition of 
the Cytomegalovirus immediate early enhancer and promoter (pCMV) and plO  
promoter replaced the polyhedrin promoter, making possible the simultaneous 
expression of the protein in insect and mammalian cells [107].
The second problem related to the Baculovirus- Sf9 expression system is that the yield 
of recombinant protein is often low. Cotransfection with Baculovirus expressing 
chaperon proteins (assist in the folding and modification of newly synthesized proteins) 
increased the yield [106]. An alternative approach was the introduction of various DNA 
elements to the virus: for example, the addition of Baculovirus homology region 1 (hrl) 
and hrS sequence regions to the viral genome increased luciferase production [108]. The 
cell lysis observed three to five days after infection of Sf9 cells by Baculovirus may be 
due to the promotion of increased proteolytic activity and other environmental factors 
that can determine degradation of any recombinant protein with its consequent low 
yield. In help circumvent this, a Baculovirus with reduced lysis capability was isolated
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by random mutagenesis. This mutant produced a high level of well folded luciferase but 
with less degradation as compared to the parental virus [109]. In all cases, the 
Baculovirus expression system has the major advantages the possibility of the 
production of several types of proteins and the relative ease with which they can be 
produced on a large-scale production for further studies. Recently, cells from insect 
larvae were used as a host for protein production, especially in Asian countries such as 
China, Japan and India. Protein expression levels in Baculovirus infected larvae can be 
very high, reducing costs for large-scale production.
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3.1.2 Materials and methods
3.1 .2 . 1  Cells and media
Sf-9 cells were purchased from Invitrogen and cultured at 27°C in SF-900 II medium 
supplemented with 5% Fetal Bovine Serum, 100 pg/ml gentamycin, 100 U/ml 
penicillin, 2 mM glutamine and 0.1% Pluronic-F6 8 . Cells were maintained in adherent 
culture and passaged at confluence. After approximately 25 passages a new batch of 
cells was thawed. For infections, the culture was adapted to suspension growth in 
spinner-flasks (Bellco) and kept at a cell density below 2xl0 6 cells/ml.
3.1.2.2 Buffers, antibodies and inhibitors
All solutions were freshly prepared and filtered. For anionic exchange chromatography: 
Buffer A contained 50 mM Tris-HCl, pH 6.5, 20 mM NaCl and protease inhibitors (PI) 
while Buffer B consisted of 50 mM Tris-HCl, pH 6.5 and 2 M NaCl, plus PI. For 
affinity chromatography Buffer C contained 50 mM Tris-HCl, pH 8 , 250 mM NaCl, 20 
mM (3-mercaptoethanol, 30 mM imidazole, 10% glycerol and PI was used. The 
antibodies used were: anti-HisG (Invitrogen), anti-phosphotyrosine clone 4G10 
(Upstate) and anti-phospho-RETY 905 (Cell Signaling), that recognizes phosphorylated 
tyrosine 905 in the RET activation loop. Protease inhibitors Leupeptin, Aprotinin and 
Pepstatin A were purchased from Sigma-Aldrich and used at 1 pg/ml final 
concentration. PP1 and PP2, RET small molecule inhibitor, were purchased from 
Calbiochem.
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3.1.2.3 Generation of recombinant virus
A hybrid Baculovirus transfer vector (pHisE) was obtained by importing an EcoRV- 
Kpnl fragment of pBlueBacHis2 (Invitrogen), containing the 6 -Histidine tag, into the 
pBlueBac4.5 plasmid (Invitrogen) that has the SV40 polyA signal for mRNA 
stabilization. RET kinase domain cDNA (nucleotide 2293-3255 of transcript variant 1; 
GeneBank accession no. NM 000323) was PCR-amplified with specific primers, RET- 
F (GGT ACCT AT GG AG AACC AGGT CTCC) and RET-R
(TACTTGGACCTTGCGGCGGTCTAGA) and cloned into the pHisE vector in 
KpnI/Xbal sites. Sequencing of the cloned insert confirmed that no mutations were 
introduced. Mutant V804M RET was obtained from wild-type RET plasmid by site- 
directed mutagenesis using the QuikChange kit (Stratagene), according to 
manufacturer’s instructions, with the following mutagenic primers: sense,
GGCCCGCTCCTCCTCATCATGGAGTACGCCAAATACGGC, and antisense, 
GCCGTATTTGGCGTACTCCATGATGAGGAGGAGCGGGCC (the nucleotide 
corresponding to the missense mutation is underlined). Homologous recombination of 
the plasmid with Bac-N-Blue viral DNA (Invitrogen) generated P-galactosidase- 
expressing, recombinant Baculovirus particles. Selection and verification of 
recombinant viral clones was performed according to manufacturer’s manual. A single 
RET-positive recombinant clone was expanded and used for RET expression. Viral titer 
was calculated for each batch of virus by plaque assay. Briefly, Sf9 cells were seeded in 
1 0 -cm cell culture dishes at 6 x l 0 6/dish and infected with 1 ml virus dilutions, ranging 
from 10-4 to 10'10. Infected cells were then overlayed with 1.25% sterile agarose 
containing 75 pg/ml X-Gal. After approximately 10 days at 27°C, blue plaques 
appeared, representing single recombinant particles. The titer (pfu/ml) was calculated as 
follows:
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number of plaques/virus dilution.
3.1.2.4 Infection and extraction of Sf9 cells
Log-phase growing Sf9 cells (2xl06 cells/ml) were infected at a multiplicity of infection 
(MOI) = 5 and incubated for 72 hours in a spinner-flask, after which the cells were 
collected by centrifugation, and the cell pellet washed with cold PBS and kept at -80°C 
until needed. In a typical experiment, cell pellet corresponding to 2xl09 cells was 
thawed on ice and resuspended in clarification buffer, 50mM TrisHCl pH 6.5, 20mM 
NaCl, protease inhibitors (109 cells in 50ml of clarification buffer). After 60 minutes, 
the suspension was sonicated twice on ice and the cell lysate was cleared by 
ultracentrifugation at 15,000 g for 2 0  minutes and the supernatant loaded on the column.
3.1.2.5 Chromatography
All chromatographic steps were controlled by the AKTA-FPLC system (Amersham) 
and carried out at 4°C. Total cell lysate was loaded on a 120-ml anion-exchange column 
(DEAE-sepharose Fast Flow resin, packed in a XK-26 column [Amersham]). The 
capture buffer was 50mM TrisHCl pH 6.5, 20mM NaCl, the elution buffer was 50mM 
TrisHCl pH 6.5, 2M NaCl; in order to obtain a greater resolution we chose a linear 
gradient 0-20% elution buffer in 4CV. Then, the positive fractions were loaded on a 
Pro-Bond (Invitrogen) nickel ion affinity resin (15 ml). In this case the capture buffer is 
50mM TrisHCl pH 8 , 250mM NaCl, 20mM p-mercaptoethanol, 30mM imidazole, 
glycerol 10%, while the elution buffer is 50mM TrisHCl pH 8 , 250mM NaCl, 20mM (3- 
mercaptoethanol, 200mM imidazole, glycerol 10%; the gradient consists of two steps 0-
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10% of elution buffer in 3CV and 10-15% in 2CV and a linear fragment 15-100% in 
8 CV.
3.1.2.6 SDS-PAGE
Samples from the various purification steps were resolved on 10% SDS-polyacrylamide 
gels. Proteins were either stained with Coomassie brilliant blue or silver nitrate, or 
transferred to a nitrocellulose membrane and analyzed by western blotting with anti- 
HisG or anti-phosphoRET antibody. For silver staining, the gel was fixed 5 minutes in 
7% acetic acid and 40 minutes in 50% methanol, washed with water, incubated 15 
minutes in staining solution (0.2 g AgN0 3  dissolved in 80 mM NH4 OH and 0.18 N 
NaOH), washed again and finally submerged in developing solution (0.005% citric acid 
and 0 .0 2 % formaldehyde) for 2-15 minutes or until the bands were visible.
3.1.2.7 Analytical qel filtration
Positive fractions from affinity chromatography were concentrated using Vivaspin 
devices (Vivascience) at 2000 g. The concentrated sample was loaded on a Sephacryl- 
S200 HR Column (Amersham) and separated at 0.1 ml/min in Buffer E containing 50 
mM Tris-HCl, pH 8 , 1 M NaCl, 10 mM P-mercaptoethanol. Eluted fractions were 
analyzed in western blot with anti-histidine antibody.
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3.1.2.8 Circular dichroism
Three hundred microgram of rRET was used in circular dichroism analysis. rRET was 
concentrated in lOOul of 50mM TrisHCl pH 8 , 250mM NaCl, lOmM p-mercapto- 
ethanol.
3.1.2.9 Light scattering
The light scattering test was performed with Dyna Pro-99-e50, using rRET in the 
following conditions: 5 mg/ml in 30mM TrisHCl pH 7.5, 150mM NaCl, 5mM DTT.
3.1.2.10 Peptide synthesis
The peptides ARDIYRASYYRKGGCAMLPVK, SRDVYEEDSYVKRSQGRiPVK 
and MARTTSQLYDAVPIQSSVVL were prepared following the solid-phase Fmoc 
amino acid chemistry [110] on a HMP (p-Hydroxymethyl phenoxymethyl polystyrene) 
resin (1.10 mmol/g) (Applied Biosystems, (Foster City, CA, USA). The chain assembly 
was performed automatically using a 431 A (Applied Biosystems) peptide synthesizer 
and Fmoc-protected amino acids activated with a mixture of 2-(l-benzotriazol-l-yl)- 
1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), N-Hydroxybenzotriazole 
(HOBt) and N-ethyldiisopropylamine (DIEA). Peptide resin cleavage and deprotection 
was achieved following the procedure of King et al. [111]. The crude peptides (50-100 
mg in 10 ml water) were purified using a preparative Reverse Phase HPLC-column 
(prepNova-Pak HR C l 8 , 6  pm, 25x10 mm, Waters, Milford, MA, USA) at 12 ml/min. 
The purity of peptides was > 95% by analytical Reverse Phase-HPLC on a 5 pm, Cl 8  
Symmetry300 column, 4.6x250 mm (Waters).
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3.1.2.11 Radioactive kinase assay
Substrate phosphorylation was performed in 50 mM TrisHCl, pH 7.5, 1 mM MnCb, 5 
mM MgCb, 30 pM [y33P]ATP (specific activity 1000 dpm/pmol) purified RET (60 ng) 
and either poly(Ghi4 Tyr) (0.1 mg/ml), enolase (2 pg) or peptides as substrates, in a total 
volume of 30 pi. The reactions were terminated at the indicated times as previously 
described [112]. In the case of peptide phosphorylation, 25 pi of the incubation mixture 
were spotted onto P81 phosphocellulose paper, which was then processed as described 
elsewhere [113]. For enolase phosphorylation and rRET autophosphorylation, the 
samples were subjected to SDS/PAGE and incorporated 33P was analyzed by a Packard 
Instantlmager. Kinetic constants were determined by GraphPad Prism software fitting 
the data directly to Michaelis-Menten equation using non-linear regression
3.1.2.12 Non-radioactive kinase assay
Purified RET -rRET- (100 ng) was incubated with or without ATP (30 pM) in kinase 
buffer (25 mM Hepes, pH 7, 1 mM MnCE, 5 mM MgCE) for 15 minutes at 30°C. The 
autophosphorylation reaction was stopped with Laemli buffer and the sample was run 
on SDS-PAGE and developed with anti-phospho-RET and anti-HisG antibodies.
The ELISA kinase assay was performed as described by Gunby et al [114] with some 
modifications. Briefly, 96-well microtiter plates were coated overnight with peptide 
substrate and washed. The reaction mixture was prepared in 100 pi with 40 ng of pure 
RET and 300 pM ATP in kinase buffer and added to the coated wells. After 15 minutes 
incubation at 30°C the plate was washed 3 times with wash buffer (0.05% Tween in 
PBS) and incubated with anti-phosphotyrosine antibody and HRP-conjugated anti­
mouse secondary antibody. Color was developed by addition of TMB substrate and
stopped with 0.18 M H2 SO4 . Absorbance was read at 450 nm with Victor microplate
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reader (PerkinELmer). Plastic absorbance was read at 570 nm and subtracted. 
Background signal was determined by including a no-ATP control and subtracted. All 
experiments were done in triplicate and repeated at least three times. The Km for ATP 
was calculated using GraphPad Prism software as the concentration required to reach 
half-maximal activity. Inhibitors were pre-incubated at room temperature with the 
enzyme for 10 minutes before the reaction was started by the addition of ATP. Data 
were always normalized against a vehicle control and analyzed by GraphPad software.
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3.1.3 Results
3.1.3.1 Expression and purification
The catalytic domain of RET was produced using the Baculovirus expression system. 
The construct represented the wild type sequence encoding the kinase domain and 
contained the active site, the ATP-binding pocket, the activation loop with regulatory 
functions and an amino-terminal His-tag to enable the purification. The amino acid 
sequence of the recombinant protein is shown below:
MPRGS/fflmrHgGMASMTGGOOMGRDLYDDDDKDRWIRPRDLOLVPMENOVSVDA
FKILEDPKW EFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRAGYTTVAVKM LKENAS
PSELRDLLSEFNVLKOVNHPHVIKLYGACSODGPLLLIVEYAKYGSLRGFLRESRKVGP
GYLGSGGSRNSSSLDHPDERALTM GDLISFAW OISOGM OYLAEM KLVHRDLAARNILV
AEGRKM KISDFGLSRDVYEEDSYVKRSO GRIPVK W M AIESLFDHIYTTOSDVW SFGVL
LW EIVTLGGNPYPGIPPERLFNLLKTGHRM ERPDNCSEEM YRLM LOCW KOEPDKRPVF
ADISKDLEKM M  VKRRD YLDL A  A  V
The His tag (labeled in bold in the sequence) is composed of six amino acids that can 
coordinate nickel ions during affinity chromatography. An Enterokinase cleavage site 
(DDDDKD) is present in the vector plasmid to permit the removal of this tag after 
purification. The RET sequence (underlined) starts at MEN and finishes at the LAA 
sequence; the remaining amino acids belong to the expression vector.
The resultant protein will have a predicted molecular weight of 41.9 kDa and a 
theoretical isoelectric point of 8 . It contains several cysteine residues that may cause
63
C h a r a c t e r i z a t i o n  of  RET c a t a l y t i c  d o m a i n
aggregation. The analysis of its primary structure reveals the following amino acid 
composition (Table 3.1)
A M IN O  A C ID %
Alanine A 5,2
Arginine R 7,1
Aspargine N 2,7
Aspartic acid D 7,1
Cysteine C 0,8
Glutamic acid E 6,3
Glutamine Q 3,5
Glycine G 8,2
Histidine H 3,5
Iso-leucine I 3,8
Leucine L 10,9
Lysine K 6,8
Methionine M 4,4
Phenilalanine F 3,3
Proline P 4,9
Serine S 6,8
Threonin T 2,7
Tryptophane W 1,9
Tyrosine Y 3,5
Valine V 6,5
T able 3.1 Amino acid composition of rRET
P113 6 2 |FGFR1_HUMAN 
P 2 18 0 2 | FGFR2_HUMAN 
P 0 7 9 4 9 I  RET HUMAN
P113 6 2 |FGFR1_HUMAN 
P 2 18  0 2 | FGFR2_HUMAN 
P 0 7  94  9 I RET HUMAN
P113 6 2 |FGFR1_HUMAN 
P 2 18 0 2 | FGFR2_HUMAN 
P 0 7 9 4 9 |RET HUMAN
AKSIPLRRQVTVSADSSASMNSG-VLLVRPS-RLSSSG-TPMLAGVSEYELPEDPRWELP 4 7 4  
TKRIPLRRQVTVSAESSSSMNSN-TPLVRITTRLSSTADTPMLAGVSEYELPEDPKWEFP 4 7 7  
HKFAHKPPISSAEMTFRRPAQAFPVSYSSSGARRPSLDSMENQVSVDAFKILEDPKWEFP 7 2 0  
* . . .  * *
gly rich loop
P I  P2 3 3  aC
RDRLVLGKPLGEGCFGQVVLAEAIGLDKDKPNRVTKVAVKMLKSDATEKDLSDLISEMEM 5 3 4  
RDKLTLGKPLGEGCFGQWMAEAVGIDKDKPKEAVTVAVKMLKDDATEKDLSDLVSEMEM 5 3 7  
RKNLVLGKTLGEGEFGKVVKATAFHLKG--RAGYTTVAVKMLKENASPSELRDLLSEFNV 77  8 
* * * * * * * * * * * . * * * * . _ * * * * * * * _ . * .  . ; *  * * : * * : : :
kinase insert
p4  P5 aD
MKMIGKHKNIINLLGACTQDGPLYVIVEYASKGNLREYLQAR RP P ----------------GLEYCYN 58  6
MKMIGKHKNIINLLGACTQDGPLYVIVEYASKGNLREYLRAR R P P ----------------GMEYSYD 5 8  9
LKQVN-HPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRESRKVGPGYLGSGGSRNSSS 8 3 7  
. * .  * . . * . * * * * . * * * * * . * * * * *  * * * . * .  * *
P113 6 2 |FGFRl_HUMAN 
P 2 1 8  0 2 | FGFR2_HUMAN 
P 0 7 9 4 9 |RET HUMAN
catalytic loop
a E  3 7  38
PSHNPEEQLSSKDLVSCAYQVARGMEYLASKKCljHi'U jARRNVLVTEDNVMKIADFGLAR 64 6 
i n r v p e e q m t f k d l v s c t y q l a r g m e y l a s q k c i | r d l a a r n v l v t e n n v m k i a d f g l a r  64 9 
LDHPDERALTM G D L ISF A W Q IS Q G M Q Y L A E M K L vj^B iA ^IL V A E G R K M K IS D FG L SR  8 97
-k • •  k • ' k-k' kk' k ' k ' k ' k»' k-k*mk
activation loop P+l loop
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P I 1 3 6 2 | FGFR1_HUMAN 
P 2 1 8  0 2 | FGFR2_HUMAN 
P 0 7  94 9 | RET HUMAN
a E F  a F
DIHHIDYYKKTTNGRLPVKWMAPEALFDRIYTHQSDVWSFGVLLWEIFTLGGSPYPGVPV 7 0 6  
DINNIDYYKKTTNGRLPVKWMAPEALFDRVYTHQSDVWSFGVLMWEIFTLGGSPYPGIPV 70  9 
DVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTTQSDVWSFGVLLWEIVTLGGNPYPGIPP 9 5 7
: k k k k k k k k k k  . k
P113 6 2 |FGFR1_HUMAN 
P 2 18  0 2 | FGFR2_HUMAN 
P 0 7  94 9|RET_HUMAN
1 0 1 7
aG  aH a l
EELFKLLKEGHRMDKPSNCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRIVALTSNQEY 7 66 
EELFKLLKEGHRMDKPANCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRILTLTTNEEY 7 69 
ERLFNLLKTGHRMERPDNCSEEMYRLMLQCWKQEPDKRPVFADISKDLEKMMVKRRDYLD
k k  k • k k k k k  k k • • k  k k  • • k  • '
P I 1 3 6 2 |FGFR1_HUMAN 
P 2 1 8  0 2 | FGFR2_HUMAN 
P07949|RET_HUMAN
1 0 7 7
LDLSMP------------------------------------- LDQYSPSFPDTRSSTCSSGEDSVFSHEPLPEEPCLPR 80 9
LD LSQP------------------------------------- LEQYSPSYPDTRSS-CSSGDDSVFSPDPMPYEPCLPQ 8 1 1
LAASTPSDSLIYDDGLSEEETPLVDCNNAPLPRALPSTWIENKLYGMSDPNWPGESPVPL
Figure 3.1.1 Similarity search demonstrated high identity with FGFR1 and FGFR2. The 
asterisks indicate the identity (the same amino acid presents in the position), while the dots 
indicate the positivity. a-helics and P-sheet are labelled in green and yellow, respectively. The 
catalytic loop sequence is red, while the activation loop is blue. The kinase insert is underlined. 
In FGFR1 sequence, the amino acids M451 and E764 labelled in pink represent the start and the 
end of the construct crystallized by Mohammadi and co-workers [17]; in RET sequence the start 
and the end of our construct are brown, M699 and A1020, respectively.
A similarity search performed by BLAST program (Expasy) revealed 52% of identity 
and 68% of positivity with fibroblast growth factor receptor 1 (FGFR1), and 51% 
identity and 68% of positivity with fibroblast growth factor receptor 2 (FGFR2) in the 
kinase domain. The alignment above (Figure 3.1.1) shows the exact position of each 
amino acid of all three proteins. It should be noted that RET presents a kinase insert 
sequence 8 amino acids longer than FGFR1 and this could represent a problem for 
crystallization because of the augmented mobility of the region.
Some biochemical properties of the protein product were defined before the purification 
was commenced. The optimum buffer to purify our protein (TrisHCl, NaHPCE), was 
identified. A buffer of 50mM TrisHCl pH 6.5 was chosen for binding of rRET in 
anionic exchange chromatography using DEAE-Sepharose Fast flow resin while 50mM 
TrisHCl pH 8 was used for Pro-bond nickel ion affinity resin in the affinity
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chromatography, p-mercapto-ethanol was added to the buffers for affinity 
chromatography to prevent the formation of disulfide bridges between cysteine residues. 
The stability of rRET, with or without freezing it and in different conditions was 
determined: the rRET protein was stable for one week after defrosting at 4°C in the 
chosen buffer. Protease inhibitors (Leupeptin, Apoprotin, Pepstatin A) were added to all 
buffers to prevent degradation.
An example of purification process optimized to produce rRET was described below.
o
Sf9 cells with infected with a high titer suspension of recombinant Baculovirus (5x10 
pfu/ml) at the ratio of 1 million cells infected with 2 0  pi of virus (corresponding to a 
multiplicity of infection of 10). After 72h of infection, the cells were harvested and 
lysed on ice for one hour, clarified and then sonicated, with a clarification buffer. 
Suspension was centrifuged at 15000g for 20 minutes and the resulting supernatant 
added to a 16XK-DEAE sepharose Fast flow column to perform the first step of 
purification. Western blotting with anti-His allowed the positive fractions to be 
identified and the positive fraction was collected at the time point shown below in 
Figure 3.1.2.
--------------DigRETDM: ll.IV JM P
mAU
80.0 \
0 2 0 0 - 4 0 0  600 800 1000 1200 ml
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rRET
Figure 3.1.2 Chromatogram of anion exchange chromatography. The arrow indicates the peaks 
containing rRET eluated from 16XK-DEAE sepharose Fast flow column. Western blot with 
anti-His antibody was performed to identify the positive fractions. In the lane 1 total lysated was 
loaded, samples 2-5 corresponded to fractions under the peak indicated by he arrow.
The positive fractions were collected and loaded on Pro-bond nickel ion resin for the 
affinity chromatography. The positive fractions were identified by silver staining and 
were collected at the time point(s) shown below in Figure 3.1.3.
ProBcndl 5mE8ago001:! UVJ MP
Figure 3.1.3 Chromatogram of Ni-NTA affinity chromatography. The rRET eluted when the 
imidazole in the buffer solution reached the concentration of 80mM in the column and the 
collection point is arrowed. The arrow indicates the peak in which rRET eluates
We identified the positive fractions by silver nitrate-stained gel, we collected, pooled 
and froze them. A sample from each preparation was quantified by Bradford assay and 
tested in ELISA.
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s
Figure 3.1.4 The silver nitrate stained gel shows the fractions of linear gradient and indicates 
the high purity of our preparation. In the lane 1 a sample from the positive fractions of DEAE 
pooled together was loaded; lane 2-5 are representative of the fractions corresponding to the 
elution peak. The absence of important contaminants indicates the high purity of our 
preparation.
3.1.3.2 Biochemical characterization
A single peak of apparent molecular size of 42 kDa eluted following analytical gel 
filtration, indicating a homogeneous preparation of monomeric protein. rRET was 
totally unphosphorylated after the purification (Figure 3.1.5 A).
Circular dichroism analysis was conducted in order to verify the correct folding and 
study the possible presence of large disordered regions within the protein, which may 
impair its ability to crystallise. Indeed, with this technique it’s possible to determine 
secondary and tertiary structures of the proteins. Our analysis revealed a profile 
compatible with secondary structures that are typical of tyrosine kinase domains (Figure 
3.1.5 B).
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Figure 3.1.5 A Gel filtration column and western blot with anti-His antibody of the fractions 
corresponding to the peak of 42KDa. B Circular dichroism spectrum of rRET. The profile 
corresponds to mixed a+(3 secondary structure of, as expected for a properly folded tyrosine 
kinase domain.
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Furthermore, dynamic light scattering used to determine the composition of the sample 
showed both monomodal and monodisperse rRET preparation, as showed in Fig. 3.1.6. 
Thus, the rRET prepared here can be used in crystallization experiments.
C.10 13.33 mm  fJ2C£*33 tjXE«<M *JCCE*05
F igure 3 .1 .6  Graph o f  dynamic light scattering (Y  axis % intensity, X  axis radius nm). The peak 
indicates that rRET preparation is monodisperse and monomodal. rRET was used at 
concentration 5 m g/m l in 30m M  TrisHCl pH 7.5, 150mM  NaCl, 5mM  DTT.
3.1.3.3 Enzymatic properties of rRET catalytic domain
In order to understand if rRET could be used also for the screening of small molecule 
inhibitor compounds identified by computational methods, the reaction conditions of in 
vitro phosphorylation and high salt inhibition upon rRET were determined. Fifty 
percent inhibition of rRET was observed at 100 mM NaCl. Thermal inactivation curves 
showed that rRET activity was reduced by 50% and 80% after 15 minutes at 30°C and 
37°C, respectively. Complete inactivation was observed after 30 minutes at 37°C. The 
kinase reaction occurred in the presence of divalent cations, such as Mn++, Mg'1”1" and 
Co++ with Mg++ being preferred. Activity was optimal at pH values between 7.0 and 8.0.
70
Characterization of RET cata ly tic  dom ain
The mechanism of rRET autophosphorylation was studied by determining the 
relationship between reaction rate and enzyme concentration. The data indicated that 
rRET autophosphorylation follows second-order kinetics. To set up a rapid and fairly 
selective assay of rRET activity, which is a prerequisite for the analysis and 
development of specific inhibitors, the following peptides were synthesized and used as 
substrates: aas 896-916 of the RET activation loop (SRDVYEEDSYVKRSQGRIPVK) 
containing the Y900 and Y905 autophosphorylation residues; the sequence 
ARDIYRASYYRKGGCAMLPVK derived from the activation loop of the oncogenic 
tyrosine kinase ALK (Anaplastic Lymphoma Kinase) and the N-terminal sequence 
MARTTSQLYDAVPIQSSWL of PDK1 since the serine/threonine kinase PDK1 has 
been described to be phosphorylated at Tyr9 by RET/PTC oncogenes. rRET activity 
was tested on these three peptides and on the synthetic peptide poly(Ghi4 Tyr). The time 
courses of peptide phosphorylation showed that poly(Glu4Tyr) was the preferred 
substrate. rRET was, however, also active on both peptides derived from activation 
loops, displaying a higher phosphorylation rate toward the RET sequence. Calculated 
kcat for RET and ALK peptide phosphorylation was 4.2 ± 0.2 and 1.1 ± 0.1 min"1, 
respectively. In contrast to tyrosine kinase-derived peptides, PDK1 peptide was a poor 
substrate of rRET in our test. This finding suggests that the molecular recognition of 
PDK1 as a substrate by RET relies not only upon primary amino acid sequence, but is 
also based on additional specificity determinants dictated by the other regions of the 
intact protein (Figure 3.1.7).
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Figure 3.1.7 Time courses of peptide phosphorylation by rRET. Peptides (400 pM) were 
phosphorylated in a radioactive assay as previously described. Data points are presented as the 
mean ± standard deviation of three measurements.
Finally, the use of common inhibitors of tyrosine kinases or compounds active against 
RET, such as PP1 and PP2 demonstrated that rRET was inhibited with an IC50 similar to 
that reported in literature, 40 and 150 nM, respectively. Results from an experiment are 
shown below (Figure 3.1.8).
Figure 3.1.8 Inhibition curves of rRET in presence of PP1 and PP2. The IC50 obtained from 
ELISA assay, 40 nM for PP1 and 150nM for PP2 are consistent with the values reported in 
literature.
The conclusion was that rRET produced here was active and properly folded. The 
results obtained from the ELISA studies were reproducible and consistent with data
■ PP1 
A PP2
-2.5 -2.0 -1.5 -1.0 -0.5 0.0 0.5 1.0
log^M PP1
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reported in literature. Thus the rRET produced here could be used in ELISA for studies 
into screening of small molecule inhibitors.
3.1.3.4 Expression of V804M mutant
It has been reported that the mutation V804M identified in some cases of sporadic MTC 
causes resistance to PP1 and ZD6474 [54]. This mutation occurs in the same position as 
in other tyrosine kinases, such as ABL T315I and EGFR T766M. In all cases the 
substitution of a threonine with a bulkier amino acid confers resistance to ATP binding 
site inhibitors. The mutant V804M (rRET 804) was produced in order to have another 
reagent with which test the effect of the inhibitor compounds. The procedure used for 
the expression and purification of this mutant protein, rRET 804, was the same as those 
used for rRET. rRET 804 was tested by ELISA in the presence of PP1 and 
staurosporine to verify its pharmacological properties. As shown in Figure 3.1.9 below, 
no inhibition of phosphorylation by rRET 804 was observed using PP1 while 
staurosporine, an all tyrosine kinase inhibitor, blocked phosphorylation.
Figure 3.1.9 Inhibition curves of rRET and V804M rRET in presence of PP1. V804M rRET is 
resistant to PP1, while rRET is inhibited with the same IC50 as usual.
1.5-
•  RET V804M 
a RET WT
-5 -4 -3 -2 -1 0
log i^M PP1
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3.1.4 Discussion
The procedure of expression and purification of the recombinant protein rRET 
containing the catalytic domain of the tyrosine kinase receptor RET is described in the 
present Chapter. The use of Baculovirus system was necessary to obtain a correctly 
folded and active protein and this method is commonly utilized to synthesize 
recombinant proteins, in particular tyrosine kinases. The level of expression of the viral 
preparation is crucial to obtain a good yield of protein and it is, therefore, essential to 
optimize the conditions of infection in terms of number of cells and amount of virus. 
Another important aspect to improve the yield is the volume of lysis buffer used to 
resuspend the cells harvested after infection. I identified a compromise between the 
necessity of efficient cell lysis and the problem of overdilution of the recombinant 
protein. Furthermore, the number of cells loaded in the 26-XKcolumn for the anionic 
exchange chromatography is not directly related to the yield since it observed tha t, after 
a certain threshold, increasing the amount of loaded material does not lead to an 
significant increase of purified rRET.
The Ionic Exchange Chromatography (IEX) is performed at pH 6.5, although rRET has 
a calculated PI equal to 8. One possibility to account for this is that perhaps the basic 
amino acids are not exposed to the solvent and do not therefore interact with the resin. 
TrisHCl buffer was used for both for IEX and for the Immobilized Metal ion Affinity 
Chromatography (IMAC), because rRET precipitates in presence of NaHPOs. As shown 
in silver nitrate-stained gel, the product after IMAC is 95% pure (Figure 3.4).
In order to perform crystallization tests, it was necessary to change the buffer 
containing the rRET (50mM TrisHCl pH 8, 250mM NaCl, 20mM J3-mercaptoethanol, 
80mM imidazole, glycerol 10%) with a more hypotonic buffer (20mM TrisHCl, 50mM
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NaCl, lOmM P-mercaptoethanol) without imidazole and glycerol that could avoid rRET 
crystal formation. The results from dynamic light scattering indicate the absence of 
aggregates and a monodisperse distribution both of which are good theoretical start 
points for the crystallization studies.
During its in vitro characterization, rRET demonstrated autophosphorylation following 
second-order kinetics (rate increases linearly with the square of enzyme concentration). 
This result is consistent with an intermolecular event. It is known that RTKs like RET 
undergo activation upon homodimerization through cross-phosphorylation [115]. 
However, since our isolated kinase domain does not have any interaction interface and 
is present in solution as a monomer, the mechanism of its autophosphorylation is not 
obvious. However, the current data suggest that the intermolecular autophosphorylation 
mechanism is inherent in the catalytic domain and can occur independently of the other 
RET domains. Therefore, the recombinant kinase domain of RET is a good model of the 
full-length enzyme.
The rRET recombinant protein was considered to be suitable for the investigation of 
screening of small molecule inhibitors for RET. A few micro liters rRET per well were 
used to phosphorylate the peptide substrate using conditions described by Mologni et al 
[52]. The inhibition achieved in presence of PP1 and PP2 with the same IC 50  values 
reported in literature [50, 51], confirmed that rRET produced here has pharmacological 
properties which are favorable for use by ELISA [114]. Moreover, the availability of the 
mutant recombinant protein, RET V804M, will be important to identify any inhibitors 
that are active on a mutated RET protein that is resistant to the common inhibitors. 
Finally, comparison of the experimental data of small-molecule compounds in the rRET 
and rRET V804M is important to validate the virtual models which were used as the 
rationale for the screening studies.
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In summary, the rRET recombinant protein containing a kinase domain exhibits features 
which should enable it to be used in crystallization studies and to used to screen for 
kinase inhibitors screening in ELISA validated assay.
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3.2 RET crystallization
3.2.1 Introduction
It is essential to know the three-dimensional architecture of the catalytic domain in 
order to analyse the mechanism of RET activation and how to efficiently inhibit it. In 
this section, I describe the recombinant proteins that have been used in the 
crystallization attempts. Collaborations were established with Prof. Zanotti’s laboratory, 
in the Dept, of Chemistry at the University of Padova, to perform crystallization 
screening.
3.2.1.1 Principles of protein crystallization
To understand cellular processes, knowledge of the three dimensional structure of 
proteins, enzymes in particular, is crucial. Two techniques are widely used for the 
structural determination at atomic resolution: nuclear magnetic resonance (NMR) and 
X-ray diffraction of crystal. While NMR does not require crystals and provides more 
detailed information on the dynamics of the molecules, it can be used only for 
biopolymers with a molecular weight of less than 30 kDa. In contrast, X-ray 
crystallography can be applied to compounds with molecular weight up to at least 10 
kDa. For proteins then X-ray diffraction is the principal method of choice.
Protein crystallization is a trial and error procedure in which the protein is slowly 
precipitated from a saturated of protein solution. An highly pure preparation of the 
protein is dissolved in a suitable solvent from which it must be precipitated in 
crystalline form. The solvent is usually water and buffer solution added by precipitating
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agents such as ammonium sulphate and polyethylenglycol (PEG). The solution is 
brought to supersaturation and small aggregates are formed. To generate crystal from 
precipitates a energy barrier has to be passed and this step is easier at high level of 
supersaturation [116]. Precipitation of the protein can be achieved by adding salt 
(salting out) or removing salt (salting in). In the first approach, ions immobilize water 
thus increasing the effective concentration of the protein, while in the second the 
absence of solvent ions induces Coulomb attraction between opposite charges on 
different protein molecules. It is also possible to decrease the repulsive forces between 
proteins or increase attractive forces. Electrostatic forces are influenced by an organic 
solvent such as alcohol or by change in pH, while hydrophobic interactions increase 
with temperature [117].
The crystallization of a protein results from a multi-parameter problem in which the 
parameters are varied in the search for optimal crystallization conditions. The most 
common parameters include protein concentration, nature and concentration of 
precipitant, pH and temperature. An appropriate statistical design for crystallization 
screening is the factorial method in which a table is constructed with a number of values 
entered for each parameter [118]. After approximate crystallization conditions have 
been found, then these conditions can be optimised. Although other strategies can be 
followed [119], a large number of attempts must still be tried in all cases.
3.2.1.2 Crystallization technique
The vapour diffusion method is commonly used in crystallization attempts [117]. 
Supersaturation is reached by diffusion of the vapour from the drop that contains 
proteins to the precipitating solution or vice versa. Drops are prepared by mixing few
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microliters (3-10pl) of protein solution with the same volume of precipitant solution, 
while precipitant partially fills the tray. In the ‘hanging drop’ method, the drop is 
positioned on a siliconized microscope glass cover slip and the slip is placed upside 
down over a depression in the tray which is filled by precipitant. In the ‘sitting drop’ 
method, then the drop is placed on a support in the tray. The latter technique is 
preferable if the protein solution has a low surface tension and it tends to spread over 
the cover slip in the hanging drop method. The crystallisation chamber is sealed with 
grease or oil and incubated at a controlled temperature till a crystal appears [120, 121]. 
However, the oldest and simplest methods used for protein crystallization is the ‘batch 
technique [117]. The principle of this method is that the precipitating reagent is 
instantaneously added to the protein solution, suddenly bringing the solution to a state 
of high supersaturation and crystals grow gradually without further processing. Several 
automated systems for microbatch crystallization has been designed to evaluate a larger 
number of conditions using just a small amount of protein [122]. 1-2 pi drops of the 
protein solution and precipitant are suspended in oil that acts as sealant to prevent 
evaporation [123, 124]
3.2.1.3 Cryo-cooling of crystal
Once a crystal appears, then the drops must be cooled. The main reason for cooling 
protein crystals is to slow the destructive processes induced by X rays [125, 126]. 
Cooling the crystals from room temperature to a cryogenic temperature must occur 
suddenly because the water in the mother liquor and in the crystal must freeze to a 
vitreous structure in order to prevent the ice formation that would damage the protein 
crystal structure by expanding the water structure in its transition to crystalline ice
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[127]. Cooling is accomplished by nitrogen gas, which is boiled off from liquid nitrogen 
or cooled in a heat exchanger. The crystal is then transferred to a solvent containing an 
anti-freeze such as glycerol, MPD, ethyleneglycol and low molecular weight PEG, to 
prevent ice formation in and around it completely. For data collection, the crystal is 
lifted from the cryoprotectant solution by a loop made from a thin fibre of rayon, nylon 
or glass and mounted in a metal capillary that can be fixed to the top of a 
goniometerhead for X rays diffraction [128].
3.2.1.4 X-ray diffraction
X rays are electromagnetic radiation with wave length of lO'MO"11 m. Electrons in the 
atoms are responsible for the diffraction; proteins consist predominantly of carbon, 
nitrogen and oxygen, elements which have only a relatively few electrons per atom, and 
have a low scattering power. Moreover, diffraction is a cooperative event between 
molecules in the crystal. In the case of larger molecules then there are fewer molecules 
in a crystal of the same size and the diffracted intensity is therefore lower. Protein 
diffraction therefore requires a high intensity source of X rays and a rotating anode tube 
or a synchrotron for very small size (< 0.1mm) crystals. The result of X rays diffraction 
is a pattern generated by constructive interference of diffracted waves. Mathematical 
software can produce the image from an electronic map [129].
3.2.1.5 Characterization of the crystal
The important parameters in the characterisation of a crystal are the diffraction limit, the 
space group and the number of protein molecule that are in the unit cell. The quality of
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the crystal depends on the ordering of the molecules in the unit cell which is defined by 
the regular packing of the molecule in the crystal. Diffraction patterns with maximal 
observed resolution corresponding to a lattice spacing of 1-1.5 A can be considered as 
of very high quality. However, most of the crystals cannot be regarded as a single 
crystal because the regular repetition of the unit cells is interrupted by lattice defects. In 
this case the diffraction pattern is the sum of several blocks with slightly different 
orientations. To recognize the space group to which the crystal belongs, one can observe 
the symmetry and the systematic absence in the pattern. Finally, the number of the 
molecules per unit cell can be estimated by the ratio of the unit cell volume and the 
molecular weight that for many crystals is between 1.7/3.5 A3/Da (Principles of Protein 
X-ray crystallography, Drenth).
In summary, X ray diffraction is a very informative technique with which one can 
obtain invaluable information concerning the exact relationship of the amino acids 
inside a protein. The result is a picture of the protein in an instant and an more in depth 
knowledge of protein dynamics derived from the resolution of several forms in different 
states. In the case of protein kinases, structures of non-phosphorylated and 
phosphorylated forms or complexes with small molecule inhibitors should clarify the 
mechanism of action of the kinase(s) and its regulation. The most important parameters 
to obtain a three-dimensional structure of the protein are the choice of correct construct 
and the identification of crystallization screening. In this field, good results are often 
associated to serendipity.
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3.2.2 Materials and methods
3.2.2.1 Concentration
Vivaspin columns 5000 Da MWCO (molecular weight cut off) were used to 
concentrate rRET and to change the buffer. The sample was centrifuged in a swing out 
angle rotor at 4000 g until the final concentration of 5-8mg/ml was achieved. The 
recombinant protein sample was then added to 50mM TrisHCl pH8, 20mM NaCl, 
lOmM P-mercaptoethanol and concentrated again. A Bradford assay was used to 
quantify the protein after concentration.
Coomassie Brilliant Blue solution (Pierce) was used to quantify protein after 
concentration. With a curve of known amounts of BSA we determined the linear range 
to extrapolate the concentration of our preparation.
3.2.2.2 His tag cleavage
Enterokinase (Invitrogen) cleavage was optimised to remove the His tag from the rRET 
protein. The reaction was maintained at 30°C for 4 hours with 20U enzyme/mg of 
rRET. Enterokinase was removed by beads according to manufacturer’s instructions 
(Invitrogen). The cleaved recombinant protein was purified by Nickel affinity 
chromatography and concentrated again.
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3.2.2.3 Crystallization attempts
Crystallization attempts were performed in Prof. Zanotti’s laboratory in the Department 
of Chemistry at the University of Padova and Hautmann Institute of Buffalo (USA). 
Both sitting and hanging drop methods were used in Italy while the microbatch method 
was used in the USA to investigate more than thousand conditions for crystallisation.
3.2.2.4 New constructs for the generation and purification of rRET
Modified constructs were obtained from wild-type RET plasmid by site-directed 
mutagenesis using the QuikChange kit (Stratagene), according to manufacturer’s 
instructions, with the following mutagenic primers: for N-deletion construct (N-Del) 
sense, ATGGCTAGCATGACTGGTGGAATCCTGGAGGATCCAAAGTGG, and 
antisense, CCACTTTGGATCCTCCAGGATTCCACCAGTCATGCTAGCCAT; to remove 
the kinase insert sequence (Kid Long) were used: 
sense CTTCCTCCGCGAGAGGCCGCCGGGCCCTCAGGGCG and 
antisense CGCCCTGAGGGCCCGGCGGCCTCTCGCGGAGGAAG.
The construct with the N-terminal deletion and without kinase insert sequence (Kid 
short) was obtained from Kid Long plasmid by direct mutagenesis using N-deletion 
primers. Recombinant Baculoviruses were produced following the procedure described 
in the previous section. New rRET forms were purified with the same protocols used to 
obtain recombinant RET wild type protein consisting of anionic exchange 
chromatography and affinity chromatography.
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3.2.3 Results
3.2.3.1 Large scale purification
As described above, rRET was produced in Sf9 cells infected with Baculovirus and 
purified with a two step procedure consisting of anionic exchange chromatography and 
Nickel affinity chromatography. Several purifications were performed to obtain 
sufficient amounts of recombinant proteins to start crystallization screening. The 
median yield from each purification was lmg of rRET from 2 billion cells. All positive 
fractions were frozen at -80°C in the elution buffer following affinity chromatography. 
The 10% of glycerol acted as a crioprotector.
rRET diluted in a large volume (200ml) must be concentrated to a final volume of 4ml 
(50x) in order to obtain a final protein concentration of 2mg/ml. Concentration was 
performed by centrifugation in concentrator columns with 30 KDa as molecular weight 
cut off. The polyethylensulphone membrane avoided protein adhesion thus favouring 
the complete recovery of rRET. During the concentration step, the buffer was changed 
by diluting the preparation and re-concentrating it. Indeed, for crystallization attempts 
the ideal buffer contains low salts and 1% of glycerol as maximum. rRET was stored in 
small aliquots at 2mg/ml in 50mM TrisHCl pH 8, 20mM NaCl, lOmM P- 
mercaptoethanol at -80°C. Flash freezing in liquid nitrogen was used to minimize 
protein degradation.
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3.2.3.2 First screenings in Padova and Buffalo
The first screening was carried out using His-tagged rRET, purified and concentrated, as 
previously described. An aliquot of rRET (2mg/ml) was further concentrated to 
6.4mg/ml and tested by the sitting drop method in the presence of strong precipitant 
agents, such as ammonium sulphate (NH^SCL, methyl-pentane-diol MPD 40%, 0.5M 
TrisHCl pH 7.5, poly-ethylen-glycol PEG400 40%, 0.5M TrisHCl pH 7.5. rRET 
precipitated in all conditions. Large scale screening of crystallization conditions by both 
sitting and hanging drop methods with commercial kits that allow to evaluate a wide 
range of different situations was started. rRET was tested in apo form or in presence of 
AMP-PNP, an ATP analog non-hydrolysable, or small molecule inhibitors such as 
ZD6474 and L6, The latter was a new chemical entity discovered by our group as RET 
inhibitor by molecular modeling.
The results are reported in table 3.2.
KIT N Conditions
structure screen I 48
crystal screen II 40 RET incubated with AMP-PNP + MgC12
Clear strategy screen I 22 precipitants pH 8.5
Clear strategy screen I 16 screen di pH 45.-5.5-6.5-7.5; RET incubated with L6
Clear strategy screen II 23 precipitants pH 6.5; RET incubated with L6
Clear strategy screen II 45 RET incubated with ZD6474
Precipitant PEG 3350 34 precipitants different pH and salt; RET incubated with 
ZD6474
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TOTAL 228
Table 3.2 Conditions of the crystallization screening performed in Padova
The best conditions identified from this preliminary screening were:
Na acetate + Na formate pH4.5 in the presence of ZD6474.
Unfortunately, the microcrystals obtained were too small for X-ray diffraction studies. 
Concurrently, we produced another 1 Omg of rRET to try the high throughput screening 
at Hauptman Woodward Institute of Buffalo (USA) [130]. The protein was concentrated 
to 8mg/ml and sent ready to use for crystallization analysis. 1573 different conditions 
were tested, without obtaining any crystals, but only multiple forms of precipitate.
Figure 3.2.1 Examples of drop picture from high through put screening performed in Buffalo 
(USA); a picture of the drops were taken every week.
Figure A shows an example of light amorphous precipitate: here the protein precipitated 
without any ordered pattern probably because the supersaturation state occurred too 
quickly. Figure B shows the presence of a birefringent precipitate that may contain little 
microcrystals of proteins or salt crystals. Although the presence of precipitate, 
especially if non-amorphous or birefringent is a good starting point for crystal growth,
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no crystal growth was observed after one month of incubation at 20°C. In other drops 
skin was observed: the skin is believed to be a layer of denaturated protein or caused by 
polyethylene glycol and its presence decreases the rate of supersaturation state and 
avoids crystal growth. Finally, some drops showed phase separation which generally 
occurs when organic solvent is added to highly concentrated salt solution and one of 
two solutes is insoluble in the other. The protein concentration is altered and becomes 
higher in the phase in which the protein is more soluble, subsequently giving rise to a 
high state of supersaturation. In some cases, unfortunately not in the current study, 
crystals can grow in boundary region that acts as nucleation catalyst (“The protein 
crystallization page” website).
3.2.3.3 Enterokinase cleavage optimisation and screening
During the first crystallization screening, the enterokinase cleavage was optimised to 
remove the His-tag from the N-terminal of rRET. Temperature, duration, salt 
concentration and amount of enzyme are the most important parameters for this 
reaction. Twenty units of enterokinase were used per milligram of rRET for 4 hours at 
30°C. The rRET was previously diluted 1:5 (v/v) to decrease the salt concentration that 
could inhibit the enzyme. Thus, the final protocol consisted of two-step purification 
procedure, followed by enterokinase cleavage and a further affinity chromatography to 
remove uncleaved rRET. Partial cleavage caused a loss of 20% of protein that retained 
the His tag and eluted from Nickel column at 80mM imidazole as untreated rRET. By 
contrast, rRET without the His-tag eluted in the flow through fractions after washing the 
column. A typical example is shown in Figure 3.2.2 below Affinity column was 
performed using the conditions described in the previous section. Positive fractions
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were pooled and concentrated again to obtain an optimal preparation for the 
crystallization screening.
Figure 3.2.2 Silver stained gel of fractions from Nickel affinity chromatography. The first lane 
in upper gel is un-treated rRET, second lane is cleaved rRET, loaded in Nickel column; RET 
cleaved eluted in flow through fraction (3-7), while His tagged-RET eluted at 80mM Imidazole 
(8-9), as usual. In lanes 10 and 11 the removed His-tag is shown.
Some precipitate was present following concentration, probably because the solubility 
of the protein diminished in the absence of His-tag. Unfortunately, further 
crystallisation studies performed using this cleaved rRET protein were also 
unsuccessful.
3.2.3.4 New constructs
Analysis of the RET model revealed two disordered regions that could prevent 
crystallization: the N-terminal portion and the kinase insert which is a region between
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the N and C lobes. The corresponding sequences were removed by mutagenesis from 
the complete RET sequence to obtain the following new constructs: NDEL was a form 
with a shorter N-terminal region, KID LONG was the construct without the kinase 
insert, while KID SHORT (derived by mutagenesis from the KID LONG plasmid), was 
represented the form without the kinase insert and with N-terminal deleted (Figure 
3.2.3). The His tag was retained to allow the affinity chromatography of all the resulting 
recombinant proteins. The Baculovirus production protocol was the same as previously 
described for rRET.
NDEL
MPRGS////////////GMAS(MTGGQQMGRDLYDDDDKDRWIRPRDLQLVPMENQVSV
DAFK)ILEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRAGYTTVAVKMLKE
NASPSELRDLLSEFNVLKQVNHPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRESRK
VGPGYLGSGGSRNSSSLDHPDERALTMGDLISFAWOISOGMOYLAEMKLVHRDLAAR
NILVAEGRKMKISDFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTTQSDVWSF
GVLLWEIVTLGGNPYPGIPPERLFNLLKTGHRMERPDNCSEEMYRLMLQCWKQEPDKR
PVFADISKDLEKMMVKRRDYLDLAAV
KID LONG
MPRGStftftftftfMjMASMTGGQQMGRDLYDDDDKDRWIRPRDLQLVPMENQVSVDAF
KILEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRAGYTTVAVKMLKENASP
SELRDLLSEFNVLKOVNHPHVIKLYGACSODGPLLLIVEYAKYGSLRGFLRESIRKVGP
GYLGSGGSRNSSSLDHPDERALTIMGDLISFAWOISOGMOYLAEMKLVHRDLAARNI
LVAEGRKMKISDFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTTQSDVWSFG
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VLLWEIVTLGGNPYPGIPPERLFNLLKTGHRMERPDNCSEEMYRLMLQCWKQEPDKRP
VFADISKDLEKMMVKRRDYLDLAAV
KID SHORT
MPRGS//////Ar////GMAS(MTGGQQMGRDLYDDDDKDRWIRPRDLQLVPMENQVSV
DAFK)ILEDPKWEFPRKNLVLGKTLGEGEFGKVVKATAFHLKGRAGYTTVAVKMLKE
NASPSELRDLLSEFNVLKQVNHPHVIKLYGACSQDGPLLLIVEYAKYGSLRGFLRES(RK
VGPGYLGSGGSRNSSSLDHPDERALTIMGDLISFAWQISQGMOYLAEMKLVHRDLAA
RNILVAEGRKMKISDFGLSRDVYEEDSYVKRSQGRIPVKWMAIESLFDHIYTTQSDVWS
FGVLLWEIVTLGGNPYPGIPPERLFNLLKTGHRMERPDNCSEEMYRLMLQCWKQEPDK
RP VFADISKDLEKMMVKRRDYLDLAAV
Figure 3.2.3 Sequence of rRET in which deleted portions were labelled in bold. In N-DEL 
construct 41 amino acids (between parenthesis) were removed. In KID LONG construct the 
kinase insert sequence (in bold, underlined) was eliminated, while in KID SHORT both N- 
terminal portion and kinase insert were removed.
In both the NDEL and KID SHORT constructs the RET sequence started 11 amino 
acids later than rRET and immediately after His tag sequence. The Enterokinase 
cleavage site was removed and the constructs retained His tag in the crystallization tests. 
In some cases the presence of this tag favoured the solubility of the protein and slowed 
down the rate with which the supersaturation state was reached. In KID LONG and KID 
SHORT the kinase insert, a loop between N-lobe and C-lobe that confers mobility to the 
lobes, was removed. All the mutated RET forms were tested by ELISA assay to 
evaluate their activity and verify that deletion did not interfere with the catalytic 
properties of the protein. The evidence of regular kinase activity of the new constructs 
indicated the proper folding of these proteins.
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Sufficient amounts of recombinant proteins were produced to perform crystallization 
screening for all KID LONG, NDEL and, lastly, KID SHORT.
3.2.3.5 Kid Long crystallization screening and microcrystals
KID LONG protein was biochemically characterized by gel filtration to verify the 
correct molecular weight and the absence of aggregated forms. The elution buffer was 
30mM TrisHCl pH 8, 300mM NaCl, ImM DTT. As shown in figure 3.2.4 the protein 
molecular weight was 39KDa, as expected, and was present as monomer.
-0,2  -
10 12 146 8 16 18 20 22 24
Figure 3.2.4 Chromatogram of analytical gel filtration of KID LONG
Crystallization screening was performed using both cleaved and His-tagged proteins. 
The presence of an Enterokinase cleavage site made it possible to remove the His-Tag 
thus producing two different proteins to test their different solubilities.
The Enterokinase reaction was performed at 4°C overnight since the absence of the 
kinase insert could increase precipitate formation. Cleaved protein was recovered by 
NiNTA resin in a batch purification.
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Microcrystals were obtained with KID LONG cleaved in presence of 0.1 M NaCl, 0.1M 
Bicine pH 9, 30% PEG 550, ZD6474. These conditions were reproducible and 
microcrystals from drop containing birefringent precipitate were obtained in repeat 
experiments
Figure 3.2.5 Microcrystals of KID LONG; arrows indicate crystals
Unfortunately, these crystals were too small to undergo X rays diffraction and no 
subsequent attempts to grow crystals were made of KID LONG.
The NDEL and KID SHORT recombinant proteins did not crystallize under any 
conditions including the promising conditions identified for KID LONG.
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3.2.4 Discussion
In this part of my thesis I tried to crystallize the kinase domain of rRET. The work was 
performed in collaboration with prof. Zanotti’s lab, I was mainly responsible for the 
production of protein suitable for crystallization experiments. The first screening was 
performed with His-tagged rRET using commercial kits. Several methods were used, 
such as hanging and sitting drop methods. Crystallization tests were performed without 
or in presence of small molecules compounds, such as ZD6474, L6 (a small molecule 
inhibitor identified by molecular modelling as RET inhibitor) and AMPNP. The 
presence of small molecule inhibitors preferentially stabilizes the kinase domain in one 
conformation [10, 15, 17], theoretically favouring the crystal growth. Concurrently, 
high throughput screening at Hauptman Woodward Institute of Buffalo (USA) was 
performed. In this case, the microbatch method was used. A large amount of conditions 
were screened without obtaining any suitable crystal conditions. Furthermore, 
enterokinase cleavage was optimized to remove the his-tag form the C-terminal. 
Temperature, salt concentration and amount of the enzyme were the most important 
parameters to control. Although the cleavage was partial and some precipitate was 
observed during the reaction, some crystallization drops were prepared. Also in this case 
crystals did not grow. New constructs were designed to produce other forms of rRET. 
N-terminal region was shorted by removing amino acids belonging to the vector and the 
first 11 amino acids of RET kinase domain. Furthermore, the kinase insert, a link region 
between C-lobe and N-lobe, was deleted to obtain another form: this loop could be 
flexible and could disturb the crystallization process, in other kinases for example 
FLT3R this region was eliminated [131]. Finally, rRET without the kinase insert and the 
N-terminal region was produced. The modifications did not alter the biochemical
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properties of rRET, as NDEL, KID LONG and KID SHORT retained the catalytic 
activity. All the new constructs were used in crystallization screening. The best results 
were obtained with KID LONG, but the microcrystals did not grow enough to be 
diffracted.
RET structure has been published in 2006 August by Knowles et al. [132]. Construct 
encompasses between 705 and 1013 amino acids, this sequence is similar but shorter 
than our rRET, in particular 6 amino acids at the N-terminal and 7 at C-terminal have 
been removed. Sometimes, few differences in construct determine the outcome of 
crystallization experiments. The conditions of crystallization are: for un-phosphorylated 
RET and phosphorylated RET 1.5ul of protein (3mg/ml) mixed to lul of reservoir 
solution (2M sodium formate + 0.1M sodium citrate pH5.5), for PP1-RET lul of protein 
(1.5mg/ml) mixed to lul of 2.8M sodium formate + 0.1M sodium acetate pH4.5 + 0.1M 
lithium chloride, finally for ZD6474-RET 1.5ul of protein (3mg/ml) mixed to lul of 
2.2M sodium formate, 0.1M sodium acetate pH4.5.
Our best conditions, identified in the first screening with rRET un-cleaved, were very 
similar to that used for un-phosphorylated-RET and phosphorylated-RET.
RET kinase domain adopts the characteristic protein kinase fold, consisting of a smaller 
N-lobe (713-805) and larger C-lobe (812-1013) connected by a hinge/linker (806-811). 
The relative position of N and C-lobes is similar in both phosphorylated and not- 
phosphorylated forms. Residues 705 to 711 of RET juxtamembrane region are present 
in RET kinase domain structure and generate a portion of N-terminal helix (aN) that 
connects to pi strand of the kinase domain via loop 712-714. Helix aN packs against 
and tethers the functionally important aC helix through apolar contacts around F709 and 
F776.
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The RET kinase domain conformation seems to be independent of the phosphorylation 
state of the activation loop and suggests that the activation loop exhibits no major auto- 
inhibitory effect either in binding ATP or substrate.
RET has been crystallized as head to tail dimer: the first contact area involves residues
IfiX IfklN ASP S prior the aC helix, interacting with the p+3 pocket and specifically 
M918; these residues are in extended conformation which masks the substrate-binding 
site of the second molecule. The second adjacent contact area in the dimer is the aN 
interacting with he side chains of F924 and F961 and with Q910 and H926.
Some activating mutations, such as M918T, P766S and E768/A919 map close to dimer 
contact region altering the regulatory component. These data confirm the model in 
which RET is present as dimer in the cellular membrane, GDNF/GFRa complex binds it 
and promotes conformational changes required for full kinase activity. Otherwise, trans­
inhibition can be overcome during the recruitment in lipid raft and the formation of 
signalling complex [133].
It’s not completely clear why RET fusion proteins that represent cytoplasmatic dimer 
form of RET are constitutively active in PTCs. An hypothesis could be that fusion 
partners maintain RET kinase domain close enough to accomplish phosphorylation in 
tyrosines important for signal transduction, such as Y1062, but quite far to be not trans 
inhibited. Further studies are necessary to well characterize RET regulation.
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3.3 RET inhibition b y  SU5416
3.3.1 Introduction
The rRET recombinant protein produced as described is suitable for use screening 
studies to identify small molecule inhibitors of RET protein. In particular, it was used to 
screen members of the 2-indolinone derivative family. This part of my PhD project 
shows the inhibition of RET signalling by new compound -SU5416- in both in vitro and 
in vivo models.
3.3.1.1 Enzymatic kinetics
An enzymatic reaction is defined the conversion of substrate to a final product mediated 
by a protein that acts as catalyst; the formation of the complex enzyme-substrate is an 
equilibrium that is not perturbed by product formation. An equilibrium reaction for this 
is given below.
ki k2 
E+S 7~*ES E + P 
k_i
In which E represents the enzyme, S is the substrate and P corresponds to the product, 
ki and k_i are equilibrium constants that regulate the association between enzyme and 
substrate, while k2 is the dissociation constant of E+P complex.
The main parameters that regulate the kinetics of the reaction are the Vmax and Km 
(Michaelis Menten constant): Vmax is the maximum rate at high substrate concentration
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(close to saturation) while Km is a constant derived from the ratio between (k_i+k2)/ki. 
Km is not an equilibrium constant, but represents one kinetic constant and its physical 
significance can be determined only when all ki k_i k2 are known. The ratio Kj/ki 
indicates the affinity of the enzyme for the substrate, thus when k2«  k_i, Km defines 
the affinity of the enzyme.
In the presence of a reversible inhibitor then the reaction rate is decreased. Several 
mechanisms of inhibition are defined from the Michaelis Menten equation, such as 
competitive, non competitive and un-competitive inhibition.
A competitive inhibitor is a compound that binds the enzyme and avoids the formation 
of substrate-enzyme complex. This interaction determines an increased Km without 
modifying the Vmax. The inhibition can be overcome by increasing the amount of the 
substrate in reaction because the inhibitor does not alter the affinity of free enzyme for 
it; only the complex enzyme-inhibitor has no affinity for the substrate. Otherwise, the 
binding of one non-competitive inhibitor to the enzyme does not interfere with the 
formation of the complex substrate-enzyme, and both inhibitor and substrate can 
interact with the enzyme at the same time giving rise to the complex inhibitor-substrate- 
enzyme. This complex is unable to generate the final product and the Vmax of the 
reaction decreases. Finally, an un-competitive enzyme has affinity only for the complex 
substrate-enzyme and its binding blocks the reaction. Both Vmax and Km are decreased 
in presence of the inhibitor.
In a phosphorylation reaction, the kinase binds ATP to transfer a y phosphate group 
onto tyrosine residues that act as a substrate. Small molecule inhibitors can interact with 
several portions of protein kinase, as previously described. Thus, understanding the 
modality of inhibition is very important to characterize an inhibitory compound.
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3.3.1.2 The 2-indolinone family
SU5416 belongs to the 2-indolinone family, a class of compounds identified initially as 
FGFR1 inhibitors. Mohammadi et al. [17] evaluated the activity of SU4984 and 
SU5402 (other 2-indolinone family members) on FGFR1 in in vitro 
autophosphorylation assays. Using purified kinase domains, an IC50 of 10 to 20pM was 
obtained while using NIH3T3 cells stimulated by acidic FGF an IC50 20 to 40pM was 
found. IC5 0 is defined as the inhibitor concentration that blocks the 50% of the 
enzymatic activity. Only SU4986 blocked the activity also of PDGFR and IRK when 
tested in the same cellular assay under the stimulation of PDGF and insulin 
respectively. In contrast, SU5402 showed higher specificity for FGFR (B). X ray 
diffraction of FGFR in complex with 2-indolinone derivatives demonstrated that both 
SU5402 and SU4986 bind to the ATP-binding pocket: the oxindole residue occupying 
the same position as the ATP adenine and adds two hydrogen bonds to the protein 
backbone in the hinge region. Numerous hydrophobic residues contribute to the 
stabilization of the interaction. Moreover, SU4986 (A) makes an oxygen aromatic 
contact with the carbonyl oxygen of A564. The piperazine ring has a Van der Waals 
interaction with G567, a highly conserved residue, while the terminal formyl group is 
disordered. All these interactions do not confer specificity for FGFR because they 
involve residues common to most protein tyrosine kinases. Conversely, SU5402 makes 
an intramolecular hydrogen bond between the pyrrole ring and 0-2 of the oxindole 
residue and the methyl group of the pyrrole ring has a Van der Waals interaction with 
G567. Moreover, the carboxylethyl group forms a hydrogen bond with N568, (probably 
involved in ATP binding), and the oxindole binding pocket is capped by F489 in the 
nucleotide binding loop. This region is well ordered only in the crystal SU5402-FGFR1. 
Thus, SU5204 showed higher specificity because of the bond with N568 and the
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stabilization of the nucleotide binding loop. In both PDGFR and IRK, N568 is 
substituted by aspartic acid which is unable to form any hydrogen bond with the 
SU5204, thus that results completely inactive; otherwise, VEGFR that has aspargine 
residues in the same position, is efficiently inhibited by SU5402. The following graft 
shows the interactions described above.
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Further studies have been carried out on members of the SUGEN family, indicating an 
important role of this class as anti-angiogenic agents [134]. In particular, SU5416 
(Semaxinib) showed inhibitory activity against the c-KIT and FLT3 tyrosine kinases 
besides to those against VEGFR [135-137]. It has been used in phase I clinical trials for 
the treatment of metastatic colorectal cancer targeting VEGFR and phase II trials for 
AML targeting c-KIT [138]. In this study SU5416 was administered to c-Kit-positive 
patients, who were resistant to conventional therapies for acute myeloid leukaemia 
(AML). Eight of 42 patients achieved a morphological or partial response, without 
showing major side effects: the main toxicities being nausea, headache and bone pain.
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Strong levels of c-Kit negatively affected the response, while a positive correlation was 
identified with high VEGFR expression levels, suggesting that the positive effects of 
SU5416 were mediated by its anti-angiogenic properties and not by the direct growth 
inhibition of leukemic blasts.
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3.3.2 Materials and methods
3.3.2.1 Cell cultures
All cell culture media were supplemented with 100 U/ml penicillin, 100 jag/ml 
gentamicin, and 2 mM Gin. The murine pro-B cell line Ba/F3 was maintained in RPMI 
medium with 10% fetal bovine serum (FBS), with CHO-conditioned supernatant as a 
source of IL-3. Three Ba/F3-derived cell lines expressing RET/PTC2 (here after 
referred to as Ba/PTC), NMP/ALK (Ba/NA, [139]) and BCR/ABL (Ba/BA, [140]) were 
generated following successful transfection cells with the corresponding fusion cDNA 
and the selection of stable transfectants using 1 mg/ml G418. These cells were kept in 
RPMI plus 10% FBS without IL-3. TPC-1, and NPA (human papillary thyroid 
carcinoma cell line, harbouring RET/PTC1 and B-RAF V600E, respectively) were 
grown in Dulbecco’s modified Eagle’s medium (DMEM) containing 10% FBS. Parental 
NIH-3T3 and NIH-3T3 cells stably transfected with RET/PTC2 (NIH-PTC2) and 
RETV804M mutant (NIH-V804M) were cultured in DMEM with 10% (parental cells) 
or 5% FBS. The insect cell line Sf9 was kept at 27 °C in SF900-II medium (Invitrogen) 
with 10% FBS and 0.1% Pluronic F-68.
3.3.2.2 Antibodies and inhibitors
Antibodies were used in western blotting according to recommended dilutions. Anti- 
HisG antibody (Invitrogen) is directed against the 6xhistidine tag followed by a glycine. 
Anti-RET (C-19, Santa Cruz Biotechnology, Santa Cruz, CA, USA) recognizes the 
short isoform of wild-type RET; anti-phospho-RET (recognizing phosphotyrosine 905
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of wild-type RET), anti-phospho-JNKl/2 (which detects active diphosphorylated 
(Thrl83/Tyrl85) JNK1 and JNK2) and anti-JNKl/2 antibodies were from Cell 
Signaling Technology (Danvers, MA, USA). Anti-phosphotyrosine (4G10) was 
purchased from Upstate Biotechnology (Charlottes-ville, VA, USA); anti-ERKl/2 and 
anti-phospho-ERKl/2 (Thrl83/Tyrl85) were from Sigma; anti-p21/WAFl (Ab-1) and 
anti-p27 (C-19)-G antibodies were bought from Merck Biosciences (Darmstadt, 
Germany) and Santa Cruz Biotechnology respectively.
SU5416 was purchased from Calbiochem, dissolved in dimethyl sulfoxide (DMSO), 
aliquoted and stored at -20 °C until used.
3.3.2.3 Proliferation assay and growth curve
Serial dilutions of kinase inhibitor were prepared in cell culture medium with 1% FBS 
in 96-well plates. Cells were then resuspended in 1% FBS medium and added to the 
plate at 104cells/well. Cell proliferation was measured at 72 h using the tritiated- 
thymidine incorporation assay as described previous [141]. Each data point was done in 
triplicate.
For growth curves, Ba/F3 and Ba/PTC cells were seeded (105/well) in 24-well plates in 
triplicate and treated with DMSO or various concentrations of SU5416. The cells were 
counted using a Trypan Blue exclusion assay every second day, diluted to keep them in 
logarithmic growth phase and fresh inhibitor was added.
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3.3.2.4 Western blot analysis of cell extracts
Ba/PTC cells were grown overnight in 1% FBS and treated with SU5416 or DMSO for 
4 h. They were then washed with PBS and lysed in 1 x Laemmli buffer (62.5 mM Tris- 
HC1, pH 6.8, 2% SDS, 10% glycerol, and 0.3 M B-mercaptoethanol). Total lysates 
corresponding to 3 x 105 cells were loaded on SDS-PAGE, transferred to nitrocellulose 
membrane and probed with anti-RET and anti-phospho-RET antibodies.
TPC-1 cells (6 x 106) were seeded in 100 mm cell culture dishes, grown overnight in 
1% FBS and treated with SU5416 or DMSO. Cell lysates were prepared after washing 
with PBS, by scraping the cells in lysis buffer (25 mM TrisHCl, pH 7.9, 150 mM NaCl, 
1% NP-40, 1 mM EDTA, 2 mM EGTA, 10 mM NaF, 1 mM Na3V04, 1 mM DTT, 1 
mM PMSF, 1 pg/ml leupeptin and aprotinin) and incubating for 40 min on ice. The 
lysates were then centrifuged for 30 min at 13 000 r.p.m. at 4 °C and the total protein 
content of the supernatants was measured by the Bradford assay. Equal amounts (100 
pg) of total protein were loaded on SDS-PAGE and analyzed by western blotting using 
phospho-specific antibodies.
3.3.2.5 Soft-aqar growth assay
NIH-PTC-L cells were seeded in six-well plates at 1 x 104 cells/well in a medium 
containing 0.33% low melting agar (type VII, Sigma) and either DMSO or 20 pM 
SU5416, on a layer of 0.5% agar, as described [40]. Fresh inhibitor was added every 3 
days to the top layer. The colonies were counted after 15 days.
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3.3.2.6 Cell-cvcle analysis
Cells were seeded in six-well plates at a density of 2 x 105/well and treated with 
inhibitor or DMSO. Cells were harvested at 24, 48, and 72 h after treatment, washed 
with PBS and fixed in 70% ethanol at -20 °C. The samples were then centrifuged and 
resuspended in PBS containing 50 pg/ml propidium iodide and 100 pg/ml RNase A, 
incubated at 37 °C for 30 min and analyzed by FACScan flow cytometer (Beckton 
Dickinson, Franklin Lakes, NJ, USA).
3.3.2.7 ATP competition assay
Increasing doses of ATP (0.011-2.4 mM) were incubated with rRET in the presence of 
DMSO, or 0.05, 0.25, and 1.25 pM SU5416, and an ELISA kinase assay was performed 
as previously described [52]. ATP binding curves were then calculated for each 
inhibitor concentration and plotted using the Lineweaver-Burke method.
3.3.2.8 In vivo target modulation
Female CD-I nu/nu mice (7-9 weeks old) were supplied by Charles River (Calco,
Como, Italy) and kept under standard laboratory conditions according to the guidelines
of the Istituto Nazionale Tumori (INT), Milan, Italy. All animal studies were approved
by the Ethics Committee for Animal Experimentation of INT. Mice were implanted
subcutaneously with NIH-PTC cells (106 cells/mouse). When the tumours were
measurable, the mice received an acute intraperitioneal dose of 50 mg/kg SU5416 in 60
pi DMSO, or DMSO alone. Mice were sacrificed 6 h after treatment and their tumours
resected and snap frozen on liquid nitrogen. Tumour mass was minced in lysis buffer
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and lysates were then prepared as described earlier. Equal amounts of total protein were 
loaded on 8% SDS-PAGE and visualized by western blot with anti-RET and anti- 
phospho-RET antibodies.
3.3.2.9 Molecular modelling
A model of the tertiary structure of the RET tyrosine kinase domain in an active 
conformation was built by homology modelling, using the phosphorylated active insulin 
receptor kinase domain (Protein Data Bank entry, 1IR3 [PDB] ) as a template. The 
amino acid sequence similarity between the RET and IRK domains is 57%. The model 
was refined using AMBER 6 software for computing molecular dynamic simulations. 
The model of V804M mutant RET was built by changing Val-804 of wild-type RET 
model into a methionine; local side chain minimization was then performed with the 
Tripos force field and Powell method, with a convergence criterion of 0.05 kcal/mol, 
using Sybyl 7.0 (Anonymous). The binding mode of SU5416 to wild-type and V804M 
mutant RET was evaluated by molecular docking, using the GOLD algorithm (Tripos 
Inc., St. Louis, MO, USA).
3.3.2.10 Inhibitor specificity profiling
Radioactive kinase assays were performed at room temperature in the presence of 
substrate peptides, [33PlATP, and 10 pM SU5416, using recombinant kinases obtained 
from various expression systems. Procedures for purification and assay of 30 of the 52 
kinases have been determined [142, 143]. The other enzymes will be described 
elsewhere. Kinase assays were performed using ATP concentrations close to the Km
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value for each kinase. All protein kinases were grouped accordingly into three 
categories, namely 5, 20, and 50 pM ATP.
3.3.2.11 Statistical analysis
Data were always generated in triplicate and mean ± S.D. is reported on graphs. Dose- 
response curves were normalized over the DMSO control and analyzed by non-linear 
regression using Graph Pad PRISM 4.0 software. IC50 data are reported as the global 
fitting of at least three independent experiments, with 95% confidence interval (Cl).
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3.3.3 Results
3.3.3.1 SU5416 inhibits RET kinase activity in vitro
A series of compounds sharing a 2-indolinone core structure was identified by 
molecular modelling as possible candidates for producing RET inhibition. These 
compounds were in an in vitro ELISA-based kinase assay (ref. 3.2.2.12), using the 
recombinant enzyme and an exogenous peptide as a substrate, as previously described, 
in order to confirm the computational results. The results described in Chapter 3.2 
demonstrated that rRET could be inhibited by small molecule compounds and used as 
reagent in the inhibitors screening. The peptide SRDVYEEDSYVKRSQGRIPVK 
derived from the RET activation loop was phosphorylated on tyrosine during the kinase 
reaction. In presence of the inhibitors, the block of rRET kinase activity was observed 
and quantified using the colorimetric reaction.
The results reported in Table 3.2.1 are the IC50 values of 2-Indolinone derivatives 
tested:
R2
Compound R1 R2 R3 RET IC50
A CH3
- 0 - 0
- 100
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Table 3.2.1 2-indolinone compounds screened in ELISA assay; Rl, R2, R3 represent the 
substitutions of 2-indolinone core. For each compound IC50 on RET kinase has been reported.
We focussed our attention on SU5416 because seemed to be the most promising 
compound of all of those screened.
SU5416
CHj
Figure 3.2.1 Chemical structure of SU5416
SU5416 inhibited RET with an IC50 of 170 nM, using 300 pM ATP in ELISA assay 
(Figure 3.2.2 A) It also showed a similar degree of inhibition on FLT-3 kinase, a well- 
known target in the same assay, but was much less active against the ABL and ALK 
kinases. An autophosphorylation assay of rRET was performed in order to confirm the 
data. Significant inhibition was seen at only 0.1 pM, supporting the finding that SU5416 
is a RET inhibitor (Figure 3.2.2 B). The same membrane was stripped and developed 
with anti-HisG antibody to confirm that similar amounts of protein have been loaded 
(Figure 3.2.2 B).
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F igure 3.3.2 rRET inhibition by SU5416: (A) ELISA assay; (B) autophosphorylation assay 
developed by anti-phosphotyrosine-905 Western blotting (upper panel); anti-HisG western blot 
is shown in the lower panel as a loading control. (C) Lineweaver-Burke plot of competition of 
SU5416 with ATP .
To determine the mechanism of inhibition, an ATP competition assay was performed, 
based on the ELISA kinase assay. The ATP dose-response curves in the presence of 
different inhibitor concentrations showed that the Vmax was not altered by the 
compound, whereas the Km for ATP increased with increasing inhibitor concentration. 
Similarly, dose-response experiments performed at different ATP doses indicated that 
the IC50 of the compound increased progressively from 0.05 pM (at 11 pM ATP) to 
over 6 pM (with 3 mM ATP): all these data supported an ATP-competitive behaviour, 
in agreement with virtual docking data which showed that SU5416 binds within the 
ATP-binding pocket (ref. 3.3.3.5) The calculated Ki of compound SU5416 for RET was 
13 nM.
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3.3.3.2 Inhibition of RET-mediated transformation
Having established SU5416 as a good inhibitor of RET in cell-free conditions, I sought 
to determine whether the compound would be toxic to cells expressing the RET 
oncogene. The activity of SU5416 was evaluated in several cellular systems to confirm 
the results. The murine pro-B cell line Ba/F3 requires exogenous IL-3 for growth and is 
commonly exploited to study the transforming ability of oncogenes. A stably 
transfected Ba/F3 clone expressing RET/PTC2 (Ba/PTC) was established. These cells 
grow independently of IL-3 and show constitutive high levels of tyrosine- 
phosphorylated proteins. Treatment with 2 pM PP1 significantly blocked the growth of 
the Ba/PTCs thus validating the assay. The addition of SU5416 blocked the 
proliferation of Ba/PTC cells in a dose-dependent manner, with an IC50 of 7.9 pM (95% 
Cl, 6.8-9.1 pM), while sparing parental Ba/F3 cells. Results are shown in Figure 3.3.3 
A-B The observed proliferation arrest correlated with a strong inhibition of RET/PTC2 
phosphorylation, as shown by the anti-phospho-RET western blot of total lysates (figure 
3.3.3 C). Densitometric analysis of phosphorylated bands revealed an IC50 of 
approximately 5 pM, consistent with proliferation data. The RET expression level was 
not affected by the treatment. In line with the results obtained in ELISA, the treatment 
with SU5416 only marginally affected the proliferation of NPM/ALK- and BCR/ABL- 
transfected Ba/F3 cells, which showed IC50 values between 30 and 40 pM.
Finally, a time-course experiment was carried out by exposing Ba/F3 and Ba/PTC cells 
to SU5416 for 10 days. The growth of Ba/PTC cells was progressively delayed with 
increasing SU5416 concentrations, while Ba/F3 cells were not affected. Results are 
showed in figure 3.3.3 D.
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F igure 3.3.3 (A) Growth curves of Ba/F3 parental cells and RET/PTC2 stable transfectants 
Ba/PTC, with and without IL-3 and PP1. (B) Dose-response curves of SU5416 in a JH- 
thymidine uptake assay of Ba/F3 and Ba/PTC cells. DMSO-treated controls are set as 100%. 
(C) Analysis of Ba/PTC total lysates, after 4 hours treatment with SU5416 at the indicated 
concentrations. D) Time-course of Ba/F3 and Ba/PTCcells without (black symbols) and with 
different SU5416 doses.
Another cellular model frequently used for oncogene studies is represented by NILI-3T3 
murine fibroblasts. The expression of RET/PTC oncogenes induces anchorage- 
independent growth [50] and morphological changes in NIH-3T3 cells. Moreover, while 
the parental NIH-3T3 cells grow as a monolayer, RET/PTC-transfected cells are not 
inhibited by cell contact and form foci. Inhibition of RET kinase activity restores the 
parental phenotype [64]. We treated NIH-PTC2 cells with 10 pM SU5416, causing 
complete RET inactivation, as shown by the lack of activation loop phosphorylation 
(Figure 3.3.4 A). After 48 h of SU5416 treatment, we observed that the morphology of 
cells reverted to a flattened, non-dense appearance (Figure 3.3.4 D), similar to parental 
cells shown in figure 3.3.4 B, indicating blockage of RET tyrosine kinase signalling. By 
contrast, DMSO-treated cells maintained a transformed phenotype (Figure 3.3.4 C). 
NIH-PTC2 cells treated with SU5416 were no longer able to grow in soft agar medium,
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or form transformation foci (Figure 3.3.4 E-F-G). These data suggest that SU5416 is 
able to abrogate the transforming potential of the RET/PTC2 oncogene.
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Figure 3.3.4 (A) Cells were treated with DMSO (-) or 10 pM SU5416 (+) for 4 hours and lysed. 
Total lysates were run on SDS-PAGE and probed with anti-phosphoRETY905 (top panel) and 
anti-RET (bottom panel) antibodies. Photographs of parental NIH-3T3 cells (B) and NIH-PTC2 
cells treated with DMSO (C) or 10 pM SU5416 (D) for 48 hours. (E-G) NIH-PTC2 cells were 
seeded in soft agar medium without (E) or with 20 pM SU5416 (F). After two weeks, large 
colonies were counted and photographed. Percent number of colonies is reported in (G). All 
pictures were taken at the same magnification.
The previous results were obtained from transfected cell lines and so it was necessary to
confirm them in human cell lines expressing RET/PTC fusion proteins: these systems,
established from human tumours, demonstrating more physiological similarity to human
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PTCs. TPC-1 cells are derived from PTC and express the RET/PTC1 fusion kinase. The 
proliferation of TPC-1 cells was inhibited in the presence of SU5416, with an IC50 of 
2.7 pM (95% Cl, 2.3-3.2 pM). In contrast, NPA, a RET-negative papillary carcinoma 
cell line carrying the V600E B-Raf mutation, was much more resistant to the treatment 
showing 50% inhibition at 40 pM (Figure 3.3.5 A). The proliferative block of TPC-1 
cells correlated at the molecular level with a complete shut off of RET/PTC1 Tyr-905 
phosphorylation, after 8 h treatment (Figure 3.3.5 B). Tyr-905 (numbering refers to 
wild-type RET) is a main switch of RET catalytic activity. As SU5416 induced the 
inactivation of RET/PTC1 kinase, an investigation was carried out into whether the 
downstream signalling pathways were affected by the treatment. RET oncogenes have 
been shown to activate a number of proliferative and anti-apoptotic signals, including 
the RAS/ERK and the JNK pathways, as reported in previous section (ref 1.3.1.3). In 
TPC-1 cells treated with SU5416 for 36 h, a reduction of both ERK1/2 and JNK1/2 
phosphorylation was observed, concomitantly with a block of RET/PTC 1 
phosphorylation (Figure 3.3.5 C). The relative phosphorylation inhibition of p44 and 
p42 ERK was 90 and 75% respectively, as determined by densitometric analysis of the 
bands. The phospho-JNK signal in treated cells was reduced by 60%.
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Figure 3.3.5 (A) Effect of SU5416 on the proliferation rate of TPC-1 and NPA cells. (B) Dose- 
dependent inhibition of RET phosphorylation in TPC-1 cells. Both RET/PTC 1 isoforms are 
detected by the antibody. Total RET is shown below for loading control.(C) TPC-1 cells were 
treated for 36 hours with DMSO (-) or 25 pM SU5416 (+) and lysates probed with the indicated 
phospho-specific and total protein antibodies.
3.3.3.3 In vivo  modulation of RET autophosphorylation
To determine whether SU5416 is able to block RET activity in vivo, nude mice were 
inoculated subcutaneously with NIH-PTC cells. These cells grow as a xenograft with 
high efficiency [40] and formed palpable tumours within 10 days. At day 14 after 
implantation, tumour-bearing mice were treated with either a single dose of inhibitor, or 
vehicle alone, for 6 h. Western blot analysis of the resected tumours showed inhibition 
of RET autophosphorylation on Tyr 905 in treated animals, when compared to control 
mice (Figure 3.3.6). RET protein levels were left unaffected by the treatment. This 
result indicated that RET catalytic activity was shut down in the tumours and confirmed 
SU5416 as a potent RET inhibitor.
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Figure 3.3.6 Western blot analysis performed on tumor lysates, using anti-phospho-RET (top 
panel) or anti-RET (bottom panel) antibodies.
3.3.3.4 Activity of SU5416 on mutant RET
The sensitivity of tyrosine kinases to different classes of inhibitors appears to be 
modulated by a key residue regulating access to the ATP-binding site, named the “gate­
keeper residue”. The corresponding amino acid in wild-type RET is a valine, which is 
small enough to accommodate inhibitors within the ATP pocket, as demonstrated in 
diffracted structure described above. However, disease-associated mutations at Val-804 
confer resistance to inhibition by PP1, PP2, and ZD6474 [54], A V804M rRET protein, 
was used in the current study to investigate the inhibitory effects of SU5416. 
Surprisingly, SU5416 did not inhibit the mutant RETV804M recombinant protein, 50% 
inhibition was not reached at concentrations up to 30 pM. In contrast, SU4984, the 
compound that inhibited FGFR1 V561M mutant [55], blocked both wt RET and 
RETV804M with similar IC50, namely, 1.3 vs 2.6 pM (Figure 3.3.7 B). The growth of 
mutant RETV804M-expressing NIH-V804M cells was not affected by SU5416 up to 10 
pM, thus confirming that SU5416 is incapable of blocking V804M-substituted RET 
kinase. In keeping with this result, phosphorylation of RETV804M was not inhibited in 
these cells. (Figure 3.3.7 C)
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Figure 3.3.7 (A-B) ELISA kinase assay showing dose-response curves of wild-type RET and 
RETV8<*4m incubated with PP1 (A) or with SU5416 and the related compound SU4984 (B). (C) 
NIH-PTC2 (wild-type) and NIH-V804M cells were treated with increasing doses of SU5416 for 
72h and counted.
3.3.3.5 Molecular modelling
To explain this unexpected result, a computational model of the active RET kinase 
using the insulin receptor kinase as a template was generated in our lab. Molecular 
docking of SU4984 within the ATP-binding site of RET revealed an orientation of this 
compound that corresponded very well with the one observed in the crystal structure of 
the inhibitor in complex with FGFR1 kinase [17]: this is in keeping with the high degree 
of similarity between the FGFR1 and RET molecules. The oxindole core is positioned 
at the same region as the adenine ring of ATP and makes two hydrogen bonds with the 
backbone of the RET hinge region. The carbonyl oxygen of E805 interacts with the 
indolinone nitrogen, while the amide nitrogen of A807 is in contact with the oxygen 
atom of the inhibitor, in exactly the same corresponding positions of FGFR1. In 
addition, several hydrophobic residues surround the cavity in which the inhibitor binds, 
thus contributing to the stabilization of compound binding. The C3 substituent points
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towards the outside of the pocket. Docking of SU5416 showed a similar binding mode, 
with two hydrogen bonds with the protein backbone. When docked onto mutant 
RETV804M, SU5416 could not bind in the same way, because of a clash with M804. 
The software did find a docking solution, but the inhibitor was flipped to 180° with 
respect to wild-type docking, losing both hydrogen bonds. This may explain the 
resistance to inhibition. The docking of inhibitor SU4984, instead, was only partially 
affected by the mutation. The compound is slightly pushed outwards because of the 
presence of the bulkier methionine but, while it loses one H-bond (with E805), this is 
compensated for a new interaction between Y806 and the N1 of the piperazine ring. The 
conservation of one interaction with the hinge region and the establishment of a new 
interaction by the phenyl-piperazinyl moiety of SU4984 suggest that its activity on 
RET mutant kinase should not be significantly reduced (Figure 3.3.8).
Figure 3.3.8 (A) Compound SU4984 from the crystal structure of the complex FGFR1-SU4984 
(1AGW) (C, magenta; O, red; N, blue) and from GOLD calculation (C, green; O, red; N, blue) 
superimposed on the model of RET. The nucleotide binding loop (yellow), the DFG motif 
(blue), the activation loop (orange) and the hinge region (red) of RET are indicated. Figure 
generated by Sybyl 7.0 [144]. (B-E) Schematic representation of SU5416 interactions with 
models of RET'"1 (B) and RETV804M (C) and SU4984 interactions with RETwt (D) and RETV804M 
(E). Residues forming Van der Waals contacts are indicated; those involved in H-bonding are 
shown in ball-and-stick representation. H-bonds are shown as dotted lines with distance given in 
Angstrom. Figures generated by LIGPLOT [145].
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3.3.3.6 Specificity of SU5416
SU5416 was discovered as a VEGFR2 inhibitor, with some activity against PDGFR but 
no inhibition of EGFR, HER2, and IGF1R [146]. It was later shown to inhibit FLT-3 
and c-Kit tyrosine kinases at nanomolar concentrations [135], as well as c-Src, MET, 
FGFR1, and Zap70 at micromolar doses [135, 147]. As for several other kinase 
inhibitors, initial assumption of selectivity was due to limited experimental testing. 
Therefore, the specificity profile of SU5416 was investigated further by analysing its 
inhibitory activity on a panel of 52 available protein kinases belonging to different 
classes, at 10 pM inhibitor, a concentration that causes 97% inhibition the activity of 
RET kinase. In order to perform this experiment SU5416 was sent to Prof. Cohen’s lab 
in the MRC protein phosphorylation unit, School of life science, at the University of 
Dundee (United Kingdom). As reported in Table 3.3.2, c-Src was inhibited by 
approximately 50%, in line with previous reports, while Src-related Lck was 70% 
inhibited. In addition, we found four serine/threonine kinases that showed less than 10% 
residual activity in the presence of the inhibitor, phosphorylase kinase (PHK), the 
checkpoint kinase Chk2 [148], the centromere-associated kinase Aurora B, which is 
often over-expressed in cancer cells [149], and mammalian Ste20-like kinase 2 (MST2), 
a pro-apoptotic factor [150]. Four other kinases (MAPKAP-Kla and lb, SGK, and 
p70S6K) were substantially (>80%) but not completely inhibited by 10 pM SU5416.
121
RET inhibition by SU5416
Activity (% o f control) Protein kinase Activity (% o f control) i
1
Protein kinase
AMPK 43 ± 8 MSK1 38 ± 4
Aurora B 5 ± 2 MST2 6 ±  1
CAMK-1 67 ± 2 NEK2a 55 ±  1
CDK2/cyclin A 92 ± 5 NEK6 91 ±  8
CHK1 29 ± 6 NEK7 88 ± 3
CHK2 7 ± 2 p70 S6K 19 ± 1
CK1 21 ± 4 PDK1 58 ± 6
CK2 81 ±  8 PHK 4 ±  0
CSK 95 ± 6 PIM2 94 ± 2
DYRKla 50 ± 2 PKA 78 ±  1
EFK2 80 ±  1 PKB&ph 81 ±  1
ERK8 55 ± 3 PKBb 89 ± 1
GSK3b 85 ± 5 PKCa 99 ± 7
IKKb 100 ± 6 PKD1 43 ± 0
JNK/SAPKlc 86 ± 2 PLK1 85 ± 8
JNK3 75 ± 1 PRAK 66 ± 4
Lck 27 ± 5 PRK2 47 ± 1
MAPK2/ERK2 73 ± 1 ROCK-II 59 ± 2
MAPKAP-Kla 12 ± 3 SAPK2a/p38 73 ± 0
MAPKAP-Klb 16 ±  4 SAPK2b/p38/32 86 ± 3
MAPKAP-K2 103 ± 2 SAPK3/p38g 78 ± 2
MAPKAP-K3 80 ± 7 SAPK4/p38d 70 ± 7  !
MARK3 31 ± 2 SGK 14 ± 4
MKK1 23 ± 2 smMLCK 23 ± 4
MNK1 78 ± 0 Src 51 ± 4
MNK2 92 ± 1 SRPK1 68 ± 2
1
Table 3.3.2 Specificity activity of SU5416 in a wide range of protein kinases
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3.3.4 Discussion
In a preliminary screening of potential RET inhibitors, it was noted that a couple of 
indolinone compounds showed good inhibition in vitro, but poor activity in cell culture. 
This was largely due to insolubility of the compounds. It was, therefore, decided to test 
other SUGEN compounds since they share the same oxindole scaffold. Particular 
attention was focussed on SU5416 because it seemed promising in computational 
modelling and it had already been demonstrated to possess good inhibitory properties in 
vivo. SU5416 inhibited RET in cell-free kinase assays at nanomolar doses, comparable 
to the IC50 values reported for Flt-3 and c-Kit [151]. Our assay also confirmed that 
SU5416 to be a potent inhibitor of Flt-3, while it blocked ALK and ABL kinases only at 
micromolar concentrations. Selectivity of this compound had also been reported by 
previous studies. Sun et al described SU5416 to be inactive against a number of other 
kinases, such as EGFR, Her-2, IGF-1R, and weakly inhibited PDGFR [147] and c-Kit 
[135]. A related molecule, RPI-1, has antitumor activity against thyroid carcinoma in 
mice [70, 71]. In molecular modelling studies, SU5416 docked in the RET active site, in 
the same position occupied by other indolinone compounds in crystallisation studies 
with the related tyrosine kinase, FGFR1. In view of its potency and selectivity and its 
good pharmacokinetics, and the fact that it is amenable to chemical modifications, the 
results described in this thesis indicate that SU5416 may be a good lead structure for 
new, more selective RET inhibitors.
Inhibition of RET by SU5416 was obtained in various model systems, including IL-3- 
dependent cells, murine fibroblasts and human PTC cells. The growth of RET/PTC-l- 
expressing TPC-1 cells was selectively growth-inhibited compared to the RET-negative 
PTC cell line NPA, originating from the same cell type as TPC-1 but carry a B-Raf
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mutation as the primary oncogenic lesion. This result indicated that growth inhibition 
induced by SU5416 is indeed mediated by RET. Involvement of the VEGFRs can be 
excluded because NPA cells express these receptors and were not affected by SU5416. 
The compound was toxic to NPA control cells only at high concentrations, possibly 
because of the non-specific inhibition of other proliferative pathways. Also, the use of 
stably transfected cell lines, such as the NIH and Ba/F3 expressing i.e. RET/PTC2, 
helped to define the role of RET oncogene in mediating SU5416 biological effects. 
Since both parental and transfected cells are genetically identical with the exception of 
the transgene, the growth arrest observed solely in the latter provides support that RET 
is the relevant target. Blockage of RET autophosphorylation was observed in TPC-1 
cells as early as 8 hours and was followed by reduced signalling through the ERK and 
JNK pathways. The RAS/RAF/ERK1/2 pathway is known to be activated by RET both 
in transfectants and in human thyroid carcinoma cell lines, through docking of She 
adaptor proteins to tyrosine-1062 [39, 152]. JNK1/2 MAPKs are normally involved in 
stress response and induction of apoptosis [153]. In thyroid tissue, activation of JNKs is 
instead induced by growth stimuli [154, 155]. Indeed, thyroid carcinoma cells are 
reported to express high levels of activated JNK, both via Dok-1 phosphorylation and 
through activation of the small GTPase Cdc42 [156]. Our results confirmed the role of 
these pathways in cellular proliferation, rather than in apoptosis process. Indeed, the 
inhibition of RET blocked the cellular growth in dose-dependent manner but did not 
result in apoptosis in TPC-1 cells. This is in agreement with previous reports which 
showed little or no evidence of cell death after block of oncogenic RET activity [50, 
64]. Either these cells are somewhat resistant to apoptosis and need longer exposure to 
drugs in order to induce programmed cell death, or the oncogenic activity of RET/PTC 
is mainly exerted by a growth advantage rather than increased survival. Indeed, a multi­
124
RET inhibition by SU5416
step model of thyroid carcinoma is emerging where RET is a very early event that 
requires secondary events (such as the loss of p53 expression) to establish full-blown 
aggressive carcinoma [157]. Cell cycle arrest induced by SU5416 coincided with a 
significant up-regulation of the CDK inhibitor protein p27, in line with a previous report 
[158]. Surprisingly, p21 expression was instead down-modulated. The same result was 
obtained in two independent experiments, using different antibodies. Although we 
cannot exclude that this effect may be due to unspecific toxicity of the compound, few 
cases have been described where p21 repression, rather than induction, correlates with 
cell cycle arrest [159, 160].
Activating mutations at valine-804 of RET kinase domain occur both in sporadic and in 
familial MTC with aggressive behaviour and are sometimes associated with a second 
RET mutation. RETV804 mutants show resistance to the kinase inhibitors PP1 and 
ZD6474 [54]. The valine 804 represents the “gate-keeper” residue in the RET kinase 
domain and, as reported in the Introduction section, the mutations at this position cause 
resistance to small molecule inhibitors. Replacement of Tyr-315 in ABL by bulkier 
residues, such as isoleucine, causes resistance to Imatinib. Similarly, PP1 is unable to 
inhibit c-SrcT341M kinase, or oncogenic v-Src, which carries an isoleucine at the 
corresponding position [53]. The same phenomenon was observed also for EGFR, 
FGFR, and PDGFR [55]. On the other hand, changing Phe-691 to a smaller threonine 
rendered the FLT-3 kinase sensitive to Imatinib [161]. In contrast, three indolinone 
compounds were found to be insensitive to mutations of the gate-keeper amino acid, 
suggesting that this class of inhibitors may represent an exception to the rule [55]. The 
possibility that RET mutant V804M was inhibited by SU5416 was investigated. Using 
SU5416, no significant inhibition at concentrations that give almost 100% block of 
wild-type RET activity was detected. This result was in contrast with the proposed
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property of indolinone compounds of entering kinases carrying bulky gatekeeper 
residues [55]. In their work, Blencke et al. [55] showed that three such compounds 
inhibited wild-type and mutant kinases with similar potency, although at rather high 
doses. In the current study, however, SU5416 did not alter RETV804M activity even at 30 
pM, showing that not all indolinones behave in a similar inhibitory fashion. SU4984, a 
compound that showed activity on mutant FGFR1 [147] was used as a control in the 
current study. This inhibitor belongs to the same series of compounds as SU5416, 
developed by Sun et al [146]. It has 1-log reduced potency against RET, compared to 
SU5416, possibly because it exists predominantly as the inactive E  isomer (referring to 
the configuration of the C-3 substituent). Unlike SU5416, compound SU4984 was able 
to inhibit mutant RET, as it could be predicted by published results [55]. A possible 
reason to account for this difference between the two compounds was provided by the 
molecular modelling study. This demonstrated that, while SU5416 loses hydrogen 
interactions in RETV804M, SU4984 does not and establishes a new H-bond, Y806. 
However, it should be noted that Y806 is thought to be phosphorylated in fully activated 
RET [162]. It is unknown at present whether the enzyme used in the current assay is 
phosphorylated on this particular residue. Should this be the case, then the interaction 
would take place only when the piperazine nitrogen is protonated.
Finally, the activity of compound SU5416 on a large panel of protein kinases is 
described. New targets of SU5416 were identified, including some serine/threonine 
kinases, unrelated to known target tyrosine kinases. This is of interest, not only for 
biochemical and biological studies on the newly identified targets, but also as a caveat 
for cell-based studies focused on known targets. In this study, biological effects were 
always correlated to RET inactivation. Although the possibility that the observations
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described here are at least partially due to off-target effects cannot be disregarded, the in- 
vitro data support the notion that RET is a direct target of SU5416.
In conclusion, we have shown that SU5416 is a potent fairly selective inhibitor of RET 
catalytic activity in biochemical and cellular assays and may represent a good starting 
structure in the search of a selective RET inhibitor, even if it does not inhibit RETV804M.
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3.4 Target validation of B-RAF and PLX4032 characterization
3.4.1 Introduction
In this section I analysed the role of B-RAF in cell growth and survival in melanoma 
and thyroid cancer cells. I used RNA interference (RNAi) technology to validate B- 
RAF as a potential therapeutic target and characterised a new small molecule inhibitor 
that was selectively active against this protein.
3.4.1.1 siRNA principles
RNAi is a gene-regulatory mechanism triggered by dsRNAs. Small interfering RNAs 
(siRNAs) consist of RNA duplexes of 21-23nt in length that are base paired with 2-nt 3’ 
overhangs, whose antisense strand is complementary to target mRNA. siRNAs mimic 
the intermediates of the natural processing of longer double-stranded RNA triggered by 
RNAse III enzymes, such as Dicer, which, together with other components of the RNAi 
machinery, specifically recognize an siRNA duplex and selectively incorporate one of 
the siRNA strands into RISCs (RNA-induced silencing complex). The RISC includes 
the catalytic endonuclease-containing complex which is ultimately responsible for the 
strong gene-knock down effect. The antisense strand to the targeted mRNA is often 
referred to as the guide strand while its base-paired sense strand is named the passenger 
strand, which is destroyed upon the incorporation of the guide strand into RISC. The 
catalytic RISC recognizes mRNAs containing perfect, or near perfect, complementary 
sequences and cleaves the mRNA at the site precisely lOnt upstream of the nucleotide 
opposite the 5’-most nucleotide of the guide strand. The mRNA fragments are
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subsequently degraded by cellular nucleases, resulting in knockdown of the expression 
of the corresponding gene.
3.4.1.2 siRNA selection
In order to exploit RNAi as a tool for gene silencing, a number of variables has to be 
considered for the generation of effective siRNAs.
Although the selection of siRNA against a gene of interest starts with an annotated 
target mRNA sequence, including its 5’-3’ untranslated regions (UTRs), splice, 
polymorphic and allelic variant, the coding sequence remains the most commonly 
targeted [163]. Several algorithms have been developed in recent years that rely on the 
intrinsic sequence and stability features of functional siRNAs [164, 165]. Following 
selection, each candidate siRNA is examined for similarity to all other mRNA 
transcripts that might unintentionally be targeted at a genome-wide level. It has been 
noted that structurally symmetric but primary sequence-asymmetric siRNAs, from 
which the target mRNA complementary guide strand has been generated, demonstrate a 
great propensity to be assembled into the RISC than the passenger strand, and show 
improved efficacy and specificity [166]. Most of the functional siRNAs have a low to 
medium G+C content ranging between 30-55%. Indeed, too low a G+C content may 
destabilize the siRNA duplexes and reduce the affinity for target mRNA binding, while 
too high a G+C content may avoid RISC loading or cleavage-product release [165]. 
Additionally, stable duplexes without internal repeats or palindromes are the better 
silencers [167].
Single nucleotide positional preferences into the siRNA sequences have been identified, 
namely, U or A at position 10, C or G at position 19 and/or A+U richness between 
position 1 and 7 [168]. These features correlate with the rule of thermodynamic
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asymmetry and the preferred nucleotides on the indicated positions may contribute to 
the bias for the selection of antisense strand, for example, A or U at position 10 may 
promote the catalytic RISC mediated passenger strand and substrate cleavage [168].
Each strand of the siRNA duplex, once assembled into the RISC, can guide the 
recognition of fully or partially complementary target mRNAs, named as on and off 
targets, respectively. Off targets can share contiguous and centrally located sequence 
complementarity over more than half of the siRNA sequence somewhere within the 
mRNA sequence [169], as well as show solely 6 or 7 nucleotides of perfect match 
preferentially in the 3’UTRs with position 2-7 and 2-8 of the guide siRNA [170]. To 
enforce the specificity, the current strategy is to select siRNAs in which the strand 
entering in RISC has some mismatches to all undesired target mRNAs [168].
3.4.1.3 Inducible systems
RNAi has the potential to permit the down-regulation of virtually any gene. It is 
important in many circumstances that this knockdown is externally controllable, for 
example, to examine the role of certain protein in human pathology. In this case, the 
effectors of the knockdown can be either short hairpin RNA (shRNA) produced from 
RNA polymerase III promoters or micro RNA (miRNA)-based shRNA expressed from 
Pol II promoters [171]. Pol III promoters are ideally suited for the production of 
shRNAs, as they produce RNA transcripts that lack the polyadenylation tail and have a 
well-defined transcriptional start site. Repression of an shRNA driven by Pol III 
promoter can be achieved by placing an Escherichia Coli Tet operator (tetO) sequence 
upstream of the transcription start site to interfere with the function of the TATA box 
through the recruitment of the tetracycline repressor (tetR). In absence of the drug, tetR 
binds to tetO and the production of shRNA is suppressed. Upon addition of tetracycline
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or doxycycline, repression is relieved by sequestration of tetR [172-174]. This was the 
system of choice used in my work. An inducible system was necessary to produce 
stably transfected cell lines. In these models, the silencing of B-RAF was modulated 
and its role in cellular context was evaluated also in long term treatment. Doxycycline 
was not toxic and did not induce aberrant responses in cells. Furthermore, a shRNA 
under control of TetO was previously used to validate B-RAF in melanoma cell lines 
[173], thus this system could be efficiently applied also to thyroid model.
Another inducible system is based on the Kruppel associated box (KRAB) domain 
found in many zinc-finger proteins and that can silence both pol II and pol III promoters 
by triggering heterochromatin formation. When tethered to specific DNA regions within 
the context of chimeric proteins, KRAB can induce a general silencing of transcription 
within up to 3 kilobases from its binding site. When KRAB is fused to the tetR DNA 
binding domain, the resulting tTRKRAB chimeric protein allows for the doxycycline- 
mediated control of any promoter placed nearby tetO sequences, in either tet-on and tet- 
off configurations depending on the tetR version used [175].
The major advantages of pol III promoter- based conditional systems are their 
demonstrated high activity in most cell types, both in vitro and in vivo, the small size of 
the expression cassettes and the robust levels of knockdown achieved with shRNA. One 
limitation, however, is their lack of tissue-specificity. In contrast, the pol II-based 
production of miRNA-based shRNA allow tissue-specific knockdown and should be 
fully amenable to exogenous control, for instance with the tet-KRAB system. 
Nevertheless, pol II promoter-based systems require that the transcript be processed by 
the enzyme Drosha to produce shRNA before Dicer-mediated processing yields siRNA, 
thus adding a level of complexity that may be detrimental in some settings [175].
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3.4.2 Materials and methods
3.4.2.1 Cell cultures
Four cancer cell lines were used in this study: the malignant melanoma cell line A375, 
the anaplastic thyroid carcinoma cell line ARO, the NPA cell line established from a 
poorly differentiated thyroid carcinoma and the PTC-derived cell line TPC1. A375 were 
grown in RPMI-1640, other cell lines in DMEM; all media were supplemented with 
10% fetal bovine serum (Sigma South America origin), 2mmol/L L-glutamine, 100 
units/ml penicillin-streptomycin (Sigma) and lOOunits/ml gentamycin.
3.4.2.2 Inducible siRNA
To generate the anti-BRAF shRNA construct, the following oligonucleotides were used: 
BRAF shRNA-1 (sense)
5 'gatcccc AG A ATT GG ATCT GG AT C ATTT C A AG AG A AT G ATCC AG AT CCA ATT C 
Ttttttggaaa-3',
BRAF shRNA-1 (antisense)
5 ’tttccaaaaa AG A ATT GG AT CT GG AT C ATT CT CTT G A A AT GAT CC AG AT CC AATT 
CTggggatc-3' [176].
This sequence was cloned in pTer + vector using Hind III and Bgl II restriction 
enzymes. The system described by van der Wetering et al. [172] was used. In this 
system the pCDNA6TR vector encodes for the Tet repressor that binds the TetON 
operon in pTER vector; in the presence of doxycycline, the Tet repressor leaves the 
TetON operon allowing shRNA expression. A375 and ARO cells were transfected using
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the Ca2PC>4 method firstly with the pCDNA6TR vector and selected with 4pg/ml 
blasticidin (Sigma Aldrich). Briefly, 3 xlO5 cells were seeded in 2 ml of medium in six- 
multiwell plates (60% confluence). On the following day, the cells were transfected 
with 1 jug of DNA and incubated at 37°C for 8 hours. The medium was then removed, 
the cells washed with PBS IX, treated with 1ml of 70% glycerol for one minute and 
then washed twice again with PBS IX. The selection procedure was started 72 hours 
after transfection. Limiting dilutions were performed and each clone was screened by a 
Luciferase assay (Stop and Glo®, Promega), following the manufacturer’s protocol, to 
evaluate the ratio between induction by doxycycline and repression in absence of the 
drug. Positive clones were then transfected with the second vector (pTer-BRAF- 
shRNA-1) and selected with 600pg/ml zeocin (Invitrogen). Stably transfected cell lines 
were cultured in the appropriate medium, adding blasticidin and zeocin every two 
passages.
3.4.2.3 Western blot and inhibitors
We seeded 3x 105 cells in 2 ml of medium in six-multiwell plate and harvested them 
after 72 and 96 hours of treatment with doxycycline 1 mg/ml or PLX4032 at the 
indicated doses. Cells were directly lysated in Laemmli buffer and boiled. Western blot 
was performed with the procedure described before. Antibodies were used in western 
blotting according to recommended dilutions. Anti-B-RAF (C l9) was purchased from 
Santa Cruz Biotechnology (Santa Cruz, CA, USA), anti-phospho-MEK 1/2 (Ser 217- 
221), anti-MEKl/2, anti-phospho-AKT (Ser473), anti-AKT, anti-p27Kip 1 were from 
Cell Signalling Technology (Danvers, MA, USA), anti-BCLXL (7B2.5) was from 
Upstate Biotechnology (Charlottes-ville, VA, USA), anti-p21CIP/WAF was purchased
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from New England Biolabs (UK), anti-NIS (clone 2.2) was from Chemicon 
International (Temecula, CA, USA) and anti-actin from Sigma .
PLX4032 was kindly provided from Plexxikon (Berkeley, CA, USA). The compound 
was dissolved in DMSO and stored at -20°C until used.
3.4.2.4 Proliferation assay
Serial dilutions of kinase inhibitor were prepared in cell culture medium with 5% FBS 
in 96-well plates. Cells were then resuspended in 5% FBS medium and added to the 
plate at 104cells/well. Cell proliferation was measured at 72 h using the tritiated- 
thymidine incorporation assay as described previously [141]. Each data point was done 
in triplicate.
3.4.2.5 Cell-cvcle analysis and apoptosis
Cells were seeded in six-well plates at a density of 2 x 105/well and treated with 
inhibitor or vehicle (DMSO). Cells were harvested at 72 h and 96 h after treatment, 
washed with PBS and fixed in 70% ethanol at -20 °C over night. The samples were then 
centrifuged and resuspended in PBS containing 50 pg/ml propidium iodide and 100 
jig/ml RNase A, incubated at 37 °C for 30 min and analyzed by FACScan flow 
cytometer (Beckton Dickinson, Franklin Lakes, NJ, USA).
Annexin V binding assay was performed following manufacturer’s protocol (Promega).
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3.4.2.6 Adenovirus infection
Adenoviruses were kindly provided by dr Carlo Gaetano (Istituto dermopatico 
deirimmacolata, Rome, Italy) [177]. Experiments were performed by plating 3 xlO5 
cells in 2 ml of appropriate medium with PLX4032 added at the indicated doses. After 
24 h the virus was diluted in 1 ml of medium containing 2% FBS, and cells were 
infected cells by incubation with the diluted virus for 2 h at 37°C. The viral suspension 
was then removed, fresh medium added and the cells were cultured for 72 h or 96 h. 
The infection efficiency was evaluated by measuring the fluorescence from green 
fluorescence protein (present in adenoviral construct as marker of the infection) (GFP) 
using a FACScan flow cytometer (Beckton Dickinson, Franklin Lakes, NJ, USA).
3.4.2.7 Statistical analysis
Data were always generated in triplicate and mean ± S.D. is reported on the graphs. 
Dose-response curves were normalized over the vehicle control and analysed by non­
linear regression using Graph Pad PRISM 4.0 software. IC50 data are reported as the 
global fitting of at least three independent experiments, with 95% confidence interval 
(CI).
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3.4.3 Results
3.4.3.1 B-Raf validation
An inducible siRNA under control of doxycycline was established to validate B-Raf as 
a target for a therapeutic intervention. The ARO cell line, derived from anaplastic 
thyroid carcinoma, was used as the test model. These cells are heterozygous for a B- 
RAF mutation (V600E/wt B-RAF) and also carry an inactivating mutation on the 
hemizigous p53 allele [178]. As described above, ARO cells were transfected with two 
plasmids: the first encoding for the Tet Repressor protein while the second one encodes 
for the siRNA sequence. After the first transfection, those clones that showed the 
highest luciferase expression in presence of doxycycline and the strongest repression in 
absence of the compound were selected. The selection was performed using a luciferase 
assay and only those clones with induction/inhibition ratio of more than 3 were 
considered for further culture. Since siRNA is an autocatalytic system, the control of the 
repression in absence of doxycycline was more important than the induction. After the 
second transfection, the silencing of the B-RAF protein and the consequent 
downregulation of downstream pathways were evaluated after 72h or 96h of treatment 
with doxycycline (lpg/ml). In particular, the effects on MEK phosphorylation (the 
direct substrate of B-RAF in the MAPK pathway) were studied. The stably transfected 
A375 malignant melanoma cell line, homozygous for B-RAF mutation (V600E/V600E) 
and p53 wild type was used as a control. The efficient siRNA silencing of B-RAF on 
this cell line has recently been published [173].
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Figure 3.4.1 Down-regulation of B-RAF protein by siRNA after 72 or 96 hours of doxycyclin 
treatment, in melanoma (A375) and anaplastic thyroid carcinoma (ARO) cell lines. Dilutions of 
untreated cells (-) lysates were loaded in order to evaluate the silencing (from left to right: 5, 10, 
15 pi); 15 pi of treated cells (+) lysates were loaded. MEK1/2 phosphorylation was inhibited in 
correspondence of B-RAF modulation. Anti-actin and anti-MEKl/2 immunoblotting are shown 
as loading controls.
From Figure 3.4.1 it can be seen that B-RAF was silenced by >70% in both cell lines 
after 72 hours compared to untreated controls. A further decrease in expression levels 
was observed by prolonging the treatment till 96h. MEK phosphorylation was also 
down-regulated in correlation with the reduced levels of B-RAF. No changes in MEK 
were, however, detected.
Cell growth was delayed in the ARO cell line and arrested in the A375 melanoma cell
line in comparison with un-treated cells (Figure 3.4.2) and cells transfected only with
the first plasmid (not shown). Furthermore, cell cycle analyses showed an important
increase the number of cells in the subGl fraction in the A375 cell line with a
consequent decrease in G1 population and an increase in G2/M, suggesting increased
apoptosis and mitotic block. In contrast, only the G2/M fraction significantly decreased
in the ARO cells, suggesting a decrease rate in cell proliferation. These experiments
were accomplished with 96h treatment at the indicated dose of doxycycline. The
induction of the apoptotic process in melanoma in consequence to B-RAF silencing was
previously observed [173, 179]. In anaplastic thyroid carcinoma B-RAF/MAPK
pathway was likely to comprise main survival mechanisms [180],
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Figure 3.4.2 Biological effects of B-RAF silencing: (A) growth curves of A375 and ARO cell 
lines in absence or presence of doxycycline; cells were treated and counted by Trypan Blue 
Exclusion assay. Doxycycline-treated A375 cells were all dead at day 7. For ARO cells, the 
treatment continued till day 9 in order to evaluate the effect in the differentiation process. (B) 
cell cycle analysis of A375 and ARO cells after 96h of shRNA induction. An increase in subGl 
and decrease in G1 fractions is evident in melanoma cells, while ARO cell line showed a 
decrease in the G2/M peak; * = p < 0.01; ** p < 0.001
One possible explanation to the delay in the growth of ARO cells could be the 
restoration of differentiation [86, 181]. To investigate this, the levels of expression of 
Sodium Iodide Simporter (NIS) after 8 days treatment were analysed using Western 
blotting. The appearance of NIS is a mark of the re-differentiation process [182, 183], 
NIS is responsible to iodide uptake in normal thyrocytes and radioactive iodide in 
targeted therapies against differentiated thyroid cancer [184, 185], Re-expression of the
131NIS pump, if correctly located at membrane level, makes I therapy possible also in 
tumours that have lost this protein [182, 183, 186, 187],
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As shown in figure 3.4.3, the expression of NIS was inversely correlated to B-RAF 
silencing. The presence of NIS was observed only after long-term treatment, probably 
because the cells need several days to adapt to a lack of the proliferative and 
dedifferentiating stimulus of B-RAF.
ARO
D ox1p g /m l  + d8
aNIS 
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Figure 3.4.3 Western blot of total lysate after long term treatment with doxycycline. NIS and B- 
RAF expression was evaluated, anti-actin is the loading control.
In summary, these results provide evidence that B-RAF could be considered as a 
possible target for small molecule inhibitors in thyroid carcinoma. Its down-regulation 
induces re-differentiation and decrease in cell growth, even if doesn’t determine 
apoptotic death in thyroid carcinoma. In contrast, apoptosis was observed in melanoma 
model, as expected [173].
3.4.3.2 PLX4032 characterization
Since we validated B-RAF as a potential target in thyroid carcinoma cell lines, the 
biochemical characterization of a new BRAF inhibitor, PLX4032, was undertaken. 
PLX4032 was recently developed by Plexxikon for the treatment of malignant 
melanoma and other malignancies with BRAF hyperactivation. This compound was 
tested on three thyroid carcinoma cell lines and on the A375 melanoma cell line. The 
ARO cell line previously characterized by siRNA as anaplastic thyroid carcinoma
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model, the NPA cell line derived from poorly differentiated thyroid carcinoma and the 
TPC1 cell line established from a well differentiated papillary carcinoma were studied. 
A study of cell lines derived from different staged tumours should enable the 
characterization of the inhibitor to be obtained. From a genetic point of view, NPA 
presents homozygous V600E B-RAF and p53 mutated [96], while TPC1 carries the 
RET-PTC1 translocation [188], as described in the previous section.
Dose- response curves indicated an efficient activity of PLX4032 in all cellular systems 
investigated at micromolar doses. Western blot analyses confirmed the inhibitory block 
on MEK phosphorylation in dose-dependent manner by PLX4032 and, therefore, a 
possible involvement of the MAPK pathway in cellular growth control [189]. Time 
course experiments showed that B-RAF inhibition started after 4 hours of treatment and
3 • •continued for 24 hours (data not shown). As expected, in H-Thymidine proliferation 
assay, the IC5 0  value was lower in the A3 75 cell line, while both the ARO and NPA 
cells demonstrated similar level of inhibition It is interesting to note that the IC5 0  of 
ARO cells doubled that of NPA. One explanation to account for this is that PLX4032 is 
more potent against V600E B-RAF and the ARO and NPA cell lines are heterozygous 
and homozygous for this molecule, respectively. The TPC1 cell line showed a 50 fold 
higher IC5 0  value, probably due to numerous signalling pathways activated by the 
RET/PTC in addition to those of the RAF-MEK-ERK pathway [37, 40, 190].
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PLX4032, pM
EC50 (pM) 95% Cl
A375 0.0472 0.04058 to 0.05448
NPA 0.1260 0.07350 to 0.2159
ARO 0.2051 0.1295 to 0.3250
TPC1 9.982 1.854 to 53.75
Figure 3.4.4 B-RAF inhibition by PLX 4032: (A) effects o f  B-RAF inhibition on 
phosphorylation o f  its direct substrate, M EK 1/2. A nti-M E K l/2 western blot demonstrated that 
PLX4032 did not interfere with the expression levels o f  the protein and did not induce M EK  
degradation. (B) Relative proliferation o f  the indicated cell lines in the presencev. o f  increasing 
concentrations o f  PLX 4032. The IC50 value (calculated as the dose that caused 50% inhibition) 
for each cell line is reported in the table.
The cell cycle was analysed using two different methods: propidium iodide staining and 
annexin V binding assay. In the first assay, the DNA content in relation to its 
subcellular localisation is evaluated in fixed cells [191]. In the second case, annexin 
specifically binds to phosphaditylserine when it’s exposed on the outer layer of the 
cellular membrane; this phenomenon usually occurs during the apoptotic process [192]. 
The concomitant coloration with propidium that recognizes non-viable cells and FITC- 
annexin V allows the discrimination between intact, early and late apoptotic cells. Both 
experiments were quantified and analysed by flow cytometry. The Annexin V assay is 
more sensitive than propidium staining and allows the distinction of early apoptotic 
cells belonging to the G1 fraction.
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Figure 3.4.5 Cell cycle analysis with propidium iodide staining after 96h treatment with 0, 1, 
lOpM PLX4032 * = p < 0.01; ** p < 0.001
As expected, on contrast to the three thyroid derived cell lines, the A375 melanoma cell 
line showed a significant apoptosis at a concentration of lOpM PLX4032. A reduction 
of the G2/M fraction of the ARO cells was observed while the NPA cell line showed an 
arrest in G1 and a less important decrease in S and G2/M phases. PLX4032 did not 
affect the TPC1 cell cycle.
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Figure 3.4.6 Effects of PLX4032 on cell cycle: Annexin V binding assay was used to determine 
the percentage of early apoptotic cells in all cell lines after 96h of treatment. A375 underwent 
apoptosis in a dose-dependent manner, while in thyroid carcinoma cell lines no significant 
apoptosis was observed even at high doses.
The apoptotic cell percentage increased in both of the A375 and NPA cell lines at lOpM 
PLX4032 whereas no significant variation was detected in the ARO cells (Figure 3.4.6). 
One possible explanation to account for this difference is that the ARO lines is derived 
from more un-differentiated tumour stage [178] and it is therefore probably that they 
possess additional chromosomal mutations that are not present in NPA. These results 
obtained on the thyroid cell lines are consistent with that recently reported using other 
B-RAF inhibitors [193].
The inhibition of MAPK signalling by a down-regulation of B-RAF or by using a 
chemical block of its enzymatic activity resulted in the same consequence in terms of 
cell growth and alterations in cell cycle in the present study. We could conclude that
143
T a r g e t  v a l i d a t i o n  of  B-RAF
PLX4032 was specific for B-RAF used at high doses and was prevalently potent on B- 
RAF mutated cell lines because of its inability to inhibit the RET-positive cell line.
3.4.3.3 Comparison between melanoma and thyroid carcinoma cell lines
It was important to investigate the reasons for the different behaviour observed between 
melanoma and thyroid carcinoma cell lines, in particular the A375 and ARO cells 
showed a significantly different response to B-RAF inhibition. It was hypothesized that 
there the involvement of other cell signalling pathway, as well as alteration(s) in anti- 
apoptotic factors expression levels or cell cycle regulators siRNA experiments were 
therefore performed in order to ensure that the effects observed were related only to 
silence of B-RAF.
A375 ARO
ctpAKT
aAKT
o B C L xl
ap27
ap21
aactin
Dox 1pg/ml
Figure 3.4.7 Western blot analysis of total cell lysate after treatment with doxycycline for 96h. 
Decreased B-RAF expression levels have been shown in figure 3.4.1 Anti- actin blot is the 
loading control.
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B-RAF down-regulation has been showed in fig. 3.4.7 and the same lysates were used 
in Western blotting studies to investigate the expression of other signalling molecules 
involved in apoptotic/proliferation pathways.
Intriguingly, an increased phosphorylation of AKT protein was observed in both cell 
lines, when the MAPK pathway was switched off (Figure 3.4.7). A possible explanation 
is that the cells may have attempted to activate pathways that may be redundant in the 
presence of B-RAF. No differences were observed in BCLxl or BCL2 levels (data not 
shown) and the activation of this anti-apoptotic pathway could be excluded in the 
thyroid cell lines. In contrast, differences in p21 expression, but not p27 was detected. 
The A375 melanoma cell line down-regulated p21 in response to B-RAF silencing, 
while up-regulation of p21 was present in the ARO thyroid cells. Similar results were 
obtained in PLX4032-treated cells (Figure 3.4.8) thus demonstrating that the changes in 
p21 expression were not due to non-specific effects of doxycycline or a side-effeet of 
shRNA.
A375 ARO
+ P L X I O p M
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Figure 3.4.8 Western blot of anti-p21 of total lysate of PLX treated cells: p21 was down- 
regulated in the A375 cell line, while it was up-regulated in ARO cells. The correspondent 
inhibition of B-RAF has been showed in fig. 3.4.4 A. Anti actin was blotted as loading control.
To evaluate the role of p21 in the resistance to apoptosis resistance two Adenovirus 
vectors were used: one encodes for p21 to restore p21 levels in A375, the other one 
encodes for an antisense p21 to knock down the protein in ARO cell line. Cells were 
transfected by the relevant Adenovirus and also simultaneously treated with PLX4032.
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The use of this small molecule inhibitor resulted in an immediate block of B-RAF 
activity with its consequent change in p21 levels. The effects on cell cycle were 
analysed using propidium iodide staining and flow cytometry. Annexin V assay could 
not be used because Adenoviruses contained green fluorescence protein gene, which 
prevents analysis using FITC-Annexin V.
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Figure 3.4.9 Role of p21CIP/WAF modulation in cell cycle: p21 expression was up-regulated 
and down-regulated by Adenoviral vector in A375 and ARO, respectively. Concomitant 
treatment with PLX4032 was perfonned. Protection from apoptosis was observed in the 
melanoma cell line, while in thyroid carcinoma no effect on programmed cell death was 
obtained. In both cases, p21 expression was modulated as expected (insets). * = p < 0.01; **p<
0.001
As shown in figure 3.4.9, both adenoviruses reversed the effects of B-RAF inhibition. In 
the case of A375, re-expression of p21 partially protected from apoptosis, while in the 
ARO cells, the G2/M fraction increased at the same level of un-treated cells. No 
evidence of apoptosis in ARO cells was observed in several experiments, thus 
confirming the natural resistance of this cell line to undergo to apoptotic process. A 
relationship was further confirmed between B-RAF and p21 expression. The silencing 
of B-RAF resulted in a lack of p21 regulation and the restoration of normal apoptotic 
process in melanoma cells or proliferation arrest in anaplastic thryroid carcinoma cells.
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3.4.4 Discussion
In this part of the project, I focussed my attention on the MAPK signalling pathway that 
is one of downstream pathways activated by RET in thyroid carcinomas. In particular, I 
was interested on understanding the role of B-RAF in this pathology and verifying if it 
could be a possible target for selective therapy with small molecule inhibitors. As 
previously described, B-RAF is often mutated in PTC and this alteration is related to the 
un-differentiated status of the tumour. An inducible siRNA was established to silence 
B-RAF expression in the ARO cell line under control of doxycycline [172]. The 
presence of a stably transfected cell line makes it possible to perform long term 
treatments without losing silencing efficiency. The melanoma A375 cell lines was 
recently used as a model to validate B-RAF expression in melanoma [173] using the 
same system and construct used in the current study. siRNA efficiently worked in both 
cell lines, silencing B-RAF protein within 96h and down-regulating the MAPK 
pathway. RAF-MEK1/2-ERK1/2 cascade regulates the progression through G1 to DNA 
synthesising S-phase, in melanoma [194], while in thyroid cancer recent evidences rely 
on RAS and G2/M checkpoint, indicating a main involvement of MAPK pathway in 
this cell cycle phase [195]. In long-term treatment, the restoration of NIS expression 
indicative of the restoration of differentiation properties of the cell was achieved [183]. 
Since B-RAF V600E expression induces dedifferentiation in the PCC13 rat thyroid cell 
line with a significant decrease in NIS expression within 6 days [86], the data presented 
here demonstrated NIS expression with the same timing, thus indicating that B-RAF 
plays an important role in this process. Furthermore, the transient expression of B-RAF 
V600E in differentiated PCC13 cell line impairs both NIS expression and its targeting to 
membrane, probably because of interference of B-RAF with TSH-mediated response
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[196]. The induction of re-differentiation could be the first step to strictly control and 
block anaplastic tumour growth.
We characterised one new compound in the three following PTC cell lines: ARO, NPA 
and TPC1. PLX4032 showed submicromolar IC50 against all cell lines that carry B-RAF 
mutation and a 50 fold higher value against TPC1 that present the RET/PTC1 fusion 
protein. Such discrepancy in effect can be related to the multiplicity of signalling 
pathways that are activated by RET [37, 40]. A decrease in MEK phosphorylation 
indicated that the proliferation arrest was due to the MAPK pathway inhibition and the 
doses of PLX4032 necessary to block MEK phosphorylation were consistent with the 
IC5 0 . Cell cycle analysis was performed by treating cells with either 1 or 10pM 
PLX4032 in two distinct assays. The A375 cell lines showed high level of apoptosis, as 
expected from previous results obtaining with inducible siRNA, while two thyroid cell 
lines, ARO and NPA, demonstrated only G1 arrest and a little apoptosis at the highest 
dose or a decrease in G2/M phase in NPA and ARO cells, respectively. In contrast the 
TPC1 cells were not perturbed by the treatment. Similar results were recently published 
by Ouyang et al. [193] using a isoquinoline compound that showed at lOpM impaired 
progression into S and G2-M and caused an G0-G1 arrest, without inducing apoptosis. 
Possible studies were performed in the present study to account for the differences in 
behaviour observed between the melanoma and thyroid carcinoma cell lines, in 
particular in ARO cells. We used siRNA inducible system to exclude any side effects 
related to the non-specificity of PLX4032. No activation of alternative survival 
pathways, such as the AKT pathway, nor anti-apoptotic factors were preferentially 
observed in any cell line. In contrast, changes of p21 were noted in the melanoma and 
thyroid carcinoma cell lines, while p27 levels didn’t change. These results obtained 
using siRNA were confirmed using a small molecule inhibitor in order to exclude in this
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case side effects due to siRNA or doxycycline. Changes in p21 expression have been 
previously described in tumour cells. It has been reported that p21 up-regulation is 
related to resistance to drug induced apoptosis and cells that are unable to up-regulate 
p21 die [197]. Moreover, in anaplastic thyroid carcinoma growth arrest induced by 
PPARy activation is mediated by the up-regulation of p21 [198]. p21 up-regulation also 
makes cells more sensitive to paclitaxel treatment [198]. The effects of adenovirally 
transduced p21 expression, induced after treatment with PLX4032, in A375 and ARO 
cells were studied in order to verify its role in apoptosis protection. The reversion in B- 
RAF inhibition effects was observed in both cell lines. A possible relationship between 
p21 expression level and B-RAF inhibition was suggested: the A375 cells that 
underwent apoptosis in the absence of a B-RAF proliferative stimulus were partially 
protected from death, while in ARO cells that had showed a delay in cellular growth the 
decreased level of G2/M was reverted.
Taken together, these data confirmed the important role of B-RAF in cancer thyroid de- 
differentiation, and open up the possibility of a restoration of a differentiated status of 
the tumour cells through the use of small molecule inhibitors. The PLX4032 compound 
showed high efficiency and specificity against the B-RAF mutated cell lines, but not 
against RET/PTC positive cell lines, supporting the importance of directly targeting the 
oncogenic protein. p21 regulation by B-RAF through MEK-ERK pathway provides a 
possible molecular explanation of different effects of B-RAF inhibition in cell lines 
analysed.
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4 CONCLUSION
This PhD project analysed the involvement of the receptor tyrosine kinase RET in PTC. 
The study utilised biochemical and biological techniques to determine the biological 
role of RET- dependent signalling in cancer. In particular, I focussed my attention on 
the characterization of new small molecules inhibitors that could selectively block RET 
pathway.
The first goal of my work was the production of a suitable reagent to perform structural 
and pharmacological studies. rRET was produced using the Baculovirus system and 
purified using a procedure optimised by myself. This protein showed biochemical and 
physical characteristics that were compatible with the further analyses that were desired. 
Indeed, the recombinant catalytic domain of rRET showed the same properties of the 
full length protein present in an in vitro cellular system and in the cells of cancer 
patients. No discrepancies between the rRET and full length RET activity in 
crystallization attempts and in inhibitor screening were observed in the current project. 
Knowledge of the three-dimensional structure of the RET catalytic domain represents 
the most important starting point to identify a specific inhibitor. Several attempts with 
different constructs were made at crystallisation but no crystals were obtained that were 
suitable for X-ray diffraction studies. Some experiments were performed in two 
independent institutes (University of Padova and Hauptmann Institute in Buffalo) in 
order to optimise the possibility of a successful outcome. Fortunately for the advance of 
my project, the RET structure was very recently solved by another group. The 
availability of such a detailed model will be invaluable for the identification of new 
selective inhibitory compounds and for exploring new binding sites rather than the 
ATP-binding pocket. Our molecular modelling was based on sequence similarity and
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was constantly improved using data from inhibitor screening. Indeed, the positive and 
negative results from my in vitro experiments made it possible to adjust the model. The 
positions of the amino acids that virtually bind the inhibitors can be modified in relation 
to IC50 experimentally determined. The work described in this thesis resulted in the 
identification of an efficient class of RET inhibitor, the further study of which resulted 
in the identification of a good molecule, SU5416, that was feasible for clinical further 
studies in PTC. SU5416 demonstrated an efficient and selective inhibition of RET, both 
in in vitro and in vivo systems. Cell based experiments showed a favourable solubility 
and in vivo data suggested that its bio-availability is compatible with exigencies of 
clinical application. Furthermore, ongoing clinical trials against other cancers indicate 
favourable pharmaco-kinetic properties of this 2-indolinone derivative. The 
administration of this drug in PTC patients could be reasonable.
The second target validated in this PhD project was identification of the 
serine/threonine kinase B-RAF. B-RAF is downstream to RET in the MAPK pathway 
and is often mutated in PTC. The selective targeting of B-RAF could therefore provide 
an opportunity to treat both RET and B-RAF positive PTC. The results presented here 
demonstrated that B-RAF could be a good target in poorly differentiated papillary 
carcinoma and in anaplastic carcinoma because of its involvement in the de- 
differentiation process. We promoted growth arrest and the acquisition of a 
differentiated status by blocking B-RAF kinase activity. Two different strategies, 
siRNA and a small molecule inhibitor, were employed to achieve these results to 
exclude any doubt relied to methodological non-specific effects. However, RET positive 
cell growth was inhibited only at high doses of compound, suggesting the necessity to 
directly act against the mutated protein in order to achieve a cellular response. The 
complex interaction existing between the various cellular signalling pathways allows
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raises the possibility that cells can overcome a single pathway block, and so are able to 
adapt to the lack of an oncogenic signal. Moreover, several mechanism can be 
controlled by the same pathway in different cell lines. Evidence to this latter point was 
obtained from my comparison between melanoma and anaplastic thyroid carcinoma cell 
lines, in which the inhibition of B-RAF-MEK1/2-ERK1/2 had completely different 
consequences on cell cycle. Nevertheless, these effects were mediated by p21 
regulation, the presence of this same protein in both cell lines indicating a common set 
of control factors. Improved knowledge of the various signalling pathways in cellular 
systems associated with analyses of patient biopsy tissues would be invaluable in the 
identification of new targets for selective treatment. Moreover, it would be possible to 
exploit the wide spectrum of one small molecule compound on cells to obtain major 
effects in vivo: for instance, SU5416 acts as anti-proliferative agent by blocking RET 
and as anti-angiogenic by inhibiting VEGFR. This dual mechanism could improve the 
efficiency of the therapy, with minimal side-effects.
This work has proposed the rational identification of RET and B-RAF inhibitors by 
analysing their signalling pathway. These results raise the possibility that PTC could be 
treated effectively with small molecule inhibitors, as is the case for other cancers, such 
as chronic myeloid leukaemia, which are linked to oncogenic tyrosine kinases.
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